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The high Mr (~55 kDa) thioredoxin reductases (TR) characteristic of higher 
eukaryotes are members of the glutathione reductase (GR) family of pyridine nucleotide 
disulfide oxidoreductases. These homodimeric enzymes catalyze the reduction of a 
cognate disulfide substrate. During the enzymatic cycle, reducing equivalents pass from 
NADPH to the conserved active site disulfide via an enzyme-bound FAD and then to the 
cognate substrate. TRs are unique in the family as electrons are then transferred to the C-
terminal active site of the adjacent molecule as part of a 16 amino acid extension (in 
place of the cognate GR substrate GSSG), prior to transfer to the substrate thioredoxin. 
Each electron transfer step occurs via thiol-disulfide exchange in a multi-step process 
mediated by a conserved catalytic acid/base. Mammalian TRs require selenocysteine 
(Sec) incorporated into the Gly-Cys-Sec-Gly-OH (GCUG) C-terminal tetrapeptide motif, 
while the TR from Drosophila melanogaster (DmTR) does not, and instead contains a 
Ser-Cys-Cys-Ser-OH (SCCS) tetrapeptide motif indicating that Sec is not universally 
necessary to catalyze the reduction of thioredoxin. 
This project has achieved three major objectives; 1) development of a 
semisynthetic method for production of mouse mitochondrial TR (mTR3) for structure-
function studies, 2) establishment of a new method to study the mechanism of TR by 
using tetrapeptides in the oxidized form equivalent to the C-terminal active sites as 
substrates for the truncated forms of both enzymes, 3) determination of the crystal 
structure of DmTR. The results show that the structure of DmTR explains the 
biochemical data and has developed a new testable hypothesis in the field for the 
requirement of Sec in mammalian TR.  
We demonstrate that the tetrapeptides tested in Aim 2 were all better substrates 
for DmTR. The data also shows a far greater dependence on Sec for mTR3 than DmTR, 
which is in agreement with that observed for the collection full-length mutants produced 
for each enzyme in Aim 1. As this method of investigation is more analogous to the other 
enzymes of the GR family, the structures of the tetrapeptides determined by NMR 
spectroscopy were oriented in the active site of the both enzymes using the diglutathione 
bound in the structure of GR as template. DmTR appears to have a more open active site 
than observed in the known structure of mTR3. Residues from the helical face of the 
FAD-domain proximal to the FAD-associated active site are less bulky in DmTR to 
accommodate the hydroxyls of the serines. This is likely to make the enzyme more 
amenable for the conformational switching of the SCCS peptide necessary to protonate 
the leaving group cysteine by the proposed catalytic acid/base. In contrast, mTR3 shows 
a more restricted interface by incorporating bulkier residues at the interface in 
conjunction with the smaller Gly residues of the C-terminal sequence GCUG. The 
tetrapeptides display a conformational preference not suitable for protonation of the first 
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Figure 1. The physiological reducing systems. 
The Thioredoxin system (A) and the Glutathione system (B) are each dependent on the 
system reductase, TR and GR respectively. These enzymes use a common modular 
architecture to perform the function of thiol-disulfide exchange. The unique properties of 
mammalian TR compared to the other related enzymes make understanding minor 










THIOREDOXIN REDUCTASE AND PHYSIOLOGY 
 
Oxygen…the key to life as we know it. Oxidation…an enemy of life as we know 
it. Oxidation is not just damage in the form of the rust on your car it is also damage 
incurred by all forms of biological macromolecules. This can lead to the inactivation of 
enzymes (1), oxidation of lipids contributing to atherosclerosis (2, 3), and DNA damage 
resulting in cancer (4, 5). While the extracellular environment is relatively oxygen rich, 
the intracellular environment is maintained in the reduced state. However, oxidation in 
both environments is also an essential process that occurs in many physiological 
reactions. The key for most oxidative processes to be beneficial rather than detrimental is 
that that the process be reversible. Because of this paradox, organisms have evolved 
systems to control and utilize oxidative processes.  
The cellular environment is maintained in the reduced state by two primary 
systems, the glutathione system (sometimes referred to as the glutaredoxin system) and 
the thioredoxin system. The key enzymes are referred to as the system reductases, 
glutathione reductase (GR) and thioredoxin reductase (TR). A comprehensive list of 
abbreviations used in this dissertation is available in Appendix A. The reductase for each 
system utilizes reducing equivalents in the form of NADPH to reduce the system’s 
respective cognate substrate, oxidized diglutathione (GSSG) or thioredoxin (Trx) (Figure 
1).  While Trx goes on directly to reduce a target substrate, there are two fates of reduced 
glutathione (GSH), the tripeptide γ-glutamylcysteinylglycine. Two molecules of GSH can 
be used to directly reduce a target or, more commonly, GSH will be used to reduce 





are available on the physiological functions of both systems (6-9). The most common 
shared function between the two systems is the reduction of protein disulfides. Central to 
the function of these systems is the process of thiol-disulfide exchange mediating the 
directed transfer of electrons between reduced and oxidized species.  
 Both systems are nearly ubiquitous in all forms of life, however, there are certain 
organisms of which there are substitutions for these systems. For example, the parasite 
Trypanosoma utilizes the analogous trypanothione system rather than the glutathione 
system (10). The system reductase is trypanothione reductase (TryR) and cognate 
substrate is trypanothione. While GRs are functionally, structurally, and mechanistically 
homologous, TRs are divided into two classes: higher eukaryotes have the class I high Mr 
TR, which is the focus of this dissertation, while prokaryotes and lower eukaryotes have 
class II low Mr TRs. These two classes have partial homology on the basis of function 
and structure, but contain structural deviations and have distinct mechanisms. No GR has 
yet been identified in Drosophila melanogaster even though glutathione is utilized (11). 
In this system, the GSH pool is maintained by the thioredoxin system via Trx. 
 The essential nature of both systems makes the reductases a significant 
therapeutic target for a broad range of disease processes. For example, the protozoa of 
which TryR substitutes for GR are the cause of several tropical diseases. Therefore, TryR 
is a target under investigation as a therapeutic target (12-14). Similarly, active site 
distinctions between the high Mr TR of mammals and that of Plasmodium falciparium, 
the causative parasite of malaria, make the Plasmodium falciparium TR (PfTR) an 





 Both the glutathione and thioredoxin systems are reducing equivalent donors to 
ribonucelotide reductase (RNR) (8), the enzyme responsible for conversion of 
ribonucleotides to deoxyribonucleotides (dNTPs) for DNA synthesis (16). This enzyme is 
a target under investigation for cancer therapy, see Arnér and Holmgren for a TR-based 
review (17). Initial studies performed in E. coli. showed Trx to have slightly lower 
activity than glutaredoxin (Grx) as electron donors to RNR. Though Trx was less active 
and showed ~10 fold higher Km (18, 19), the cellular Trx concentration is considerably 
higher than Grx (20, 21). Trx knockout in yeast results in a 40% reduction of the dNTP 
pool in vivo (22). However, the impact for inhibition of these systems for higher 
eukaryotes in relation to ribonucleotide reductase has yet to be determined. Elevated 
levels of TR in human tumors have been reported (23, 24) but the degree of up-regulation 
and purpose of the elevated levels is uncertain (25).   
The mammalian thioredoxin system is unique in its broad range of substrates 
compared to other systems. Transcription factors such as NF-ΚB (26, 27) involved in 
oxidative stress and inflammatory responses have been demonstrated to be redox 
regulated by Trx. This redox control of transcription factors, and its involvement in the 
response to reactive oxygen species, implicate TR as a player in afflictions such as 
rheumatoid arthritis (28), cancer (17), aging, and HIV (29). Several other substrates 
unique to mammalian TR have been identified. The antioxidant ascorbate (vitamin C) can 
be reduced by TR (30) as can lipid peroxides (31). The unique roles that mammalian TR 
plays in so many physiological processes makes understanding the mechanistic 






THE GLUTATHIONE REDUCTASE FAMILY 
 
Thioredoxin reductases from higher eukaryotes are members of the glutathione 
reductase (GR) family of pyridine nucleotide-disulfide oxidoreductases (32). The 
Structural Classification of Proteins (SCOP) identifies the protein family as FAD/NAD-
linked reductases belonging to the FAD/NAD(P) binding domain Superfamily and Fold 
(33). Proteins in this family of which structures are available are GR (34), TR (35, 36), 
TryR (37), and LipDH (38). There are many structures for most of these proteins, 
especially GR. The references given above are representative structures of each enzyme 
used in direct structural comparisons in this dissertation. Glutathione, trypanothione, and 
lipoamide are all small-molecule substrates whereas thioredoxin is a 12 kDa protein 
(Figure 2). More distantly related family members include: alkyl hydroperoxide 
reductase, NADH peroxidase, NADH-dependent ferredoxin reductase, flavocytochrome 
C sulfide dehydrogenase, and apoptosis inducing factor (AIF). Although these proteins 
are generally related via the binding of FAD and/or NAD, their structural topologies are 
quite different from the GR family as reviewed by Dym and Eisenberg (39).  
Structural Overview.  
The proteins of the GR family are homodimeric (25) and have a three domain 
modular structure, which is diagramed in Figure 3. Each contains a N-terminal FAD 
binding domain followed by a NAD(P) binding domain. Each of these domains is 
structurally similar and composed of a three-layered sandwich, which will be described 





in a head to head fashion (Figure 4), essentially a mirror image, to place the flavin and 
nicotinamide in proper orientation for electron transfer. The domains are tethered by a 
two antiparallel β-strands with each strand representing the transition from one domain to 
the other. The C-terminal domain is the dimerization/interface domain for this class of 
proteins and is generally a five-stranded anti-parallel β-sheet with two alpha helices on 
either side. The high Mr TR (class I) characteristic of higher eukaryotes are ~55 kDa per 
monomer and have an additional C-terminal extension of 16 residues (compared to GR), 
which contains an additional active site disulfide (Figure 5). Prokaryotes and lower 
eukaryotes utilize class II TRs which are ~35 kDa per monomer.  Class II TRs do not 
have the C-terminal domain characteristic of most members the GR family and dimerize 
via the FAD domain (40).  
FAD Binding Domain.  
The FAD binding domain is the most highly conserved domain among family 
members (alignment Figure 6). This is not unexpected as the FAD is permanently bound 
to the protein although non-covalently, with a few exceptions within the family such as 
fumarate reductase and sarcosine oxidase. The domain contains a variant of the 
Rossmann $"$"$ fold as the central motif in a three-layered sandwich; a five or six-
stranded parallel central sheet, alpha helices on one face, and a three-stranded anti-
parallel sheet on the other (Figure 7) (41). The anti-parallel sheet is the crossover 
connection to the directional change in the Rossmann fold. This retains the typical +3 
topology of the Rossmann fold where strand number four in the sheet is strand seven 





domain such that stand five, six for some structures, follow the NAD(P) binding domain 
in the sequence. 
 The FAD molecule is divided into two modules connected via a pyrophosphate. 
The first module is the adenosine monophosphate (AMP) and lies within a well-defined 
groove created by the topological switch in the parallel $-sheet and a hydrophobic pocket 
between the two $-sheets. The adenine lies in the pocket with the N6 coordinated by a 
backbone carbonyl in a conserved position at the N-terminus of strand one of the anti-
parallel sheet. This residue is generally a small hydrophobic residue such as a glycine, 
alanine or valine.  The ribose and phosphate extends through the groove with the 
phosphates coordinated by the highly conserved FAD binding motif. This motif is the 
most conserved sequence found within the domain. The motif is GxGxxGx(17)D/E and is 
located in the loop and N-terminal end of the helix between strands one and two of the 
Rossmann fold. The x represents any residue with some preference for hydrophobic 
residues in the 17-residue stretch. This motif provides both a structural platform and 
binding determinants for the adenosine monophosphate and pyrophosphate moieties. The 
backbone amides of the GxGxxG motif provide hydrogen bonds to the pyrophosphate 
and the D/E coordinates the 2’-OH of the ribose. In many structures, there is a conserved 
water molecule mediating the interaction with the pyrophosphate (42).  
Charge stabilization of the pyrophosphate is believed to come from the positive 
helix dipole as the GxGxxG is the N-terminal end of helix 1 of the FAD domain (43). In 
the GR and TryR structures, the glutamate side chain hydrogen bonds to both the 2’ and 
3’-OH whereas in the E. coli TR structure it appears to be the backbone carbonyl of the 





provides a hydrogen bond to the phosphate of the AMP. The second module of the FAD 
is the flavin mononucleotide, which contains the linear ribitol and the isoalloxazine ring 
of the flavin. The ribitol places the FAD in a linear conformation above the $-sheet 
platform, placing the flavin in contact with the alpha-helical face containing the active 
site. 
 The FAD domain contains the active site disulfide representative of the GR 
family, with exception of the small TR. It is located in the extended alpha-helical 
segment that connects strand two to strand three in the parallel β-sheet. The conserved 
redox active site sequence Cys-Val-Asn-Val-Gly-Cys (CVNVGC) sequence generates a 
short alpha helix followed by a longer helix, which is separated by a short loop created by 
the VNVG. This places the cysteines on the same face such that, when oxidized, the 
disulfide bond bridges across the loop. The N-terminal Cys is referred to as the 
interchange thiol and is responsible for electron exchange with the GSSG substrate (44). 
The C-terminal Cys is the charge-transfer Cys responsible for interacting with the Flavin. 
Reaction of reduced GR with iodoacetamide results in labeling of the interchange thiol 
while the C-terminal Cys is maintained in the charge-transfer state (44).   
Immediately C-terminal to the active site is a conserved lysine that coordinates 
the N5 of the flavin. Interestingly, the small TR has a similar short helix followed by a 
longer loop yet does not contain the active site motif. The local structure is maintained 
however, the small TR loop transitions to a helix that connects directly to the crossover 
$-sheet whereas the other members of the family extend towards the NAD(P) binding 
domain and reconnect to the FAD domain through an additional helix resulting in a 





connecting helix in E. coli TR such that it occupies the substrate binding pocket 
representative of the other members of the family. 
NAD(P) Binding Domain.  
The NAD(P) binding domain demonstrates a similar architecture to that of the 
FAD domain although it is smaller and not as well conserved. While the FAD is 
permanently bound, the NAD(P) must bind and dissociate during the catalytic cycle. 
Therefore binding is less stringent and involves an induced fit (45). The domain 
architecture also contains a three-layered sandwich with the alpha helices being shorter 
and the parallel $-sheet containing only four strands. The GxGxxG motif is also 
conserved, although not as well as in the FAD binding domain. An important difference 
is the coordination of the ribose of the similar AMP module. Members of the family that 
bind NADP rather then NAD contain a pair of arginines in the loop where the D/E 
normally resides. These residues hydrogen bond to the phosphate on the 3’-OH and it 
appears that 2’-OH points toward the solvent. A series of mutations, including the Arg 
residues, allows for switching of substrate specifity from NADPH to NADH (46). 
A conserved tyrosine from the NADP domain, Tyr197 in GR, shows a significant 
conformational change between the oxidized and reduced states of the enzyme (34, 47). 
Upon binding of NADPH, the Tyr rotates to allow the orientation of the flavin and 
nicotinamide for electron transfer. This same conformational change has also been 
reported for mouse mitochondrial TR (mTR3) (35). This residue was initially suggested 
to provide a cap to protect the flavin from access to solvent. However, mutagenesis to 





resulted in a shift from the normal Ping-Pong Bi Bi mechanism to an Ordered-Sequential 
mechanism (48).  
 While the overall architecture is maintained within the family, there is a simple 
non-conserved sequence in a short alpha helix prior to the sequence returning to the FAD 
domain. This short helix contains the active disulfide for small TR. The end of this helix 
faces the FAD domain and contains the active-site sequence, CATC. The combined 
structures for E. coli TR demonstrate a significant conformational change that is unique 
to the Class II TR (49). The NAD(P) domain twists ~60o to expose the active disulfide to 
the open face of the structure, opposite the dimer interface, for interaction with 
thioredoxin. This sequence is GITS for GR and CISS or CITS for large TR, TryR and 
LipDH while the flanking regions are relatively well conserved. However, since this 
active site faces the dimer interface, it is inaccessible to a large substrate such as 
thioredoxin. 
The Dimerization Domain.  
The C-terminal dimerization domain represents ~30% of the sequence for the 
proteins of this family. As the name implies, it is this domain that is responsible for dimer 
formation thereby assembling the functional active site. It is this domain that provides the 
catalytic acid/base histidine for the active site of the enzyme. The conserved active site is 
composed of the FAD and the conserved disulfide (CVNVGC) from the FAD domain of 
Chain A, and the His-Glu dyad (His464 and Glu469 in Figure 5) from Chain B, as 
proposed from the crystal structures of GR (34, 50). Residues from chain B are given a 





terms of the catalytic cycles covered in the next section. The His-Glu dyad is shown for 
the structures of GR and mouse TR3 in Figure 4. The communication between the FAD 
active site disulfide on Chain A and the catalytic acid/base on Chain B was verified by 
the preparation of heterodimeric GR from E. coli where one subunit contained the 
Cys47Ser mutant and the other subunit contained the His439Gln mutant (51, 52). Each 
mutant showed poor activity when prepared as a homodimer while the heterodimeric 
form showed ~50% of wild-type activity. 
Proper dimer assembly is also a significant contributor to the catalytic 
mechanism. Several mutagenesis studies have been performed with GR targeting residues 
at the dimer interface. Though dimeric enzymes require elements from both monomers, 
cooperativity has not been reported for wild type enzymes under normal conditions. The 
E. Coli GR mutant Gly418Trp results in an enzyme having high cooperativity for GSSG 
binding with Hill coefficient of 1.76 (53). Mutations in this region can also disrupt the 
standard Ping Pong mechanism (54).      
The additional thiol-disulfide exchange step characteristic of TR utilizes a 16 
amino acid C-terminal extension (absent in GR) and typically contains a Cys-Cys dyad, 
which forms an intramolecular disulfide. Upon reduction of this dyad by the N-terminal 
redox center (on the opposite chain), the substrate (Trx) can then be reduced. The 
relationship between the N-terminal active site and the C-terminal active site was 
demonstrated using the heterodimer method developed for GR by Deonarain et al. 
mentioned above. In these experiments the interchange thiol Cys88 of Plasmodium 
falciparum (PfTR), was mutated to Ala in one construct while Cys535 was mutated to 





poor activity towards Trx while the heterodimers showed ~50% of wild-type activity. 
This provided evidence that the N-terminal active site was in redox communication with 
the C-terminal active site. 
With the exception of PfTR, which contains four intervening residues, the 
disulfide forms between adjacent Cys residues of the C-terminal dyad. This vicinal 
disulfide bond has a very low frequency in the Brookhaven Protein Data Bank (PDB) as 
is discussed by Perczel and coworkers (56, 57) and results in a type VII β-turn (58).  Only 
TR has been identified as having a catalytically competent vicinal disulfide. Examples of 
proteins containing a vicinal disulfide include bacterial toxins (59), the nicotinic 
acetylcholine receptor (58), hepcidin (60), and methanol dehydrogenase (61). For these 
proteins it is suspected that the vicinal disulfide has a structural function. Mercuric ion 
reductase also contains a C-terminal vicinal disulfide but it does not appear essential for 
enzyme function (62). 
Mammalian TRs (mTR) are distinguished in this group since they contain the rare 
amino acid selenocysteine (Sec, U) as part of the C-terminal dyad forming the redox-
active motif Gly-Cys-Sec-Gly (GCUG) (63, 64).  Drosophilia melanogaster TR (DmTR) 
lacks Sec as part of this motif and has the C-terminal sequence Ser-Cys-Cys-Ser (SCCS) 
(11, 65) (Figure 5).  Thus, high Mr TRs can be divided into enzymes that contain Sec and 
those that have a conventional Cys residue (66). TryR is interesting in that it also has a C-
terminal extension, but the sequence is not conserved in comparison to TR and does not 






Substrate Binding.  
Glutathione reductase is the structural model for the family and has been 
extensively studied. Both the alpha helical face of the FAD domain and the C-terminal 
end of the dimerization domain provide substrate-binding determinants for GSSG (34). 
Most of the binding contacts for GSSG in the structural complex appear water mediated 
with the most significant direct contacts formed between Chain A and GSHI. Many of the 
substrate-binding residues are conserved in TR yet the enzyme cannot reduce glutathione 
or trypanothione. The arginine in position 37 for GR serves to anchor the carboxyl group 
of GSHI. Trypanothione does not have carboxyl groups at both ends of the molecule and 
therefore has hydrophobic substitutions at position 37 and 106 and an acidic substitution 
at position 117. The extensive structural investigations of substrate binding residues for 
GR and TryR have allowed for engineering of trypanothione specificity in human GR 
(67) as 14 of 19 amino acids suggested to bind GSSG in GR are identical in TryR.   
In the case of TR, the C-terminal tail is essentially the substrate for the FAD 
domain-conserved active site substituting for GSSG (68). Since glutaredoxin and 
glutathione peroxidase are the primary targets for GSH and are similar to Trx, it is as if 
TR has evolved by incorporating the GSSG-like moiety into the protein. The size of 
thioredoxin makes it inaccessible to the active site of GR, TryR and LipDH. 
Alternatively, the C-terminal extension of rat TR occupies the binding site making it 
inaccessible to glutathione, trypanothione, and lipoamide. The conservative substitution 





coordination of the C-terminal carboxylate of rat TR1 (36). There is no current data 
pertaining to the residues involved in Trx binding for large Mr TRs. 
 
SPECTRAL CHARACTERISTICS OF FLAVIN AND FLAVOPROTEINS 
 
To better understand the methods currently used for investigating mechanistic 
details within the GR family, an introduction to the spectral characteristics of flavin must 
be presented. Much of the work describing the electronic states of flavin derivatives was 
pioneered by Vincent Massey as reviewed in (69) and has been used to distinguish 
between free flavin and flavoproteins and their mechanisms (70, 71). Many classes of 
enzymes utilize a flavin moiety, which can participate in either one-electron or two-
electron processes as investigated potentiometrically by Michaelis et al. (72). It is this 
characteristic that allows the flavin to be so versatile and results in several electronic 
states (73). Each of these states has specific spectral properties as shown in Figure 8 (74) 
using Old Yellow Enzyme as the example showing all four electronic states. The 
simplified equation most commonly shown for the reduction of FAD is described in 
equation 1. 
FAD + 2e- + 2H+ → FADH2   (1) 
The yellow color associated with a flavin derivative is indicative of the moiety in 
the oxidized state. The color comes from an absorbance peak at ~448 nm that is shifted to 
longer wavelengths for flavoproteins, ~460 nm for GR and TR (71). This peak for 





shoulders were determined to be a function of the hydrogen-bonding environment 
between the protein and the isoalloxazine ring (71). As with most species with an 
aromatic nature, there is also an absorbance maxima in the near ultraviolet. This peak is 
~375 nm for flavin and a slightly shorter wavelength for a flavoproteins, ~370 nm for GR 
and TR. Complete reduction of flavin to FADH2 results in a decrease in extinction for the 
UV peak and a loss of visible color. This loss of color upon reduction, however, is not 
observed in all flavoproteins (70). 
As free flavin and flavoproteins have unique properties, the same can be said for 
the GR and TR compared to enzymes such as glucose oxidase (71, 73). For example, 
photoreduction and reoxidation experiments with glucose oxidase results in all flavin 
species being observable (75). The reduction of GR, however, under physiological 
conditions displays different properties (Figure 8 inset) (76). While the spectra of the 
oxidized enzyme (spectra 1) resembles that of the free flavin, it is clear that the reduced 
form of the enzyme using NADPH (spectra 2) or sodium borohydride (spectra 3) does not 
resemble that of the reduced free flavin in the form of FADH2. The characteristic reduced 
spectrum is not typically seen in GR family proteins under normal conditions. To achieve 
this state, long incubations in excess NADPH or chemical reducing agents such as 
dithionite are most commonly required (70, 77-79). The reduced spectrum of GR instead 
appears to be a hybrid between the oxidized and anionic semiquinone states (73).  
The most notable characteristic of NADPH-reduced GR or TR is a red color that 
is demonstrated by the absorbance change at 540 nm in the inset of Figure 8. This color 
indicates the essential species and primary intermediate of the mechanism of these 





adduct with the C4a position of the isoalloxazine ring of the flavin and active site 
cysteine. An adduct intermediate with substrate at this position is also proposed for many 
other classes of enzymes (69). This transient species becomes the primary charge-transfer 
intermediate upon reduction of the disulfide. Preliminary investigations for spectral 
characteristics of the GR protein family were performed using LipDH (80-83).  The two-
electron reduced enzyme showed the same red color mentioned above with proton 
inventories suggesting a proton from dihydrolipoamide being taken by the catalytic 
acid/base. The adduct formed between the cysteine and FAD with the subsequent 
formation of the charge-transfer complex as the reduced intermediate for the GR results 
in equation 2, which is typically how the FAD in the reaction cycle is represented for GR 
and TR. 
FAD + NADPH → FADH-    (2) 
 
THE GLUTATHIONE REDUCTASE CATALYTIC CYCLE 
 
Catalytic Overview.  
GR is a two-substrate, two-product (or three, with a GSSG producing 2 GSH) 
enzyme, shown in equation 3, following Ping-Pong Bi-Bi kinetics similar to that of 
LipDH (84, 85), as reviewed in (86). Massey and Williams (87) originally proposed the 
catalytic cycle of GR which has since been divided into two phases: a reductive half-





reduced by the consumption of NADPH resulting in the formation of the thiolate-flavin 
charge-transfer complex. The enzyme is re-oxidized upon consumption of GSSG in the 
oxidative half-reaction, which is the prototypical enzymatic thiol-disulfide exchange. The 
steps in each half-reaction have been studied extensively by stopped-flow kinetics, as 
best described in (88, 89) using the spectral characteristics of the flavin. The reaction was 
predicted to be acid/base catalyzed with the residue identified in the C-terminal region of 
GR (90). A representation of the GR catalytic cycle is shown in Figure 9. 
GSSG + NADPH + H+ → 2GSH + NADP+   (3) 
His467′ for human GR (His439′ for E. coli.) from chain B has since been 
identified as the acid/base catalyst in GR and is conserved throughout the protein family. 
It has been shown to be essential in both the reductive half-reaction and oxidative half-
reaction for GR (48, 88, 91), LipDH (80, 92), and PfTR (93). His467′ is activated by 
Glu472′ (human GR) forming a catalytic dyad that acts as a potential charge-relay system 
between the dyad and the N-terminal thiol of the active site disulfide, as first proposed 
from the crystal structure of GR (50). For the discussion of the catalytic cycle, I have 
chosen to use the GR comparison as it functions to reduce a disulfide like TR rather than 
to oxidize a dithiol as is the case for LipDH.  
Flavin Spectra and Enzyme Kinetics.  
In the previous section we introduced the spectral characteristics of flavin and 
flavoproteins in terms of the redox state of the flavin in three states - oxidized, reduced, 





primary flavin states but more than three steps. As can be seen in the flavin spectra in 
Figure 8, differences in the redox state results in changes throughout the spectrum. 
Therefore, a subset of relevant wavelengths has been established for kinetic analysis (88, 
89). The easiest to understand is the thiolate-flavin charge-transfer complex observed at 
540 nm. The second is a charge-transfer complex between FADH- and NADP+ at 670 
nm. The complete oxidation of flavin results in an absorbance maxima at ~460 nm but 
partial oxidation is a characteristic of these proteins during each half-reaction. Therefore 
this state is followed at 440 nm. 
The method developed at The University of Michigan by Ballou and Arscott 
utilizes a stopped-flow spectrophotometer adapted for anaerobic conditions. These 
conditions are necessary to prevent auto-oxidation of the flavin. While the rapid reaction 
kinetics using flavin spectra provides more details than steady state kinetics, it is not 
without limitations. There are several species that are spectrally equivalent and cannot be 
distinguished for GR (88) or TR (78, 79, 93). Of special interest are the catalytic 
intermediates involving the thiol-flavin charge-transfer.  
The Reductive Half-Reaction of GR.  
During the reductive half-reaction (Eox to EH2(B)), the FAD-associated disulfide 
from chain A is reduced upon consumption of electrons from NADPH. Three primary 
phases have been spectrally observed for this reaction (88, 89). The first phase, binding 
of NADPH and formation of the NADPH - FAD charge-transfer complex is complete 
within the dead time of the stopped-flow instrument. The second phase includes the 





transfers electrons to the N-terminal disulfide and occurs via the thiolate-FAD charge-
transfer complex. The mutant His439′Ala (E. coli GR), was reported to result in a modest 
16 fold decrease in the overall rate for the reductive half-reaction. A closer inspection 
reveals different spectra upon NADPH reduction of the wild type and mutant enzymes 
(88). The mutant enzyme at the end of the reaction has much more reduced flavin 
characteristic and less charge-transfer absorbance indicating the two proteins are in 
significantly different states. While the rate differences are addressed in the discussion, 
the magnitude of the difference in the spectra (especially at 440 nm) is not.  
The Oxidative Half-Reaction of GR.  
The oxidative half-reaction (EH2(B) to Eox) is the reduction of GSSG that results 
in the re-oxidation of GR.  For each NADPH consumed in the reductive half-reaction, 
two GSH molecules are produced from a single GSSG in the oxidative half-reaction. The 
intermediate of the oxidative half-reaction (EH2(C)) is a mixed disulfide formed between 
the cysteine of GSH I and the active site interchange thiol (Cys58) from chain A (94). 
This step is referred to as interchange.  This intermediate is seen crystallographically in 
PDB 1GRE compared with the bound oxidized GSSG in PDB 1GRA (34) now at <2 Å 
refined from the initial 3 Å structures (47). The high temperature factors of GSGII and 
the fewer direct contacts to GSHII from GR in combination with GSHI as the interchange 
moiety indicates that GSHII is likely the first leaving group. The significance of this 
intermediate is biochemically supported by GSH/GSSG equilibrium experiments and is 
hypothesized to be the major form of GR physiologically (94). Unlike the reductive half-





followed by a single state as EH2(B) and EH2(C) are spectrally equivalent. This means: 1) 
formation of the mixed disulfide, 2) protonation of the first leaving group, 3) resolution 
of the mixed disulfide, and 4) protonation of the second leaving group are incorporated 
into a single rate constant (88).  
This challenge was partially addressed by earlier experiments using mixed-
disulfide substrates (95). The substrates GS-SNB (mixed disulfide of glutathione and 5-
thio-2-nitrobenzoic acid) and GS-SNP (mixed disulfide and 2-thio-4-nitropyridine) were 
evaluated as substrates for GR using kinetic isotope effects on kcat with varying deuterium 
concentrations. The mixed disulfide substrates have an aromatic thiol group with a low 
pKa and would not require protonation, unlike GSH. Each substrate indicated a proton 
transfer step as partially rate-limiting and results from either substrate indicated that the 
same rate-limiting step was being observed. While the aromatic thiol should be the first 
leaving group (94) with GSH as the interchange mixed disulfide, it was hypothesized 
from this data that the GSH was the first leaving group. The rationale provided is that for 
the system to be in equilibrium, the GSH would have to be the first leaving group. At 
equilibrium, the free GSH would be able to re-attack the interchange mixed disulfide. If, 
however, the aromatic disulfide were the first leaving group, the reaction should be 
irreversible. Why the aromatic disulfide would be the second leaving group in this 
experiment is not quite clear. One possibility could be a function of binding or orientation 
of this modified substrate in the active site (96), which is not accounted for.  
His439′ has been shown to be essential to the oxidative half-reaction for 
protonation of the first leaving group, the thiol of GSHII (88). This half-reaction was 





leaving group is essential in the oxidative half-reaction. Protonation and subsequent 
dissociation is essential to prevent the re-attack of the interchange mixed-disulfide by 
GSHII and thereby driving the reverse reaction (88). The final step of the oxidative half-
reaction is the resolution step. The resolving thiol, Cys63, attacks the interchange mixed 
disulfide and reforms the enzyme Cys58-Cys63 disulfide with release of the second 
molecule of glutathione (GSHI). Thus, the enzymatic thiol-disulfide exchange process 
characteristic of this family of proteins involves an interchange step (requiring an 
interchange cysteine) and a resolution step (requiring a resolving cysteine). 
 
THE HIGH Mr THIOREDOXIN REDUCTASE CATALYTIC CYCLE 
 
 The addition of a second thiol-disulfide exchange in TR results in a significantly 
more complicated reaction cycle (Figure 10) as best described for PfTR (93) and DmTR 
(78) with partial insight from mammalian TR (79). The reductive half-reaction of TR 
includes transfer of electrons from the N-terminal dithiol to the C-terminal disulfide (this 
is equivalent to the combination of the reductive and oxidative half-reactions in GR) as 
well as the consumption of an additional equivalent of NADPH. The oxidative half-
reaction of TR is the thiol-disulfide exchange between the C-terminal dithiol and the 
disulfide of Trx. The steady state cycle therefore alternates between two-electron and 
four-electron reduced states of TR, EH2 to EH4, as shown for DmTR (78) and PfTR (93). 
It is assumed from this work that EH4(B) is the predominant product of the reductive 





As much mechanistic detail as is inferred from this work, only three discernable 
rate constants have been determined for the entire reductive half-reaction (93) from a 
model with at least eight steps. The first constant is the consumption of the first 
equivalent of NADPH foming the FADH- - NADP+ charge-transfer complex and the 
second rate constant being the formation of the thiolate-FAD charge-transfer complex. 
This is similar to the analysis for GR. This means the third rate constant represents the 
thiol-disulfide exchange between the N-terminus and C-terminus with the spectra 
complicated by the consumption of the second equivalent of NADPH. Referring to 
Figure 10, these are the steps from EH2(B) to EH4(B).    
Mutation of either residue of the His-Glu catalytic dyad for PfTR results in 
significant decreases in rate for both the reductive half-reaction and the oxidative half-
reaction (93) with the His mutation almost completely destabilizing the thiolate-flavin 
charge-transfer complex. Similar results are seen by the authors for the equivalent 
mutations in DmTR, but have yet to be published. This is in agreement with that observed 
for the equivalent mutants in GR (88, 89) and LipDH (97, 98).  Similarly, mutation of the 
equivalent Glu477 in human TR results in a 6 fold reduction in kcat (99). The perturbation 
of the reductive half-reaction appears greater in magnitude for the His mutation in PfTR 
than mentioned above for GR. These results indicate 1) the importance of the catalytic 
acid/base in both half-reactions for GR and TR; 2) could imply the catalytic acid/base is 
also involved in thiol-disulfide exchange between the C-terminus of TR and the disulfide 
of Trx. The latter has been proposed in a mathematical model for mammalian TR (100) 





attacking thiolate of TR and/or protonation of the leaving group thiol of Trx. However 
there is currently no experimental evidence for this.  
It is quite possible that the decrease in rate for the His and Glu mutants of PfTR 
(93, 101) represents the unfavorable formation of EH2(B) rather than catalytic association 
with Trx. The authors note that the thiolate charge-transfer complex in the His mutant is 
nearly absent. If the model of the catalytic cycle is correct and EH2(B) is formed prior to 
Eox during reoxidation in these experiments, the His mutation could be a function of 
reoxidation of the N-terminal disulfide instead. Like the reductive half-reaction, three rate 
constants were determined for the oxidative half-reaction of PfTR. The first rate constant 
for the His or Glu mutants is 50% of the wild type enzyme and is attributed to the thiol 
disulfide exchange with Trx indicating these residues are not directly involved with Trx. 
The second rate constant is attributed to the reaction of EH2(D) with the excess Trx in the 
experiment. This rate would reflect conversion from EH2(B) to EH2(D) and is 
significantly slower in the His and Glu mutants. The third rate constant is the slowest of 
the three and reflects the complete reoxidation of the flavin.  
It can be interpreted from this data that the decrease in rate for the His and Glu 
mutants for PfTR in the oxidative half-reaction are actually steps in the reductive half-
reaction. Each of the three rate constants for the oxidative half-reaction is significantly 
lower than the rates determined for the reductive half-reaction (93). This is consistent 
with results for DmTR where the single determined rate constant of 11 s-1 was suggested 
to be the conversion of EH2(B) to EH2(D) during the oxidative half-reaction (78). The 
overall rate constant of 5 s-1 for reduction of Trx was determined, indicating this step is 





consistent for what is observed for GR where the protonation of the first leaving group in 
the oxidative half-reaction is the overall rate-limiting step (88, 95). The only caveat being 
that GSSG is now replaced by the C-terminal disulfide in TR. This may sound confusing 
at first, but it can be better understood by comparing Figure 9 to Figure 10 and 
establishing the important relationship in equation 4.  
EH2(B) → Eox  (GR)  =  EH2(B) → EH2(D)  (TR)   (4) 
 
SELENOCYSTEINE IS ESSENTIAL TO MAMMALIAN TR 
 
 Earlier in the Introduction, it was implied that mammalian TR has unique 
functional properties in comparison to the other proteins in the family. Yet we have not 
discussed what makes mammalian TR unique. For simplification purposes, TRs have 
been discussed in general terms of the catalytic cycle, since all high Mr TRs share the 
active site containing C-terminal extension. There are two major subclasses of this C-
terminal active site. Looking more closely at the sequence alignment in Figure 5, the one 
letter code U (selenocysteine) is in the penultimate position for mammalian forms while 
others contain C (the one letter code for cysteine).  Therefore the two classes are those 
whose active site contains a Cys-Cys dyad and that which contains a Cys-Sec dyad, 
where Sec is the three letter code for selenocysteine.       
  Sec containing proteins are found in prokaryotes, eukaryotes and archea but are 
relatively rare. In humans for example, only 25 proteins have currently been identified 





synthesis but requires a unique cis element and several unique trans factors as the codon 
for Sec is the normal termination codon UGA (Figure 11). The cis element is the 
selenocysteine insertion sequence (SECIS), a specific stem loop structure in the mRNA. 
This sequence is adjacent to the UGA codon in prokaryotes but is found in the 3΄ 
untranslated region for eukaryotes (see (102) and references therein). It also requires 
specialized enzymes for the assimilation and incorporation of selenium into Sec (103, 
104). The process is metabolically expensive for the organism and challenging to 
manipulate for the scientist interested in recombinant protein production.  
Bacterial formate dehydrogenase was the first enzyme where selenium was 
demonstrated as required for function (105). Several other enzymes, such as glutathione 
peroxidase and 5΄ deiodinases, were also identified as requiring selenium though the 
nature of the selenium moiety was not clarified, as reviewed by (106). Enoch et al. 
demonstrated that selenium was likely a covalent component of formate dehydrogenase 
and suggested the presence of a selenol (107). In the following year, selenium was 
identified as incorporated into the selenoprotein A, an essential component of clostridial 
glycine reductase, as Sec by the Stadtman group at the NIH (108). The same group did 
not identify Sec as the penultimate residue in human TR (63) until 20 years later. Sec 
since has been shown to be essential to the function of mammalian TR. Replacement of 
the catalytic Sec residue in the mammalian enzyme with a Cys residue results in a large 
decrease (>100 fold) in catalytic activity towards the cognate substrate Trx (109). Sec is 






Selenium is an essential trace element and the key component of many 
biologically important selenocompounds (110, 111) but is also toxic at increased 
concentrations (112, 113). The incorporation of Sec into mammalian TR is responsible 
for expanding the substrate range to include peroxides and lipid peroxides (31, 114), 
ascorbate (30, 115) and seleno-compounds such as selenite (116), methylseleninate (117), 
selenodiglutathione (118). This indicates TR may also be a component of the systems 
regulating the seleno-metabolite pool (17). Sec incorporation into TR has also been 
proposed to be one of the links between selenium supplementation and cancer prevention 
(119) as reviewed by (120).  
While the incorporation of Sec may provide a selective advantage by expanding 
the substrate range, it is not required to catalyze the reduction of Trx by TR. One such 
example is DmTR, which has high activity towards its cognate Trx and good activity 
towards Trx from E. coli (11, 65).  Gromer et al. (65) proposed that it is the flanking 
serine residues in the Ser-Cys-Cys-Ser (SCCS) motif that aid in deprotonating the 
catalytic Cys residue, thus obviating the need for Sec in this enzyme.  Yet, when the Ser 
were mutated to Gly residues, only a 7 fold reduction in activity is observed. This is not 
the >100 fold loss in activity for the mutation of Sec to Cys in the mammalian enzyme or 
for mutating the catalytic His in GR (88) or PfTR (93, 101). The same authors proposed 
the conserved His (His106) as a second catalytic acid/base in DmTR (65). However, 
mutation to Phe or Gln results in a similar 3-7 fold loss in activity as observed in the 
mutation of the C-terminal Ser residues (121) with the author’s interpretation being that 
His106 was not essential to catalysis. Clearly there is a discrepancy in the interpretation 





Caenorhabditis elegans (CeTR2), which has a Gly-Cys-Cys-Gly (GCCG) motif, also has 
a high activity towards E. coli Trx (122). In CeTR2 there are no flanking Ser residues. 
This is also the case for PfTR which has the sequence Gly-Cys-Gly-Gly-Gly-Lys-Cys-




 The question this project addresses can be phrased based on the direction of the 
approach. For those who focus on mammalian TR, the question is “why selenocysteine?” 
Taking into consideration that other higher eukaryotes catalyze the same reaction without 
Sec, the question may also be phrased “why not cysteine?” It has been long inferred that 
Sec is essential for mammalian TR due to the low pKa of Sec (~5.2) making it a better 
nucleophile than Cys which has a pKa ~8.3 (125). This is the motivation behind the 
proposal of Gromer et al. on the function of the flanking Ser for DmTR (65). However 
CeTR and PfTR function without flanking Ser residues. It is also hypothesized that the 
low pKa of Sec makes it a better leaving group. However the catalytic acid/base essential 
to both half-reactions is conserved throughout the protein family, so why would the low 
pKa of Sec be essential to mammalian TR but not DmTR, CeTR2, or PfTR? The purpose 
of this project is to develop a testable hypothesis for the requirement of Sec in 
mammalian TR. 
Aim 1 is to develop a method for semisythetic production of mammalian TR. The 
method produces the full-length enzyme from a ligation of two separately produced 





terminal amino acids is produced for the first module as a TR-intein-chitin binding 
domain fusion protein in E. coli. The second module is a C-terminal peptide with a N-
terminal Cys. Using this method we will generate C-terminal mutants for structure 
function studies to investigate the positional and sequence dependence of Sec in the C-
terminal active site for mammalian TR. This method will allow 1) avoidance of the 
complications of Sec incorporation by recombinant methods, 2) the incorporation of 
synthetic functional groups or site-specific radiolabels that would not be possible using 
standard recombinant techniques. 
Aim 2 is to develop a new technique, termed peptide complementation, to study 
the mechanism of TR. This technique will allow us to look at a specific reaction in the 
catalytic cycle in a manner similar to that of GR. The formation of an intramolecular 
disulfide bond between vicinal residues like that of the C-terminus of TR results in an 
eight-membered ring. This ring must be opened (reduced) by the FAD-associated active 
site during the catalytic cycle. Oxidized tetrapeptides, equivalent to the C-terminus of TR 
are used as substrate for the truncated form of TR missing the final three residues. These 
tetrapeptides are reduced by the FAD-associated active site just as GSSG is reduced by 
the same active site in GR. This approach will allow us to determine the activity of Cys-
Cys and Cys-Sec peptides in this step of the catalytic cycle for correlation to activities of 
the semisynthetic mutants. 
Aim 3 is to determine the crystal structure of DmTR for comparison to 
mammalian TR. The NMR structures of the tetrapeptides established as substrates for the 
truncated TR are modeled into the active site by orientation of the Cys residues to the 





is expected to correlate to the biochemical data collected from Aims 1 and 2 and develop 





Figure 2. Glutathione reductase family cognate substrates. 
Substrates of the Glutathione Reductase family of pyridine nucleotide disulfide 
oxidoreductases. The substrates are labeled with the shown redox state in parentheses. 
Diglutathione (GSSG) (34), trypanothione (37), and dihydrolipoyl (129) are small 
molecule substrates while thioredoxin (Trx) (130) is a ~12 kDa protein. The reversible 











Figure 3. Diagrammatic representation of GR structure. 
Glutathione reductase on the left is compared with thioredoxin reductase on the right. 
Each homodimer is assembled in a head to tail fashion. Each monomer has a N-terminal 
FAD domain, a central NADP domain, and a C-terminal dimerization domain. The 
conserved FAD-associated active site disulfide is indicated in gray. The GR substrate 











Figure 4. Ribbon diagram of GR and TR. 
(Top) Ribbon diagram of glutathione reductase (34) showing the FAD (ruby), the bound 
GSSG (blue), catalytic residues (red). (Bottom) Ribbon diagram of mouse thioredoxin 
reductase 3 (35) showing the FAD (ruby), the bound NADP (black), catalytic residues 
(red), the arrows indicate the 16 amino acid C-terminal extension. The N indicates the N-






Figure 5. Multiple sequence alignment (C-terminal). 
Multiple sequence alignment generated by Clustal W (131) of the C-terminal 
dimerization domain with either the PDB ID or accession number in parentheses. The 
sequences are glutathione reductase (GR) from H. sapiens (PDB 1GRA), GR from E. coli 
(PDB 1GER), Thioredoxin reductase (TR) 2 from H. sapiens (Q9NNW7), TR1 from R. 
norvegicus (PDB 1H6V), TR3 from M. musculus (PDB 1ZKQ), TR1 from C. elegans 
(AF148217_1), TR3 from C. elegans (NP_498971.1), TR from P. falciparum 
(NP_704777.1), TR1 from D. melanogaster (AF301144_1), TR from A. mellifera 
linguistica (AAP93583.1), TR from A. gambie (CAD30858.1), mercuric reductase 
(MerA) from B. licheniforms (CAC14663.1), dihydrolipoamide dehydrogense (LipDH) 
from H. sapiens (EAL24389.1), trypanothione reductase (TryR) from T. congolense 








Figure 6. Multiple sequence alignment (FAD Domain). 
Multiple sequence alignment generated by Clustal W (131) of the FAD domain with 
either the PDB ID or accession number in parentheses. The sequences are glutathione 
reductase (GR) from H. sapiens (PDB 1GRA), GR from E. coli (PDB 1GER), 
Thioredoxin reductase (TR) 2 from H. sapiens (Q9NNW7), TR1 from R. norvegicus 
(PDB 1H6V), TR3 from M. musculus (PDB 1ZKQ), TR1 from C. elegans 
(AF148217_1), TR3 from C. elegans (NP_498971.1), TR from P. falciparum 
(NP_704777.1), TR1 from D. melanogaster (AF301144_1), TR from A. mellifera 
linguistica (AAP93583.1), TR from A. gambie (CAD30858.1), mercuric reductase 
(MerA) from B. licheniforms (CAC14663.1), dihydrolipoamide dehydrogense (LipDH) 
from H. sapiens (EAL24389.1), trypanothione reductase (TryR) from T. congolense 
(AAA30258.1). The alignment shows the FAD binding motif (Top) and conserved FAD-








Figure 7. The FAD domain topology. 
(Left) The Rossman Fold of the FAD-Binding Domain from rat thioredoxin reductase 1 
(36). The conserved GxGxxGx(17)D/E is Gly19 to Gly23 as the phosphate binding motif 
and D-42 to coordinate the ribose of the adenosine. This is the Top panel of the alignment 
in Figure 6. (Right) The topology diagram of the domain shows arrows indicating strands 
and columns indicating helicies. The N indicates the NADP domain and the red arrow 











Figure 8. Spectral properties of flavin. 
Spectral characteristics of the flavin moiety of Old Yellow Enzyme in various redox 
states taken from (74). The inset is of the human glutathione reductase taken from (76) in 
the oxidized form (1), NADPH reduced (2), and sodium borohydride reduced (3). The 
spectral characteristics of the reduced GR under normal conditions do not resemble that 
of the reduced flavin. It best represents a mixture between the oxidized and the anionic 
semiquinone. The shoulder at 540 nm (inset) is the charge-transfer complex between the 









Figure 9. The catalytic cycle of GR. 
The Catalytic cycle of Glutathione Reductase. The steady state cycles between Eox and 
EH2. From Eox to EH2(B) is the reductive half-reaction. From EH2(B) back to Eox is the 
oxidative half-reaction. The colors for each enzyme species represent the characteristic 
wavelength: the oxidized enzyme is yellow (440 nm – 460 nm), the FADH- - NADP+ 
charge-transfer complex is shown in blue (670 nm), and the thiolate-FAD charge-transfer 
complex is shown in red (525 nm – 540 nm). The GSSG substrate is shown in green, the 
















Figure 10. The catalytic cycle of TR. 
The Catalytic cycle of Thioredoxin Reductase. The steady state is though to cycle 
between EH2 and EH4. From Eox to EH4(B) is the reductive half-reaction. From EH4(B) 
back to EH2(B) is the oxidative half-reaction. The enzyme species color code is as shown 
in figure 9. The C-terminal disulfide and the catalytic acid/base from Chain B are shown 






Figure 11. Docoding of the UGA codon. 
Eukaryotic decoding of the UGA codon for the cotranslational incorporation of 
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Figure 12. Representation of semisynthetic TR. 
Semisynthesis of mammalian thioredoxin reductase. Selenoproteins are difficult to 
produce recombinantly due to the complicated cellular machinery, which must be 
manipulated for decoding of the UGA Sec codon. Semisythesis produces the wild type 
enzyme by the ligation of two modules via a thioester intermediate: 1) the truncated form 
of the enzyme missing the three C-terminal amino acids and 2) the synthetically produced 
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Here, we report the development of an alternative method for producing an active 
mammalian TR containing selenocysteine. This method uses expressed protein ligation to 
create a semisynthetic TR. TR contains selenocysteine in a C-terminal tripeptide with a 
Cys-Sec-Gly sequence, where the Sec residue is the penultimate amino acid (63). The 
location of the Sec residue in the C-terminus (Figure 12) makes TR an ideal candidate 
for semisynthesis. Our strategy for producing a semisynthetic TR is shown in Figure 13. 
Introduction to Semisynthesis.  
The term semisynthesis refers to the production of a functional entity, a single 
polypeptide chain enzyme for example, from two or more separately produced 
components. There are three categories of semisynthesis: 1) native chemical ligation 
(NCL), 2) expressed protein ligation (EPL) which is intein mediated, and 3) 
complementation. Unlike the first two techniques (127), complementation is a non-
covalent association of the components. The best example of complementation is the 
production of functional ribonuclease from two separate polypeptide chains achieved by 
Richards (134). This technique will be addressed in Chapter 4.  
The ligation methods both require the formation of a thioester intermediate at the 
C-terminal end of the N-terminal fragment, which is attacked by the N-terminal Cys of 
the C-terminal fragment. In native chemical ligation, the thioester is generated by 
synthetic means whereas in expressed protein ligation (Figure 14) the thioester is 
generated at the junction of a fusion protein. The fusion protein contains the N-terminal 





protein junction by the N-terminal Cys of the intein. Like complementation, this 
technique has also been used successfully with ribonuclease (135), as well as for 
producing modified potassium channels (136, 137), and to investigate cell-signaling 
mechanisms (138) using modified phosphoproteins. 
The intein is a naturally occurring self-splicing protein element found in several 
simple organisms such as certain bacteria as well as single-cellular eukaryotes (139). 
Analogous to RNA self-splicing introns, which join two flanking exons, the intein 
catalyzes the ligation of two flanking protein segments (140). This reaction is catalyzed 
via formation of a thioester intermediate formed by the N-terminal Cys of the intein. 
Upon ligation of the segments, the intein is released, as reviewed in (141). 
Most often the two ligation techniques are used independently to assemble two 
fragments, as we have used with EPL to produce semisynthetic TR. However, the two 
methods can be used is combination to perform a two-step ligation product from three 
fragments (Figure 15). This has been utilized for the insertion of a fluorescent probe in 
between the Src homology domains 2 and 3 of a protein tyrosine kinase (142). In this 
method, the C-terminal domain  (containing an N-terminal Cys) is produced 
recombinantly and purified. The label to be inserted is incorporated into a short, 
synthetically produced peptide. This peptide includes three features: a C-terminal 
thioester, the incorporated label, and a N-terminal factor Xa protease sequence.  This 
peptide is mixed with the C-terminal domain to form the first ligated product by NCL. 
The product is treated with the factor Xa protease generating a new N-terminal Cys. The 
N-terminal domain is produced as the intein fusion protein of which the new N-terminal 








Peptide Synthesis.  
Fmoc-selenocysteine(pMob)-OH was synthesized as reported previously(127, 
128). This derivative of Sec was then used to make the Cys-Sec-Gly tripeptide (CUG) or 
the Ac-GCUG tetrapeptide using solid-phase peptide synthesis as described (143). 
Peptide were purified by preparative HPLC from the Shimadzu Corporation (Kyoto, 
Japan) and verified by Matrix Assisted Laser Desorption Time of Flight Mass 
Spectrometry on a Voyager DE PRO Workstation from Applied Biosystems 
(Framingham, MA). A comprehensive list of materials used in this dissertation is 
available in Appendix B.   
Mutagenesis and Transformation.  
DNA primers were purchased from Integrated DNA Technologies Inc. 
(Coralville, IA) for the mutation of the Sec residue (encoded by TGA) at position 489 to 
cysteine (encoded by TGT) (mutant Sec489Cys). A comprehensive list of PCR primers 
used in this dissertation is available in Appendix C. The template used was plasmid 
pTR3, which contained the full-length sequence of the mouse thioredoxin reductase-3 
gene (mTR3 GenBank accession number AF171053) was a generous gift from Vadim N. 
Gladyshev. Mutagenesis was performed by PCR on the GeneAmp PCR System 2400 
from Perkin-Elmer Life Sciences Inc. (Boston, MA) using Vent DNA polymerase. The 
PCR product was purified using the QIAquick purification kit from Qiagen (Valencia, 
CA) according to product instructions. The PCR product containing the mutated sequence 
was inserted into the pTYB3 plasmid (New England Biolabs) by restriction digestion 
with Nco I and Sap I for 2 h at 37 C followed by purification with a Qiagen spin 
column, and ligation with T4 DNA ligase at 16 C for 16 h. The ligase was heat 
inactivated at 70 C for 30 min, followed by incubation at 37 C with Eco RI. Eco RI 
cuts only the plasmid that has not been ligated with the PCR insert, thus enriching the 
pool of positive clones. The resulting plasmid (pTYB3TR), also containing the gene for 
ampicillin resistance and a T7 promoter, was used to produce the thioredoxin reductase-
intein-chitin binding domain fusion protein in E. coli ER2566 cells.  
E. coli DH5  cells, purchased from Stratagene (La Jolla, CA) were transformed 
with pTYB3TR by addition of 100 ng of plasmid to 200 µL of cells and incubation on ice 
for 30 min. The cells were heat shocked at 37 C for 2.5 min and placed back on ice for 
5 min. A 1 mL aliquot of LB broth was added to the cells and the mixture incubated at 37 
C for 60 min. The cells were then plated onto LB-ampicillin agar and incubated 
overnight. Colonies were then picked and used to inoculate 3 mL of 2×YT medium 
containing 0.2 mg/mL ampicillin and grown in a shaking incubator for 24 h at 37 C. 
The plasmid was purified from culture using the Perfectprep Plasmid Mini Kit from 
Eppendorf (Hamburg, Germany). Transformants were screened by restriction analysis 
and then analyzed by agarose gel electrophoresis. Positive clones were then sequenced to 
verify the complete coding sequence of mTR3.  
An additional construct was also generated for the truncated form of TR missing 





construct is used to produce either the truncated form of the enzyme or for ligation of the 
synthetic peptides to produce the wild type enzyme by semisynthesis.  
Thioredoxin Reductase Expression and Cleavage from Chitin Resin.  
The full-length U489C mutant and a truncated version of mTR3 that was missing 
the C-terminal CUG tripeptide were expressed in E. coli ER2566 cells (New England 
Biolabs). The cell culture (6 L) contained 0.2 mg/mL ampicillin, and cells were grown at 
25 C until an OD of 0.6 at 600 nm was achieved. Expression was then induced for 6 h 
by the addition of IPTG to a final concentration of 0.5 mM. Cells were harvested by 
centrifugation and frozen at -20 C overnight. The cell pellet was homogenized with 300 
mL of buffer containing 150 mM sodium chloride (NaCl) in 50 mM 3-(N-
morpholino)propanesulfonic acid (MOPS) at pH 7.0 and probe-sonicated on ice for 20 
min. The suspension was then centrifuged at 9000 rpm in a Beckman J21B preparative 
centrifuge (JA-14 rotor) from Beckman Coulter (Fullerton, CA).  
The supernatant was gravity-loaded onto a column containing chitin resin (New 
England Biolabs) with a bed volume of 50 mL, and the column was washed with 
MOPS/NaCl until the absorbance at 280 nm of the eluant dropped to <0.1. For the 
truncated product and the full-length U489C mutant, the column was then equilibrated 
with cleavage buffer [50 mM MOPS, 150 mM NaCl, and 70 mM N-
methylmercaptoacetamide (NMA) or β-ME (pH 7.2)]. The resin-bound TR-intein fusion 










Ligation of the CUG Peptide to Truncated Construct.  
The ligation of the synthetic CUG peptide to the truncated enzyme was performed 
with concomitant cleavage from the chitin resin. The resin-bound truncated construct was 
cleaved from the chitin resin with cleavage buffer containing 12 mM peptide (305 µmol-
100 mg) added directly to the chitin column. On the basis of typical protein yields, this 
represents a 3000:1 peptide:protein ratio. For a more optimized procedure with respect to 
ligation efficiency, the same amount of peptide (in cleavage buffer) was added to the 
chitin column in which only half the total amount of protein (supernatant from 3 L of cell 
culture instead of 6 L) was loaded onto the column. For a direct comparison of our 
methods of TR production, the peptide Cys-Cys-Gly (CCG) was also ligated to produce 
the Sec489Cys mutant by semisynthesis. 
Final Purification of Enzymes.  
The protein was batch eluted from the chitin resin with 1-3 column volumes of the 
cleavage buffer, depending on preparation scale. The ligated product was dialyzed 
extensively with the MOPS/NaCl buffer at pH 7.0 with a molecular mass cutoff of 6000 
Da for removal of any unligated peptide. A separate control experiment was performed in 
which the truncated form of mTR3 was isolated in the same manner as the semisynthetic 
TR. Each step in the purification of the truncated mTR3 was the same except that 
tripeptide CUG was not added to the chitin column.  
The pooled protein fractions were prepared for the next step in the purification by 





to 7.5. Samples were then gravity-loaded onto a column containing Fast Flow 6 Low 
Substitution Phenyl Sepharose from Pharmacia-Amersham Biosciences (Uppsala, 
Sweden) with a bed volume of 60 mL. Protein was eluted from the column with a 400 
mL gradient of ammonium sulfate (from 1.0 to 0 M) with collection of 4 mL fractions. 
Collected fractions were evaluated by the absorbance at 280 nm and 460 nm, as well as 
12% SDS-PAGE. Fractions containing mTR3 were pooled, dialyzed against 10 mM 
potassium phosphate and 10 mM NaCl (pH 7.8), and gravity-loaded onto DEAE-
Sephacel from Sigma Diagnostics (St. Louis, MO) with a bed volume of 60 mL. The 
protein was eluted with a 400 mL linear gradient of NaCl (from 10 to 300 mM), 
collecting 4 mL fractions. Fractions containing mTR3 were verified by SDS-PAGE, 
pooled, dialyzed against 100 mM potassium phosphate (pH 7.4), 1 mM EDTA, and 150 
mM NaCl, and concentrated using Centriprep 10 concentrators from Millipore (Bedford, 
MA). The purification process was monitored via 12% Tris-glycine SDS-PAGE with 
Novex precast gels from Invitrogen (Carlsbad, CA) and stained as previously described 
(144).  
Determination of the Selenium Content of the Semisynthetic TR.  
Semisynthetic TR was analyzed by inductively coupled plasma mass 
spectrometry (ICP-MS) to determine the selenium content of the enzyme. The TR 
samples were in phosphate-buffered saline, and the corresponding buffer was also 
analyzed in parallel as a control. The selenium content (in parts per million) was then 





"Off-Resin" Ligation Efficiency.  
The cell extract from 6 L of E. coli cells was loaded onto a chitin-agarose column 
as described above. After being extensively washed with column buffer, the resin was 
treated with cleavage buffer to elute the protein. The eluate was concentrated as before 
and then dialyzed against 50 mM MOPS buffer (pH 7.0) with 150 mM NaCl to remove 
excess NMA. The concentrated protein sample was then divided into four aliquots. The 
CUG tripeptide was added to each of three aliquots at a concentration of 5 mM: one 
aliquot received 50 mM NMA, the second aliquot received 50 mM NADPH, and the third 
aliquot received buffer. The fourth aliquot received only buffer, contained no peptide, 
and served as the negative control. The samples were allowed to incubate at room 
temperature for 4 h, after which they were dialyzed against 50 mM potassium phosphate 
buffer (pH 7.4) containing 150 mM NaCl and 1 mM EDTA to remove excess peptide and 
reagent. After dialysis, the samples were assayed using 90 µM thioredoxin (Trx) to 
determine a specific activity.  
Enzymatic Characterization of Thioredoxin Reductase.  
The TR mutants were assayed for activity towards DTNB, Trx, and hydrogen 
peroxide as described by Arner (145). All assays were performed on a Cary 50 UV/VIS 
spectrophotometer from Varian (Walnut Creek, CA) at 25 oC, pH 7.0, and were initiated 
by addition of enzyme. Concentration of homodimeric TR was determined using the 
flavin extinction coefficient of 22.6 mM-1cm-1. Activity was monitored over two minutes 





by the Michaelis-Menten equation using KaleidaGraph 4.02 from Synergy Software 
(Reading, PA) and activities reported as moles of NADPH consumed per minute per 
mole of homodimeric TR. 
DTNB Reductase Activity.  
The DTNB assay contained 0.2 mM NADPH and 10 mM EDTA in 100 mM 
potassium phosphate. For each concentration of DTNB, activity was corrected for 
background by addition of buffer only. Activity was measured by the increase in 
absorbance at 412 nm, calculated using the extinction coefficient for TNB-, 13.6 mM-
1cm-1, and divided by two to account for the production of 2TNB- per NADPH consumed. 
The concentration of TR in the assay was 2 nM. 
Thioredoxin Reductase Activity.  
The Trx assay contained 0.15 mM NADPH, 1 mM EDTA, and 10 mg/mL insulin 
in 50 mM potassium phosphate. Activity was background corrected for each 
concentration of Trx by addition of buffer only as well as in the absence of substrate. 
Activity was measured by the decrease in absorbance at 340 nm for the consumption of 
NADPH and calculated using the extinction coefficient of 6200 M-1cm-1. The 
concentration of the semisynthetic mTR3 in the assay was 2 nM. The concentration of 
each mutant TR was adjusted to achieve a similar change in absorbance at 340 nm as that 







Peroxidase Activity.  
The hydrogen peroxide assay for semisynthetic mTR3 is formulated similar to 
that of the DTNB assay with activity measured at 340 nm and background corrected as 
with the previous assays. The concentration of semisynthetic TR in the assay was 50 nM 
and the concentration of each mutant TR was adjusted to achieve a similar change in 
absorbance 340 nm. 
Production of Thioredoxin.   
The clone containing the gene for Trx A from Escherichia coli was a gift from 
Ronald T. Raines (146) and was produced similar to methods previously described (32). 
Calcium chloride competent E. coli BL21DE3 cells were transformed with 50 ng of DNA 
and plated onto LB agar supplemented with 200 µg/mL ampicillin. Single colonies were 
used to inoculate 100 mL ampicillin-containing LB media and allowed to shake overnight 
at 37 oC. 
One liter of LB media supplemented with 200 µg/mL ampicillin was inoculated 
with 10 mL of starter culture and grown to an OD of 0.6 at 600 nm while shaking at 37 
oC in a C25KC Shaker Incubator from New Brunswick Scientific. The cells were induced 
for 3 hours at 37 oC with 0.5 mM IPTG then harvested by 10 minute centrifugation at 
10,000 rpm in a JA-14 rotor using a Model J-21B centrifuge from Beckman and pellets 
frozen at –20 oC. 
 Cells were thawed on ice, homogenized in 20 mM Tris pH 8.4 containing 1 mM 





centrifuged as above for 90 minutes and the supernatant loaded onto DEAE sephacel, 70 
mL bed volume, from Sigma-Aldrich equilibrated in the lysis buffer. After loading, the 
column was washed with buffer until the OD at 280 nm of the effluent was 0.05. The 
sample was eluted using two 400 mL gradients containing NaCl (0 mM to 0.1 mM and 
0.1 mM to 0.25 mM). Fractions were collected and evaluated by absorbance at 280 nm 
and SDS-PAGE. Fractions containing Trx were pooled adjusted to 60% ammonium 
sulfate and centrifuged as above for 60 minutes. The pellet was solubilized in a minimal 
volume of 20 mM Tris pH 8.4, 250 mM NaCl, and 1 mM EDTA. 
 A 2mL sample was loaded onto a Sephacryl S-100 HR (98 cm X 3.3 cm) gel 
filtration column from Pharmacia-Amersham Biosciences (Uppsala, Sweden) 
equilibrated with sample buffer. Collected fractions were evaluated by absorbance at 280 
nm and SDS-PAGE. The fractions containing Trx were pooled, concentrated using an 
Amicon Ultra with 5000 molecular weight cutoff from Millipore. Purity was >95% as 
judged by 15% SDS-PAGE and Trx concentration was calculated using the extinction 
coefficient at 280 nm of 13,700 M-1. 
Determination of the Mass of Truncated and Semisynthetic TRs.  
The enzymes were concentrated to 1 mg/mL in 10 mM ammonium bicarbonate 
buffer (pH 8.0). The protein samples were then spotted on a 100-well plate at various 
dilutions. A solution of sinnapinic acid at 10 mg/mL was overlaid onto the protein spots, 
and the samples were left to air-dry. A Voyager-DE MALDI-TOF mass spectrometer in 
the linear mode was then used to analyze the samples. The instrument was externally 
calibrated using BSA.  
Peptide Mass Mapping of Tryptic Fragments.  
Purified thioredoxin reductase (truncated or semisynthetic) at a concentration of 
0.3 mg/mL was digested using 10 µg/mL sequencing grade trypsin (Promega) in 150 mM 
ammonium bicarbonate at 37 C for 16 h. The digested sample was stored frozen until 
mass spectrometric analysis. Samples for MALDI-TOF were prepared by serial dilution 
in 10 mg/mL matrix, 2,5-dihydroxybenzoic acid (DHB), or -cyano-4-hydroxycinnamic 
acid (CHCA), with a 50% acetonitrile/0.05% TFA mixture as a diluent. Samples were 
applied to the MALDI plate as 1 µL spots and dried under vacuum.  
A Voyager-DE PRO Workstation (Applied Biosystems) was used to analyze 
MALDI-TOF samples. Positive ion spectra (mass + H+) were collected in reflector mode 
with an accelerating voltage of 20 000 mV and a delayed extraction time of 175 ns. Data 
were collected as the accumulated spectra containing a minimum of 10 spectra at 50 laser 
shots per spectrum. Monoisotopic masses were corrected by external calibration using 
Applied Biosystems Calibration Mixture 2: angiotensin I (1296.6853), ACTH clip 1-17 
(2093.0867), clip 18-39 (2465.1989), and clip 7-38 (3657.9294) prepared in the 
equivalent matrix. The resulting (mass + H+) data were compared to a theoretical digest 
generated using the ExPASy Peptide Mass Proteomics tool.  
Digested samples were also analyzed by LC-MS using a Thermo-Finnigan LCQ 
Deca XP Plus liquid chromatograph via ion trap mass spectrometry with peaks subjected 
to MS/MS fragmentation sequencing by collision-induced dissociation. Full MS of parent 
ions and MS/MS fragmentation data were processed using the Turbo-SEQUEST database 









fragment (SGLEPTVTGCUG), molecular formula of Se1C44H73N12O18S1 representing the 
oxidized form, was compared to the theoretical isotope pattern generated using MS-
Isotope from USCF ProteinProspector version 4.0.5.  
 
RESULTS AND DISCUSSION 
 
Expression and Purification.  
We have constructed a fusion protein that consists of mouse thioredoxin 
reductase-3, intein, and chitin binding domain. The chitin binding domain is a small 
peptide that has a high affinity for the chitin-agarose fusion, and this resin provides a high 
level of purification of the fusion protein. The fusion construct is made so that glycine 
487 of mTR3 is the amino acid at the junction between mTR3 and the intein. Addition of 
a cleavage buffer containing thiol (NMA, β-ME or DTT) causes elution of the thioester-
tagged mTR3 from the affinity column. The fusion protein appears as a band near 110 
kDa in the 12% SDS-PAGE gel. Figure 16 shows a 12% SDS-PAGE gel of pooled 
protein fractions from each step in the purification process. As the chitin resin is an 
affinity resin, the purity of the eluted mTR3 (either truncated or semisynthetic) is very 
good with only minor contaminants showing. These contaminants are removed after the 
phenyl-sepharose and DEAE chromatographic steps as shown in Figure 16. The elution 
profile for semisynthetic mTR3 for each column is shown in Figure 17.  
The purity of the truncated mTR3 is such that large crystals can be grown from 





that of the truncated enzyme as shown in Figure 16. The purity is also verified by the 
characteristic absorbance spectra of TR. Three main peaks are observed for the oxidized 
enzyme (86). The 275 nm peak is the protein peak and the 370 nm and 460 nm peaks are 
the characteristic flavin peaks. The flavin spectra are shown in Figure 18 and a summary 
of corresponding wavelengths in Table 1. For the oxidized form of the enzyme, the 460 
nm peak is expected to be larger than the 370 nm peak at a ratio of ~1.1 which is what is 
typically observed for our proteins. A purity ratio of ~8.5 for the 275 nm to 460 nm peak 
has been established for rat TR1 (109). The rat TR1 and mTR3 have similar predicted 
extinction coefficients for the protein sequence (147), 59,205 and 60,110 M-1cm-1 
respectively. Therefore, the 275 nm to 460 nm ratio should be similar for mTR3. Purified 
mTR3 also shows a 275 nm to 460 nm ratio of ~8.5.  
The purified proteins have excellent stability when stored in the final dialysis 
buffer of 50 mM potassium phosphate pH 7.4, 150 mM NaCl, 1 mM EDTA. Storage at 4 
oC shows no loss of activity for >12 months. Preparation of a 50% glycerol stock for 
storage at –20 oC showed no loss in DTNB reductase activity after 18 months. Protein 
solution is concentrated most effectively using the Millipore Amicon Ultra. The storage 
pH of 7.4 and the DEAE purification at pH 7.8 is to aid in the solubility. Concentrated 
protein stored at pH 7.0 tended to form precipitate which can partially be recovered by 
incubation with DTT. Precipitate was also observed for higher yield preps during the 
dialysis step prior to the DEAE purifcation, which was addressed by using pH 7.8 during 
this step. However, the protein must still remain dilute until bound to the column and 10 
mM NaCl is added to help prevent the precipitation. These observations lead to the 





NaCl the limit of solubility is 10 – 15 mg/ml. Increasing to 300 mM NaCl allows for 
concentration to 30 mg/ml, which was critical to the crystallographic progress in Chapter 
5.      
Selenium Content of the Semisynthetic Enzyme.  
The selenium content of the semisynthetic enzyme determined by ICP-MS was 
found to be 0.63 mol of selenium/mol of enzyme. Our yield of TR from this method was 
24 mg from 6 L (4 mg/L) of cell culture. The selenium content of the semisynthetic 
enzyme using half the bound resin of the initial trial was found to be 0.91 mol of 
selenium/mol of enzyme, with a yield of 9 mg of enzyme from 3 L (3 mg/L) of cell 
culture. By comparison, the selenium content of the recombinant mTR3 prepared by 
fusing a bacterial SECIS element to the 3' end of the gene had a selenium content in the 
range of 0.4-0.5 mol of selenium/mol of enzyme depending on the preparation (148). In 
both cases, the final preparations of enzymes are a mixture of the truncated form and the 
full-length form. The ligation efficiency can be estimated from ICP-MS analysis since the 
ligated tripeptide is the only source of selenium for the enzyme. 
DTNB Reductase Activity.  
A summary of activities for DTNB is shown in Table 2. DTNB is a small 
molecule disulfide that is a non-physiological substrate as can be seen by the high 
micromolar to low millimolar values for Km. These high values for Km are consistent with 
reports in the literature, however unlike with the substrate Trx, kcat is rarely reported for 





activity towards DTNB than a Sec to Cys mutant (109) or a C-terminal truncation (149). 
Therefore, it is rather surprising to see that all of our mutant forms have very high DTNB 
reductase activity (>60% of wild type). However, for each of the mutants, the Km is 3 to 7 
fold higher, resulting in a significant decrease in catalytic efficiency, kcat/Km. The 
semisynthetic wild type at 63% and 91% selenium incorporation have similar activities. 
The 63% incorporation has ~5% greater activity than the 91% but the higher 
incorporation has the higher kcat/Km.   
A similar phenomena has been reported for the non-selenium containing DmTR 
and PfTR. The C-terminal mutant Cys535Ala of PfTR shows 64% of wild type activity 
with ~2 fold increase in Km, while mutation of the FAD associated Cys88 has essentially 
no activity (55). The same is the case for DmTR where the C-terminal mutants display 
DTNB reductase activity with a 7 fold increase in Km (78). Unfortunately, no kcat is 
reported for DmTR of PfTR. These results are similar to what we observe for mTR3. It is 
not clear why there is such a broad range of activities for DTNB by these proteins while 
the range of activities for Trx are rather narrow. Regardless of whether there is a relevant 
value for kcat, it does provide an alternative means to semi-quantitatively assess the 
production of a functional protein for those mutants that are inactive to Trx. The 
questions regarding DTNB as a substrate for the truncated and mutant forms of TR will 
be further addressed in the following chapters.      
Activity toward Thioredoxin.  
The peptide complementation system described above led to the development of a 





of the enzyme through a peptide linkage. The semisynthetic enzyme could be constructed 
by addition of peptide CUG to the cleavage buffer, as described above. Since this peptide 
has an N-terminal cysteine residue (and is not N-acylated), the sulfhydryl group of the 
cysteine residue can attack the C-terminal thioester group of the enzyme. Rearrangement 
then occurs to the amide form (141). To test whether the peptide becomes truly 
incorporated into the enzyme, we tested the ability of the semisynthetic enzyme to reduce 
Trx. The presence of a Sec residue has been shown to be necessary to reduce E. coli Trx 
with high efficiency (109). The semisynthetic enzyme at a concentration of 2 nM 
exhibited excellent activity toward E. coli Trx in comparison to both the truncated form 
and a mutant form of the enzyme in which a cysteine residue replaces Sec489 as part of a 
full-length construct. A Michaelis-Menten plot for our semisynthetic construct in 
comparison to the Sec489Cys mutant is shown in Figure 19, and a summary of our 
kinetic data is given in Table 4. As shown in Figure 7, the Sec489Cys mutant has much 
lower activity, as would be expected and as was reported previously (109). In contrast to 
the cysteine mutant enzyme, our semisynthetic enzyme shows very high activity, with 
values of kcat ranging from 1500 to 2220 min-1, depending on the preparation. This high 
activity strongly indicates that the C-terminal tripeptide was successfully ligated to the 
thioester-tagged enzyme. The enzyme preparation with a higher kcat value resulted from 
using a higher peptide:protein ratio during the ligation and resulted with an enzyme with 
a higher selenium content (91% Se). The truncated enzyme (ending with amino acid 487 
and missing the tripeptide) has no detectable activity toward oxidized Trx. 
The thioredoxin reductase activity of our enzyme compares very favorably to the 





semisynthetic enzyme is in the range of 35-70 µM. This is 10-20-fold higher than the Km 
reported for rat TR1 with human Trx, but the sequences of the two enzymes are only 56% 
identical so some difference in Km is to be expected (the difference is between the 
cytosolic form of the rat enzyme and the mitochondrial form of the mouse enzyme). This 
is nearly identical for that observed for the originally identified human TR (24) which 
showed a 3.7 µM Km for rat Trx but 34.0 µM Km for E. coli Trx as was the case for rat 
TR1 with E. coli Trx (145, 150). As was observed for the DTNB assays, the Sec489Cys 
produced recombinantly or by semisynthesis display similar kinetic parameters. 
Comparison of the Activity of Semisynthetic TR to That of Recombinant TR.  
The activity of the semisynthetic enzyme was compared to that of the 
recombinant mTR3. The latter protein was expressed in E. coli and contained 0.5 equiv 
of selenium (148). The recombinant TR enzyme is made by fusing a bacterial SECIS 
element to the 3' end of the TR3 gene. This allows for heterologous expression of the 
recombinant enzyme in E. coli. The results in Figure 20 show that the recombinant 
mTR3 and the semisynthetic mTR3 have similar activities with both E. coli Trx and 
recombinant rat Trx2. The recombinant mTR3 has an estimated kcat of 1770 min-1. These 
data further verify that the semisynthetic method resulted in a functional TR. 
Peroxidase Activity.  
Mammalian thioredoxin reductases also exhibit hydrogen peroxidase activity. 
This activity is a characteristic feature of the mammalian enzymes because non-selenium-





(109). Figure 21 shows the results of our hydrogen peroxidase activity assays with our 
semisynthetic enzyme and the Sec489Cys mutant. The mutant enzyme has barely 
detectable hydrogen peroxidase activity, while the semisynthetic enzyme shows high 
peroxidase activity with a kcat of 71 ± 7 min-1 and a Km of 6.6 ± 0.50 mM. This rate was 
achieved with 200 nM semisynthetic enzyme present in the assay though the plot shows 
very poor saturation. The kinetic data derived from Figure 21 compare favorably to the 
data reported by Zhong and Holmgren (109) for reduction of H2O2 by human placental 
TR1. The high peroxidase activity of our enzyme provides additional strong support for 
the incorporation of the selenocysteine-containing tripeptide by our semisynthetic 
approach. 
Ligation Efficiency for Off-Resin Ligations.  
As shown in Figure 13, our method of making a semisynthetic TR makes use of 
the addition of the oxidized tripeptide to a thiol-containing cleavage buffer, which is then 
added directly to the resin-bound protein. The thiol in the cleavage buffer can either 
liberate the protein from the resin to produce a thioester-tagged protein or reduce the 
oxidized tripeptide, which in turn could directly attack the resin-bound protein and 
become incorporated as part of the polypeptide chain. Alternatively, the liberated 
thioester-tagged protein can undergo a thioester exchange reaction with the reduced 
tripeptide and then be incorporated into the polypeptide via a stable amide bond. All three 
pathways lead to the eventual incorporation of the tripeptide into the larger polypeptide 
of mTR3. The key to ligating this tripeptide to the larger polypeptide of mTR3 is keeping 





the cleavage buffer functions to effect cleavage of the resin-bound protein and also to 
keep the tripeptide reduced so that it can ligate to the liberated thioester-tagged protein.  
We compared the efficiency of the ligation when the peptide is added directly to a 
slurry of resin-bound TR and cleavage buffer to that of addition of the peptide to a 
semipurified, concentrated form of the thioester-tagged TR off-resin. Concentrated 
thioester-tagged protein was treated with either oxidized peptide or oxidized peptide with 
70 mM NMA. After dialysis to remove excess peptide and reagents, the resulting 
enzymes were assayed for thioredoxin reductase activity. The results are summarized in 
Table 5 and clearly show that the efficiency of ligation is much higher when the peptide 
is added directly to the slurry of resin-bound TR and cleavage buffer. One reason for this 
decline in efficiency when the ligation is done off-resin is that the lifetime of the 
thioester-tagged TR may be short in this protein context. Hydrolysis of the thioester 
would yield the C-terminal carboxylate form of the protein, which is unproductive with 
respect to ligation. Second, the reduced tripeptide can directly attack the resin-bound TR-
intein fusion protein with concomitant ligation. This process should be kinetically faster 
than when an intermediary thiol attacks first.  
In the absence of thiol, the CUG peptide is likely to oxidize to form the 
intramolecular selenylsulfide or dimeric peptides. Either fate will decrease the ligation 
efficiency. An interesting observation is that the NADPH ligation sample resulted in 
three fold higher activity than the buffer only ligation. This suggests that the enzyme can 
reduce the tripeptide to promote ligation. This would not be unexpected as the conserved 






Determination of the Mass of Truncated and Semisynthetic TRs.  
The mass spectrographs of the truncated and semisynthetic TRs are shown in 
Figure 22. The predicted masses of the truncated and semisynthetic enzymes are 52,857 
(carboxylate form) and 53,164 Da, respectively. The experimentally observed masses 
were 52,787 and 53,144 Da, respectively, and are in good agreement with the expected 
values. An overlay of the two spectra shows a clear mass increase due to the presence of 
the ligated peptide. The experimental mass increase of the semisynthetic enzyme is 357 
Da, which is very close to the expected mass increase of 329 Da. 
Peptide Mass Mapping of Tryptic Fragments.  
To unambiguously demonstrate that our peptide had been ligated to the C-
terminus of mTR3, we undertook a peptide mass mapping experiment. In this 
experiment, both the truncated and semisynthetic enzymes were digested with trypsin and 
analyzed by MALDI-TOF MS and ESI-MS. Figure 23 shows a peptide with a sequence 
of SGLEPTVTGCUG found in the ESI-MS experiment, which is at m/z 1169.3 
(calculated value of m/z 1169.4). The mass of this peptide corresponds exactly to the 
mass of the C-terminal peptide containing Sec. Further proof of the identity of this 
peptide is provided by a MS/MS experiment shown in Figure 24. In this experiment, the 
peptide is fragmented by collision-induced dissociation (CID), and the resulting ions 
unambiguously identify the sequence of the peptide as the peptide corresponding to the 
C-terminus. This data in combination with the enzymatic activity data indicate successful 





SGLEPTVTGCUG is very difficult using MALDI-TOF. The sequence is very is 
hydrophobic and, as trypsin cut C-terminal to Lys and Arg, is less likely to hold a 
positive charge. Should this technique be used for future analysis, the protease LysC 
would be a better choice. LysC will cut C-terminal to Lys only and the sequence 
preceding our C-terminal Fragment is Lys-Arg. Digesting with LysC would leave the N-
terminal Arg and likely improving the ionization using MALDI. Approximately 70% of 
the total peptides were identified by mass mapping (Figure 25). A summary of all of the 









Figure 13. Method for semisynthetic production of mTR3. 
Thiol-mediated cleavage of the mTR3-intein fusion construct by addition of exogenous 
thiol. The junction between mTR3 and the intein exists in equilibrium between amide and 
thioester forms. Addition of exogenous thiol causes cleavage of the target protein from 
the thioester form of the fusion protein. (B) Mechanism of incorporation of tripeptide 
CUG into the mTR3-intein fusion protein. The ligation is achieved by adding oxidized 
tripeptide to the cleavage buffer containing 70 mM thiol. The excess thiol both reduces 
the tripeptide and causes cleavage of mTR3 from the intein fusion. The reduced peptide 
can then attack the thioester-tagged protein and become stably ligated to the protein 
because of the presence of the N-terminal amino group, which enables rapid 











Figure 14. Mechanism of expressed protein ligation. 
Example of semisynthesis using expressed protein ligation utilizes a target-intein-chitin 
binding domain fusion protein. Generation of the thioester at the ligation junction is 







Figure 15. Native chemical ligation and expressed protein ligation. 
Example of Semisythesis using native chemical ligation (Ligation 1) and expressed 
protein ligation (Ligation 2) to insert a label in between two protein domains adapted 
from (142). Both protein domains are produced recombiantly, with the N-terminal 
domain produced as the intein fusion protein. The factor Xa protease cleaveage site 










Figure 16. SDS-PAGE of semisynthetic and recombinant mTR3. 
SDS (12%)-PAGE characterization of recombinant mouse thioredoxin reductase 3: lane 
1, cell culture pre-induction; lane 2, IPTG-induced cell culture; lane 3, supernatant of the 
cell lysate; lanes 4 and 8, molecular mass markers; lane 5, truncated TR cleaved from the 
intein on-resin by 2-mercaptoethanol and eluted from the chitin resin; lane 6, truncated 
TR eluted from the phenyl-Sepharose column; lane 7, truncated TR after elution from the 
DEAE column; lane 9, purified semisynthetic TR after elution from the DEAE column; 









Figure 17. Chromatographic elution profiles for semisynthetic mTR3. 
Elution profile of semisynthetic mTR3 from phenyl sepharose (■) and DEAE Sephacel 








Figure 18. Flavin spectra for semisynthetic and recombinant mTR3. 
Absorbance spectra for semisynthetic (●), Sec489Cys mutant (□), and truncated (●) 




Table 1. Spectral properties of mTR3. 
 
         λmax nm  λmax Absorbance Ratioa  
Enzyme 1 2 3 (1) / (2) (3) / (1) 
Semisynthetic 463 376 275 1.04 ± 0.11 8.55 ± 0.91 
Sec489Cys 462 375 276 1.00 ± 0.15 8.10 ± 0.22 
Truncated 463 377 276 1.11 ± 0.05 8.66 ± 0.65 
 
aRatios are averages for 3 preparations of the semisynthetic, 3 preparations of the 












Table 2. DTNB reductase activity of mTR3 semisynthetic and mutant enzymes. 
 




aTR-Gly487 856 ± 43 2.72 ± 0.43 5.2 x 103
bTRSec489Cys 794 ± 78 1.75 ± 0.41 7.6 x 103
cTR-semisynthetic Sec489Cys 908 ± 37 3.08 ± 0.32 4.9 x 103
TR-semisynthetic (63% Se) 1307 ± 102 0.59 ± 0.16 3.7 x 104
dTR-semisynthetic (91% Se) 1251 ± 71 0.46 ± 0.09 4.5 x 104
 
aThe truncated enzyme ends at Gly487 and is missing the C-terminal tripeptide. 
 
bThe full-length mutant in which cysteine replaces the catalytic selenocysteine residue 
and is produce recombinantly. 
 
cThe full-length mutant in which cysteine replaces the catalytic selenocysteine residue 
and is produce by semisynthesis. 
 









Table 3. DTNB reductase activity reported for homodimeric TR in the literature. 
 
Enzyme at (min ) -1  (mM) 
Rat TR1 native (109) 2666  
Rat TR1 native (150) 4000 
109) 126 
330 ± 36 0.7 ± 0.2 
0.66 
Rat TR1 recombinant (151) 1726 0.12 
Rat TR1 Sec to Cys mutant (  
Human TR native (149) 4000 0.08 
Human TR truncated (149) 92 4.5 
Human TR Sec498Cys (149) 34 0.7 
nopheles gambiae (152) A






Enzyme kcat (min-1) Km (µM) 
(s  M-1) 
 




a No activity No activity  TR-Gly487 NA
b 4.1 ± 0.11 49.1 ± 3.2 103
c 4.2 ± 0.24 72.5 ± 8.6 1.0 x 103
1500 ± 81 5
d  2220 ± 78 67.6 ± 6  105
e 3000   106
TRSec489Cys 1.4 x 
TR-semisynthetic Sec489Cys 
TR-semisynthetic (63% Se) 35 ± 5 7.1 x 10
TR-semisynthetic (91% Se) 5.4 x
rat TR1 35 1.4 x
aThe truncated enzyme ends at Gly487 and is missing in e. 
ch cysteine replaces the c c seleno ine residue 
and is produce recombinantly. 
ull-length mutant in which cysteine replaces the catalytic selenocysteine residue 
and is produce by semisynthesis. 
dData from optimized procedure using a higher ratio of peptide to protein as described 
under Methods. 
eTaken from (145, 150), purified from rat liver and assayed using E. coli Trx. 
 the C-term al tripeptid
bThe full-length mutant in whi atalyti cyste
cThe f
  
Michaelis-Menten plot of V /E  vs thioredoxin concentration for semisynthetic enzyme 
 a 
tic data are the average of four replicates per Trx 
n.  
Figure 19. Trx activity plot for semisynthetic mTR3. 
o T
(□) and the Sec489Cys mutant (● with insert). Both curves could be fitted to










Figure 20. Trx activity of semisynthetic and engineered SECIS produced mTR3. 
oli by using an engineered SECIS The activity of the recombinant TR produced in E. c
element (148) is represented by the circles.  The activity of the semisynthetic TR is 
represented by the squares.  E. coli thioredoxin (closed symbol) and rat thioredoxin-2 









Figure 21. Peroxidase activity plot for semisynthetic mTR3. 
Peroxidase activity of semisynthetic enzyme ( ) and the Sec489Cys mutant (●). Activity 













Table 5. Comparison of methods used to construct a semisynthetic TR. 
 





On NMA 2 1008 
Off NMA 100 48 
Off NADPH 100 27 
Off none 100 8 
aThe enzyme was assayed using 90 µM thioredoxin as substrate.  All other assay 




Figure 22. MALDI-MS of semisynthetic and truncated mTR3. 
The semisynthetic (theoretical average mass = 53,164) spectrum is in black with an 
average mass of 53,144, and the truncated (theoretical average mass = 52,857 for 
carboxylic acid, 52,944 for thioester tagged) spectrum is in light gray with an average 
mass of 52,787. The difference in mass is clearly observable. The semisynthetic spectrum 
has a shoulder, which lines up with the peak of the truncated spectrum. The peak width of 










Figure 23. ESI-MS of semisynthetic mTR3 C-terminal tryptic fragment. 
ESI-MS of the C-terminal tryptic fragment of mTR3, peptide sequence 
GLEPTVTGCUG. The peptide corresponds to the C-terminal peptide of mTR-3 
ontaining the ligated tripeptide CUG. The inset at the right is the predicted isotope 
attern for this peptide containing selenium. The mass of the peptide corresponds to the 












Figure 24. ESI-MS-MS of semisynthetic mTR3 C-terminal tryptic fragment. 
ESI-MS-MS of the C-terminal tryptic fragment of mTR3, peptide sequence 
SGLEPTVTGCUG. The peptide was fragmented by Collision-Induced Dissociation. Ions 































igure 25. MALDI-TOF of semisynthetic mTR3 digested with trypsin. 
ge mass spectrum for trypsin digest of semisynthetic mTR3. A 
few peptides are indicated for orientation. (B) Sequence coverage for the trypsin digest of 





















STRUCTURE-FUNCTION STUDIES OF THE C-
TERMINAL TETRAPEPTIDE MOTIF OF 








Figure 27. The pathway for transfer of electrons to Trx by mTR3. 
The catalytic cycle for mammalian thioredoxin reductase. This Chapter investigates 
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In the study pre  production of mouse 
mitochondrial thioredoxin reduc
the C-te ng TR 
m Drosophila melanogaster ymes can be divided chemically: 
those containing Sec and those containing Cys, and they can also be divided structurally: 
 site contains a vicinal disulfide and that which does not, Plasmodium 
group. 
The vicinal disulfide forms an eight-membered ring that must be a) opened by the FAD 
ated dithiol and b) closed after reduction of the substrate thioredoxin (Trx). Each of 
e of the ring 
increases by three atoms and likely reducing the strain. The second is proper orientation 
of the catalytic residues involved in each step. The results show that insertion of Ala 
residues between the cysteines in DmTR results 100 fold or greater decrease in Trx 
activity whereas the equivalent insertions between the Cys and Sec residues of mTR3 
results in only a 4 fold decrease.  
We have also investigated the role of the C-terminal carboxylate charge. In the 
structure of rat TR1 (36) it was suggested that the conserved position, Lys29, would form 
a salt bridge with the C-terminal carboxylate to correctly position the C-terminus for 
thiol-disulfide exchange with the N-terminal active site. A similar role was suggested for 
Arg351 from a TR-Trx complex modeling study (100). In neither case is biochemical 
evidence provided. As either Lys29 or Arg351 could serve different functions, simple 
 
sented here, we have used semisynthetic
tase (mTR3) to investigate the enzymatic dependence on 
rminal structure of the Sec-containing TR compared to the Cys-containi
(DmTR). These enzfro
those whose active
falciparum (PfTR). Here we have investigated two forms of the vicinal disulfide 
associ
the steps in the catalytic will have structural implications in two forms. Firstly is the 





utagenesis would be unable to distinguish a specific interaction. Therefore, we have 
used semisynthesis to modify the C-terminal carboxylate to a neutral carboxamide. This 
mutant shows a significant increase in catalytic activity indicating that the proposed salt 
bridge is likely not involved in catalysis. 
Finally, we have investigated the dependence on the relative position of Sec in the 
Cys-Sec dyad for mTR3. We have produced the mutant Gly-Sec-Cys-Gly (GUCG) that 
shows poor activity similar to Sec489Cys. This indicates the Sec incorporation is for a 
specific function and that the residue must be the C-terminal moiety of the dyad. This 
relates directly to the results for the Ala insertion mutants and suggests that the role of 
Sec is not in nucleophillic attack on Trx but possibly as the leaving group during thiol-




 produced by Fmoc solid phase synthesis 
as previously described (
Biosystems (Framingham, MA). Synthesis of the CUG peptide with C-terminal 
m
Peptide Synthesis.  
Selenocysteine containing peptides were
143). Peptide were purified by preparative HPLC from the 
Shimadzu Corporation (Kyoto, Japan) and verified by Matrix Assisted Laser Desorption 
Time of Flight Mass Spectrometry on a Voyager DE PRO Workstation from Applied 





Cloning and Expression of mTR3.   
Cloning and Expression of DmTR.  
The Drosophila melanogaster TR clone (accession number AF301144), was a 
generous gift from Stephan Gromer.  For production of DmTR in E. coli, we subcloned 
the cod  (via PCR amplification) into plasmid pTYB1 of the Impact 
System
resin from PE Biosystems (Hamburg, Germany) to yield the carboxamide upon cleavage 
from the resin. 
The expression, purification and semisynthesis for mutants in this section are as 
described in the previous chapter. An additional mutant of mTR3 with the C-terminal 
sequence of Ser-Cys-Cys-Ser (SCCS) was produced by mutagenesis (via PCR 
amplification). Reaction conditions and methods were as described for the GCCG mutant 
in Chapter 2. To help the reader distinguish the mTR3 mutants from the DmTR mutants 
in this study, the abbreviation mTR3 will precede the C-terminal sequence (mTR3-
GCUG for example).  
ing region of DmTR
 from New England Biolabs, to generate the TR-intein-fusion protein.  Primers 
were purchased from Integrated DNA Technologies Inc. (Coralville, IA).  Primers were 
designed for production of the full length TR containing the C-terminal tetrapeptide Ser-
Cys-Cys-Ser (SCCS488-491), a truncated TR, removing the C-terminal tripeptide CCS489-






of Vent DNA Polymerase, 2-3 mM magnesium chloride, in a volume of 
100 µL.  Each PCR was performed on a GeneAmp PCR System 2400 from Perkin Elmer 
Life Sciences, Inc. (Boston, MA) using 25 cycles with the following parameters: 96 oC 
for 45 
oli DH5α cells were made competent via the Inoue method (153) 
and the d DNA.  The culture was plated onto LB agar 
containing 200 µg/mL ampicillin and incubated at 37 oC.  Individual colonies were used 
to inoc
ein and are affinity purified from chitin agarose as described 
for the mTR3 (Chapter 2). Escherichia coli ER2566 cells were used for production of 
The PCR reaction mixtures contained 100 pg template DNA, 50 pmol of each 
primer, 2 units 
sec, 50 oC for 30 sec, and 72 oC for 180 sec.  The product was analyzed by 
analytical agarose gel electrophoresis and then purified using the QIAquick Purification 
Kit from Qiagen (Valencia, CA).  The PCR product and plasmid pTYB1 were each 
incubated with Kpn I and Nde I for 2 h at 37 oC, purified using the QIAquick kit, then 
ligated at 16 oC for 16 h using T4 DNA ligase at 37 oC. To enhance the amount of 
positive clones, the ligation was digested Sal I, a unique restriction site removed upon 
product insertion.  E. c
n transformed with 50 ng of  purifie
ulate 100 mL of LB containing 200 µg/mL ampicillin and allowed to shake at 37 
oC overnight.  Plasmids were purified using the QIAfilter Plasmid Prep Midi from 
Qiagen, screened by 1% analytical agarose gel electrophoresis, and verified by 
sequencing at the University of Vermont DNA Sequencing Facility using an ABI 3100-
Avant Genetic Analyzer. 
Production of C-terminal Mutants of DmTR.  
Each of the TR mutants from Drosophila are expressed as the TR-intein-chitin 






Thioredoxin Activity pH Optima.  
rx was tested as a function of pH for each construct. Due to the 
insolubility of insulin below pH 7.0, each assay utilized 500 µM Trx, which is 
approximately ten times greater than the calculated Km. To avoid differences in ionic 
strength
inant wild-type (WT) and mutant DmTR. The cells were transformed with 50 ng 
of plasmid, plated on LB-ampicillin plates containing 200 µg/mL ampicillin, and 
incubated at 37 °C overnight.  A single colony was used to grow a 100 mL inoculum 
culture of LB (200 µg/mL ampicillin). This culture was incubated overnight at 37 °C with 
shaking. Ten milliliters of inoculum culture was added to a 1 L baffled Pyrex Fernbach 
flask containing TB media at pH 7.0 containing 200 µg/mL ampicillin. The cells were 
incubated at 37 °C with shaking (100 rpm) until the O.D. 600 nm reached 1.0. The cells 
were then chilled on ice until the temperature decreases to 20 °C and induced by adding 
IPTG to a to final concentration of 0.5 mM followed by incubation at 20 °C overnight 
with shaking (100 rpm). The cells were harvested by centrifugation in a Beckman J21B 
centrifuge (JA-14 rotor) at 7000 X g at 4 °C for 10 min and then stored at –20 °C. Cells 
are thawed on ice and homogenized in MOPS buffer, and lysed by sonication with a 
Branson 350 Sonifier (Danbury, CT). The wild type enzyme, C-terminal sequence SCCS, 
as well as the C-terminal sequence mutants SCACS and SCAACS were released from the 
intein by the addition of NMA.  
Activity towards T
, each assay contained buffer with a final concentration of 30 mM citrate/ 30 mM 
Tris/ 30 mM phosphate adjusted from pH 5.5 to 9.5 with the exception of the GUUG 





Production of TR.  
e number of positive clones was performed with Sal I as 
there is also a Hind III restriction site in the DmTR coding sequence. The expression of 
DmTR was significantly increased in TB media versus LB media. Initial production of 
the tru
the assay was that which was used for the Trx Michaelis-Menten profile: 2nM for wild 
type mTR3 and 25 nM for wild type DmTR. The concentration for each mutant was 
adjusted to get signal similar to that of the respective wild type. Each assay contained 
0.15 mM NADPH and 1 mM EDTA. The activity was measured at 340nm and 
background corrected. The data in duplicate were normalized to the percent of maximal 
activity for each given mutant and plotted as Activity % vs. pH.  
 
RESULTS AND DISCUSSION 
 
The expression and purification methods for DmTR are identical to mTR3 with 
the exception of expression in pTYB1 rather than pTYB3. The reason for this is due to 
the presence of Nco I and Sap I restriction sites within the DmTR sequence. The 
background digest to increase th
ncated form of DmTR yielded approximately 20 mg per 6L of cell culture in LB 
media. This was also the case for mTR3 in the previous chapter. Expression in TB media 
yielded 20-30 mg per 1L of media for DmTR.  Improvement was also shown for mTR3, 
though not to the same degree (35 mg per 6L culture). Subsequently, the mutants 
produced for this study were produced in TB media as described in the methods section 





 band still remaining on 
e resin after a 24-hour incubation with cleavage reagent. Like mTR3, very little elution 
aining a cleavage reagent (lane 9). This experiment 
ielded 127 mg from 6L of cell culture (21 mg/L), with a significant amount still retained 
on the resin. Estimation from the SDS-PAGE and NaOH strip of the chitin resin indicates 
only about 50-70 % is cleaved from the intein. Cleavage of DmTR from the intein was 
also tes
A representative SDS-PAGE for expression and chitin cleavage for the wild type 
DmTR can be seen in Figure 28. Excellent solubility of the fusion protein is 
demonstrated by comparison of the lysate supernatant (lane 13) and the lysate pellet (lane 
12). For each of the cleavage reagent cocktails, the eluant and chitin retained samples 
respectively are shown. The cleavage from the intein was significantly slower than 
observed for truncated mTR3 as can be seen by the fusion protein
th
is observed with buffer not cont
y
ted from pH 7.5 to 8.5 using NMA with similar results. Yield was only slightly 
improved by sequential rounds of incubation with fresh cleavage reagent. This indicates 
that a significant amount of DmTR remains as the fusion protein. 
The truncated form of DmTR shows incomplete cleavage from the intein though 
yield in this step is not an issue due to the high level expression for DmTR. Poor cleavage 
from the intein was seen with the mTR3-SCCS mutant where the majority of the fusion 
protein was retained on the resin. The yield for this mutant was only 2.6 mg for 6L of cell 
culture. This is less than 10 % of a typical yield for mTR3. These results indicate that a 







Sufficient activity towards the natural substrate Trx has been shown to be 
dependent on the incorporation of selenocysteine as the penultimate reside in mammalian 
thioredoxin reductase. During the TR catalytic cycle the conserved cysteine position is 
expected to form a disulfide intermediate with Cys52 and the Sec489΄ being the leaving 
group. Upon resolution of this disulfide and release of the C-terminus in its reduced form, 
the Sec residue is then the attacking nucleophile to form a mixed selenylsulfide with the 
substrate Trx. The re-oxidation of the C-terminus occurs by attack on the mixed 
selenylsulfide by the resolving cysteine, Cys488΄, of mTR3 with subsequent release of 
reduced Trx. As shown in Table 6, sequence containing the C-terminal carboxamide was 
considerably more active (3010 min ) than the naturally occurring carboxylic acid (2220 
min ). The mTR3-GUCG shows similar activity to the Sec489Cys mutant, 8.3 and 4.1 
min  respectively, while the mTR3-GUUG mutant was even less active. As indicated by 
the % peptide incorporation, the ligation reaction is less efficient with Sec as the residue 
attacking the thioester. However, even with correction for the incorporation, the GUCG 
and GUUG mutants would still have poor activity compared to wild type. Mutation to the 
SCCS motif of DmTR shows similar activity to that of the Sec489Cys mutant. Similar 
results for the human homologue of TR have recently been reported (154). Interestingly, 
the insertion mutants mTR3-GCAUG and mTR3-GCAAUG show ~25 % of the wild-
type activity. 
 The TR activity was also evaluated as a function of pH. Both the leaving group 
and nucleophillic effects of the conserved selenocysteine position would be expected to 








contrib e on pH. The optimal pH for activity 
towards Trx was determined for each of the TR mutants from pH 5.5 to 9.5 with the 
exception of the mTR3-GUUG mutant, which required pH 10.0 to reach maximal 
activity, Figure 29. Both the wild type carboxylic acid and carboxamide achieve optimal 
activity at a similar pH, approximately 7.0 to 7.2, whereas the Sec489Cys mutant has a 
pH optimum between pH 8.0 and 8.5. This is as would be expected due to the pK  of 5.3 
for selenocysteine and the pK  of 8.2 for cysteine where at physiological pH the cyteine is 
expected to be protonated and therefore less nucleophillic than the selenol.  
This is not the observation for the mTR3-GUCG mutant where the interchange 
position and the resolving position have been reversed. For this mutant, there is only a 
modest alkaline shift in pH optima to which is still 0.5 units lower than the Sec489Cys 
mutant Figure 29. This mutant has a similar k  for Trx as the Sec489Cys at pH 7.0. The 
pH optima measured during the steady state is likely to include a contribution from the 
resolving position of TR. In the wild-type enzyme with high activity, the low pK  of the 
selenol is expected to dominate the reaction profile. In the mutants with lower activity, 
however, we begin to see the impact of the resolving position. This may explain the 
lower pH optima for the mTR3-GUCG mutant where the selenocysteine is in the 
resolving position.   
 The insertion mutants mTR3-GCAUG and mTR3-GCAAUG have activity 
towards Trx that is 25 % of wild type and is 100 fold higher than the mTR3-GUCG and 
mTR3-GCCG mutants yet the pH optima is near 8.0. In these insertion mutants, the 
relative position of the Sec has been retained. If the Sec position were responsible for 
interchange with the N-terminal active site, one would expect poor activity for the Ala 









Low Activity TR Trx Assays and Consumption of NADPH.  
in Chapter 1 
(Figure
H2 and EH4. Therefore, TR mutants that have poor activity towards 
insertion mutants. Therefore the insertion is expected to impact: 1) the strain on the ring 
formed when in the C-terminus exists in the oxidized state and; 2) the potential distance 
the TR resolving cysteine would be from the mixed selenylsulfide between Sec489΄ and 
Cys32 of Trx. It would be expected that both of these difference would affect the rate but 
a shift in the pH optima higher than that of the mTR3-GUCG mutant is unexpected.  
The proposed general mechanism of a high Mr TR was discussed 
 10) in terms of individual steps. Theses steps are an extrapolation of the 
mechanistic investigations of GR where each type of enzyme has two distinct cycles; the 
reductive half reaction where NADPH is consumed to reduce the enzyme and the 
oxidative half reaction where the enzyme is re-oxidized by consumption of the cognate 
substrate GSSG or Trx. GR converts between the oxidized form (Eox) and the 2-electron 
reduced form (EH2) to complete both cycles, with consumption of 1 equivalent of 
NADPH. The addition of the C-terminal active site for TR requires an additional 
equivalent of NADPH (EH4) to be consumed before Trx can be reduced. Fully reduced 
GR (EH4) or TR (EH6) form extremely slowly. This means that TR in the steady state 
will cycle between E
Trx could still consume 1-2 equivalents of NADPH per subunit in the pre-steady state. 
And this is what we typically observe in the Trx assay.  
Enzymes that have the lowest activity towards Trx require 1-2 µM enzyme in the 
assay. When performing these assays, it was observed that there was a significant change 






mutants produced are functional enzymes.  
Activity for DmTR Towards Thioredoxin.  
 using reagents other than thiol. 
The ne
due to the high TR concentration resulting in a visible consumption of NADPH at the 
start of the assay followed by the slow decrease in absorbance during the assay even in 
the absence of Trx. While this analysis is at best semi-quantitative compared to the 
establish stopped-flow method developed by Arscott, Ballou, and Williams (78, 93), it 
does provide support in addition to the DTNB reductase activity that the low act
The Trx activity of the mutants produced for DmTR can be seen in Table 7. 
Residue insertions between the Cys residues for DmTR results in a loss of activity that is 
much greater than that observed for mTR3. Both mutants show poor activity towards Trx 
with a 142 fold and 328 fold decrease from wild type respectively. Nearly identical 
results are observed for mitochondrial TR from Caenorhabditis elegans (CeTR2) where 
Ala insertions result in >100 fold loss in activity (Brian M. Lacey, personal 
communication). This is in stark contrast to the equivalent mutations for mTR3 which 
still retain ~20 % of the wild type activity. The only difference is the Sec residue for 
mTR3. 
Modifications of the C-terminal carboxylate of DmTR show a gain in activity 
similar to that of mTR3 (Adam P. Lothrop, personal communication). These 
modifications are produced by cleavage from the intein
utral hydroxamic acid produced by cleavage with hydroxylamine shows a 70 % 
increase in activity, which is in agreement with that observed for the mTR3 carboxamide 





Comparison of DTNB Reductase Activities.  
The small molecule disulfide DTNB has long since been used for quantification 
of free thiols in proteins (155) as well as to evaluate thiol-disulfide exchange reactions 
(156), a
s the semisynthetic wild-type enzyme has a kcat of 1251 ± 71 min-1. The increase 
in kcat f
this increase in activity along with a 3 fold decrease in Km. The pH optima for the wild 
type enzyme is ~8.0 with no change observed with either of the carboxyl variants. An 
alkaline shift is observed for the Ala insertions mutants (Figure 30) as it is for the 
equivalent mutants from CeTR2. These trends are identical to that observed for mTR3. 
s is the process catalyzed by TR. The DTNB can therefore be a substrate for the 
C-terminal selenylsulfide (or disulfide) and the N-terminal disulfide as discussed in the 
previous chapter. Each TR in this study displays significant DTNB reductase activity. We 
also observe product inhibition with very high concentrations of DTNB near 5-10 times 
Km. In both mTR3 and DmTR, the presence of the C-terminus imparts an increase in 
DTNB reductase catalytic efficiency (kcat/Km) compared to the truncated forms of TR. 
This is consistent with that observed for DmTR (78) as well as PfTR (55). 
For our truncated form of the mTR3 (Table 8), we observe a kcat of 856 ± 43 min-
1 wherea
or the wild type represents the activity of the selenylsulfide relative to the N-
terminal disulfide towards DTNB. The truncated enzyme also exhibits a 6-fold increase 
in Km compared to wild type. This increase in Km is also seen in full length Sec489cys 
mutant as well as the semisynthetic mTR3-GUCG and mTR3-GUUG forms. The 
semisynthetic variants mTR3-GCAUG and mTR3-GCAAUG do not display a significant 






(55). The mTR3 low efficiency group (5000-20,000 s-1 M-1) includes the truncated, 
SCCS, GCCG, GUCG, and GUUG mutants. The wild-type efficiency group (~5 X 104 s-1 
M-1) in
ces in both kcat 
and kcat  
f
type. The DTNB reductase data can therefore be divided into three groups on the basis of 
catalytic efficiencies (kcat/Km) that correlate to Trx activities. The mutants with poor Trx 
activity have the lowest DTNB efficiency and are similar to truncated mTR3. This is 
attributed to the increase in Km, as has been reported for mutants of DmTR (78) and PfT
cludes both Ala insertion mutants where the single Ala shows an increase in 
efficiency while the double Ala shows a decrease. The C-terminal carboxamide mutant is 
distinguished as a high efficiency group at 105. This is >10 fold higher than the wild-type 
group when the 28 % lower selenium content of this mutant is taken into consideration. 
The non-selenium containing DmTR also show excellent activity towards DTNB 
with results that very similar to the mTR3. The respective wild type enzyme has a kcat of 
178 min-1 for truncated DmTR (Table 9), and 157 min-1 for the wild type. This is ~12 % 
the activity seen in the wild-type mTR3. The DmTR also shows the decrease with the 
double Ala insertion seen with the mTR3. There are much smaller differen
/Km for DmTR. For mTR3 there is a 10 fold increase in kcat/Km while it is only 3
old for DmTR. The kcat/Km for DmTR fall into the low efficiency group for mTR3. The 
C-terminal hydroxamic acid of DmTR shows a significant increase in efficiency (2.3 
fold). The thiocarboxylate does show an increase in activity but has identical efficiency 
when compared to wild type. These results are in agreement with what is observed in the 
mTR carboxamide mutant where neutralization of the negative charge at the C-terminus 





Peroxidase activity is characteristic of the selenium incorporation in mammalian 
TR. Like DTNB, it also has been reported to have a low millimolar Km and is likely not a 
physiologically relevant activity for the enzyme. Peroxidase activity plots for thioredoxin 
reductase previously reported show poor saturation, but have been limited to 
concentrations less than 5 mM (109, 157). In performing this study, we have expanded 
the profile to 70 mM peroxide. The results demonstrate poor saturation for wild type 
carboxylic acid and carboxamide forms, Figure 31A, as well as the Sec489Cys mutant. 
We previously reported an activity of 71 ± 7 min  with a Km of 6.6 ± 0.5 mM when 
limiting the analysis to substrate concentrations equivalent to that reported in the 
literature (5 mM). After repeated extended analysis of the wild type carboxylic acid 
enzyme we observe an activity of 1753 ± 257 min  with a Km of 259 ± 33 mM using 50 
nM enzyme while the carboxamide has an activity of 3204 ± 351 min  with a Km of 167 
± 17 mM using 20 nM enzyme. A result of this is the extremely low kcat/Km which are 
>100 fold lower than DTNB (Table 10).   
As shown in Figure 31B, the profiles of the mTR3-GCAUG, mTR3-GCAAUG, 
and mTR3-GUCG mutants display a different property, however. The mTR3-GUCG 
required 500 nM enzyme and shows only about 10-15 % of the activity of the mTR3-
GCAUG and mTR3-GCAAUG yet each of these three mutants shows saturation with 
estimated Km values of 14 mM, 6.8 mM, and 9.5 mM respectively. These values are in 
better agreement with previous estimations. The interpretation of this data is that, while 
the wild type enzyme displays significant peroxidase activity, a definitive estimation of 








kinetic present a reasonable binding event. 
We have, however, produced three mutants with mM K  values are more indicative of a 
potential binding event. A complete summary of the data is shown in Table 10. 
We also tested the impact of the concentration of the co-substrate NADPH on the 
saturation profile. Figure 32A shows the wild-type enzyme while Figure 32B shows the 
mTR3-GCAUG mutant. With each enzyme the saturation curve remains the same from 
25 µM to 500 µM NADPH. In each case, progress curves remained linear over the 2-
We have determined that the Cys containing enzymes are far more dependent on 
vicinal residues to reduce the natural substrate Trx than the Sec containing enzyme from 
mouse. The mTR3 mutant GCAUG retains 16 % k  while the GCAAUG mutant has 22 
% k  when compared to the wild type sequence GCUG. This is in stark contrast to that 
which is observed for DmTR and CeTR2. The SCACS mutant for DmTR shows a 142 
fold reduction in k  while the GCACG mutant for CeTR2 shows a 145 fold reduction in 
k . For the double insertion, the SCAACS mutant for DmTR shows a 328 fold reduction 
in k  while the GCACG mutant for CeTR2 shows a 90 fold reduction in k .  
parameters is not applicable, as it does not re
m
minute time frame of the assay with the exception of the 25 µM NADPH at the 70 mM 
peroxide concentration where linearity was maintained to 90 seconds due to eventual 
depletion of NADPH. A characteristic of the DTNB assay is the observation of product 
inhibition at very high concentrations of substrate. This effect is not observed with H2O2 
as substrate.   












Ala insertions shift to pH 8.5 (Figure 30). The kinetic parameters are 
determined at pH 7.0 where wild type mTR3 activity is at maximum. At this pH, the 
mTR3 Ala insertions still retain 70-80 %, the wild type DmTR 80%, and the DmTR Ala 
insertio
or electron 
transfer from the FAD associated disulfide by salt bridge formation during the catalytic 
Insertion of each Ala is expected to progressively reduce the ring strain. In a 
strictly chemical sense, the larger ring is expected to be more stable and therefore less 
reactive in the ring opening step. In contrast there should be a corresponding d
barrier to closing the ring. Therefore, the combined impact of ring strain on the 
enzymatic cycle is currently unknown and cannot be eliminated as a contributing factor 
in each of these enzymes. This is demonstrated by the partial loss of activity for the 
GCAUG and GCAAUG mTR3 mutants. However, simply replacing a single selenium 
atom in the ring with a sulfur atom, as is the case for both DmTR and CeTR, results in a 
far greater loss of activity.  
The pH optima determined for wild type mTR3 is 7.0-7.2 while the Ala insertions 
both shift to pH 8 (Figure 29).  Similarly, the wild type DmTR has an optimal pH of 7.5 - 
8.0 while the 
n 50 %, of their respective maximal activities. However, the shift in the pH 
optima is only responsible for ~20 % of the loss in activity for the Ala insertions and 
adjusting solution pH will not recover the 100 fold loss in activity observed in DmTR and 
CeTR2. The identical shift in pH optima indicates an alteration in the same chemical step, 
but one that is compensated for by the presence of selenium in mTR3. 
We have also investigated the impact of the negative charge of the C-terminal 
carboxylate in catalysis. It was suggested from the crystal structure of the rat enzyme that 






r than 3 fold increase in activity with a 10 fold increase in 
kcat/Km 
From interpretation to hypothesis. 
36). If this were a critical interaction, alteration of the C-terminus would be 
expected to decrease activity. A second possibility is that the proximity of the negative 
charge to electron and proton transfer during the enzymatic cycle would be inhibitory to 
the enzyme in which case neutralization should result in an increase in activity. Our 
results indicate that a specific interaction with, or charge contribution from, the C-
terminal carboxylate does not appear critical to catalysis.  
Neutralization of the carboxylate charge by conversion to the carboxamide for 
mTR3 results in a 2-fold increase in activity towards Trx and peroxide. The carboxamide 
mutant also shows a greate
with the negatively charged substrate DTNB. These results are similar to what is 
observed for small peptide thiol-disulfide exchange reactions investigated by Zhang and 
Snyder (158) where the 5-fold decrease in thiol disulfide exchange for the peptide Cys-
Cys compared to Cys-Cys-Ala was hypothesized to be due to the proximity of the 
carboxylate to the thiol. Substitution to a hydroxamic acid for DmTR also shows the 
same behavior as the mTR3 carboxamide with both Trx and DTNB as substrate. The lack 
of a change in pH optima indicates a chemical step has likely not been altered in these 
variants but possibly involves product release. 
Under Michaelis-Menten conditions we are looking at the impact on the overall 
rate of catalysis. Therefore, the effect we see reflects the combination of the ring opening 
step, where the C-terminus becomes reduced, and the ring closing step, where the C-





TR and CeTR Ala mutants as 
there is
 ring formation by reducing the energy 
barrier of ring strain but becomes less favorable due to the increase in conformational 
entropy. Again, these forces should impart the same effect for each of the equivalent TR 
mutant
reactions (Figure33); 1a) formation of a mixed disulfide with 1b) the first leaving group, 
and 2a) resolution of the mixed disulfide with 2b) a second leaving group. If these 
mutants perturb the structural position for formation of either mixed disulfide, one would 
expect equivalent results. Since this is not what is observed for the Ala insertions, we can 
eliminate 1a from each step as the critical point for mTR3. However, this assumption 
must be made cautiously due to the low activity for the Dm
 no biochemical data that defines which Cys forms the interchange with the FAD 
associated active site.  
Once the mixed disulfide is formed, the structural position should be fixed and 
therefore its role as the second leaving group should also be retained, eliminating 2b from 
each step. Resolution of the mixed disulfide in the ring opening step is performed by the 
FAD-associated resolving cysteine Cys62 and is conserved, therefore 2a for the ring 
opening can also be eliminated.  
Even after elimination of several reactions for mTR3 we are still left with the first 
leaving group (1b) of the ring-opening step and the TR-Trx mixed disulfide resolution 
(2a) of the ring closing step. The ring closing step is governed by two opposing forces. 
For example, insertion of residues will favor
s in the absence of an altered chemical step. Therefore it is the hypothesis here that 
disruption of the vicinal disulfide results in the alteration of an enzymatic chemical step, 
likely during ring opening, that is more critical in the non-selenium containing TRs. This 





size of the ring. With such the dramatic loss of activity of mTR3 with Trx for the GUCG, 
GCCG, and SCCS mutants in comparison to the GCAUG and GCAAUG mutants, we 
conclude that maintaining the Sec C-terminal to the Cys is essential but the vicinal nature 
is not.  
Each of the mTR3 mutants produced in this study that display poor Trx and H2O2 
activity fall into the DTNB efficiency category (due to increased Km) characteristic of the 
truncated enzyme. This is important, as it is likely that the DTNB reductase activity of 
these mutants is attributed to the FAD-associated active site. We suspect that the loss of 
activity
c of a chemical reaction and not enzymatic. Therefore, 
one wo
  
 for these mutants is due to the poor reduction of the C-terminal motif by the 
FAD-associated active site (the ring opening step). This is best demonstrated by the 
mutant mTR3-GUCG. This mutant also has significantly lower Trx and H2O2 activity 
with DTNB efficiency similar to that of the truncated enzyme. The peroxidase activity 
profile of the WT is characteristi
uld expect the peroxidase reaction to be independent of the Sec position once the 
C-terminal motif is reduced. Since a significant loss in activity is observed 
experimentally, this further supports our interpretation that the C-terminal motif is not 
efficiently reduced in the ring opening step. Combining the results from all three 
substrates (Trx, DTNB, and H2O2) we hypothesize that the Sec is required for mTR3 in 
the ring opening step, likely functioning as the leaving group (LG1 in Figure 33). We 
will address this hypothesis experimentally in the next Chapter.  
  
 Figure 28. SDS-PAGE of DmTR cleavage from the intein. 
Evaluation of DmTR cleavage from the intein with alternative reagents by 10 % SDS-
after NMA elution; lane5, ammonium sulfide eluted; lane 6, resin after ammonium 
lane 9, buffer only eluted; lane 10, resin after buffer elution; lane 11, blank; lane 12, pre 
stripping with 1% SDS. Eluant lanes represent equivalent loads, as do the lanes 
 
 
PAGE. Lane 1, loaded chitin resin; lane 2, markers; lane3, NMA eluted; lane 4, resin 
sulfide elution; lane 7, hydroxylamine eluted; lane 8, resin after hydroxylamine elution; 
induction; lane 13, cell lysate supernatant. Resin-bound samples are evaluated by 










Table 6. Semisynthetic mTR3 thioredoxin reductase activity. 
 
Enzyme kcat (min-1) Km (µM) % Peptide Incorporation 
kcat / Km 
(s-1 M-1) 
amTR3-G- COO- No activity No activity NA NA 
bmTR3-GCCG- COO- 4.1 ± 0.11 49.1 ± 3.2 NA 1.4 x 103
mTR3-SCCS- COO- 5.0 ± 0.06 32.0 ± 8.8 NA 2.6 x 103
cmTR3-G-CUG- COO- 2220 ± 78 67.6 ± 6 91 5.5 x 105
dmTR3-G-CUG-CONH2 3010 ± 351 41.6 ± 5.0 63 1.2 x 106
mTR3-G-UCG- COO- 8.3 ± 0.1 36.1 ± 1.3 32 3.8 x 103
TR3-G-UUG- COO- 1.2 ± 0.1 64.8 ± 16.1 10 3.1 x 102m
mTR3-G-CAUG- COO- 350 ± 14 20.8 ± 3.5 100 2.8 x 105
mTR3-G-CAAUG- COO- 501 ± 41 34.9 ± 10.0 100 2.4 x 105
erat TR1 3000 35 NA 1.4 x 106
aThe truncated form of the enzyme missing the C-terminal tripeptide Cys-Sec-Gly. 
bThe full length mutant Sec489Cys.  
cThe wild type enzyme, the hyphen between Gly and Cys (or Sec) indicates production 
by semisynthesis. 
dThe wild type enzyme produced by semisynthesis with a C-terminal carboxamide. 
eTaken from (145, 150), purified from rat liver and assayed using E. coli Trx. 
  
Figure 29. Trx activity as a funct H for mTR




ion of p 3. 
key indicates the C-terminal sequence following mTR3-G; -GCUG-COO (●), -GCUG-













Table 7. DmTR thioredoxin reductase activity. 
 
Enzyme kcat (min-1) Km (µM) 
kcat / Km
(s-1 M-1) 
aTR-S- COO- No activity No activity NA 
bTR-SCCS- COO- 299.4 ± 7.4 173.3 ± 8.1 2.9 x 104
cTR-SCCS-CONHOH 513.3 ± 33.3 172.5 ± 21.7 5.0 x 104
dTR-SCCS-COS- 491.9 ± 19.6 67.8 ± 7.3 1.2 x 105
TR-SCACS- COO- 2.12 ± 0.3 298.3 ± 58.0 118 
TR-SCAACS- COO- 0.91 ± 0.2 166 ± 58.0 91 
aThe truncated form of the enzyme missing the C-terminal tripeptide Cys-Cys-Ser. 
bThe wild type enzyme.  
e produced as the C-terminal hydroxamic acid (Adam P. Lothrop). 
carboxylate (Adam P. Lothrop). 
cThe wild type enzym
dThe wild type enzyme produced as the C-terminal thio
 
  
Figure 30. Trx activity as a function of pH for DmTR. 
Activity towards thioredoxin as a function of pH for the DmTR mutants SCCS (●), 











Table 8. DTNB reductase activity for semisynthetic mTR3. 
 
Enzyme kcat (min-1) Km (mM) 
kcat / Km
(s-1 M-1) 
amTR3-G-COO- 856 ± 43 2.72 ± 0.43 5.2 x 103
bmTR3-GCCG- COO- 794 ± 78 1.75 ± 0.41 7.6 x 103
mTR3-SCCS- COO- 627 ± 18 0.53 ± 0.19 2.0 x 104
cmTR3-G-CUG- COO- 1251 ± 71 0.46 ± 0.09 4.5 x 104
dmTR3-G-CUG-CONH2 3284 ± 133 0.13 ± 0.02 4.2 x 105
mTR3-G-UCG- COO- 751 ± 51 1.61 ± 0.34 7.8 x 103
3
1010 ± 26 0.26 ± 0.03 6.5 x 104
mTR3-G-CAAUG- COO- 999 ± 44 0.43 ± 0.08 5.6 x 104




aThe truncated form of the enzyme missing the C-terminal tripeptide Cys-Sec-Gly. 
bThe full length mutant Sec489Cys.  
cThe wild type enzyme, the hyphen between Gly and Cys (or Sec) indicates production 
by semisynthesis. 







Table 9. DTNB reductase activity for DmTR. 
Enzyme kcat (min-1) Km (mM) 
kcat / Km
(s  M ) 
 
-1 -1
aTR-S-COO- 178.0 ± 7.0 0.75 ± 0.09 4.0 x 103
bTR-SCCS-COO- 157.0 ± 12.4 0.22 ± 0.07 1.2 x 104
TR-SCACS-COO- 187.5 ± 17 0.20 ± 0.06 1.7 x 104
TR-SCAACS-COO- 94.9 ± 4.1 0.25 ± 0.03 6.3 x 103
aThe truncated form of the enzym e C-t tide Ser. 
b . 
e missing th erminal tripep  Cys-Cys-




Michaelis-Menten plots in the form of Vo/ET vs. hydrogen peroxide concentration for 
 reductase C-terminal mutants. Panel A shows the wild-type 
enzyme with the naturally occurring carboxylic acid (●) and wild-type peptide sequence 
roduced as a C-terminal carboxamide (□). Panel B shows the GCAUG (●), GCAAUG 
















Table 10. Peroxidase activity of semisynthetic mTR3. 
 
Enzyme kcat (min-1) Km (mM) 
kcat / Km
(s-1 M-1) 
amTR3-G- COO- 2.1 ± 0.04 65 ± 17 0.5 
bmTR3-GCCG- COO- 19.6 ± 1.9 233 ± 36 1.4 
cmTR3-G-CUG- COO- 1753 ± 257 259 ± 46 113 
mTR3-G-CUG-CONH2 3204 ± 351 167 ± 24 320 
TR3-G-CAAUG- COO- 125 ± 6.4 6.8 ± 1.2 306 
d
mTR3-G-UCG- COO 19.7 ± 0.8 9.5 ± 1.2 35 
mTR3-G-UUG- COO
-
- 6.0 ± 0.7 47 ± 10 2.1 
mTR3-G-CAUG- COO- 284 ± 3.9 14 ± 0.7 338 
m
aThe truncated form of the enzyme missing the C-terminal tripeptide Cys-Sec-Gly. 
The full length mutant Sec489Cys. 
cThe wild type enzyme, the hyphen between Gly and Cys (or Sec) indicates production 
by semisynthesis. 




Figure 32. Peroxidase activity as a function of NADPH concentration. 
activity for s c mTR DPH co trations at 25 
 200 µM (○ ×  is wild , B is the C-
Hydrogen peroxidase emisyntheti 3 with NA ncen
µM (●), 100 µM (□),
terminal mutant GCAUG. 









Figure 33. Steps of thiol-disulfide exchange for TR. 
The steps for thiol-disulfide for thioredoxin reductase that occurs between the FAD-
associated active site (Cys57, Cys62) and the C-terminus, the ring opening step. 1a) Upon 
reduction of the FAD-associated disulfide, Cys57 will form the interchange (IC) with a 
Cys from the C-terminus with the other Cys being the first leaving group (LG1) which 
would need to be protonated (1b) if Cys but would not be if Sec. The resolution step, 2a 
and 2b, should proceed as in the GR cycle. The same general cycle subsequently occurs 
between the C-terminus or TR in the reduced state and the oxidized disulfide of Trx and 















 TRUNCATED THIOREDOXIN REDUCTASE AS A 
DISULFIDE OXIDOREDUCTASE INVESTIGATED 






Figure 34. Peptide complementation of TR. 
Peptide Complementation of thioredoxin reductase (TR). Oxidized tetrapeptides 
orresponding to the C-terminal c
fo
active site motif of TR are substrates for the truncated 











In the course of developing the semisynthetic method, we also attempted to 
produce a non-covalent semis  a technique called peptide 
complementation. In such a system, a truncated enzyme missing part of its active site can 
b  
complements nt example 
f peptide complementation is the S-protei /S-peptide system developed by Richards 
(134).  In our peptide complementation system, we demonstrate that tetrapeptides in the 
oxidized form equivalent to the C-terminal active sites of both mTR3 and DmTR, only 
weakly complement thioredoxin reductase activity but behave more like substrates for the 
truncated enzymes. This is reasonable because as part of the enzyme, the oxidized form 
of the C-terminal tetrapeptide must be reduced by the N-terminal redox-active dithiol 
during the enzymatic cycle. A disulfide bond formed between vicinal Cys-Cys (or Cys-
Sec) residues results in the formation of an eight-membered ring and this assay examines 
the kinetics of the ring opening step that occurs during the enzymatic cycle of TR. The 
observation that oxidized tetrapeptides can serve as substrate for the truncated forms of 
onstrate that TR, like GR, may be considered a disulfide oxidoreductase where its 
33 of Chapter 3). We observe that for each of the peptides assayed, DmTR showed higher 
ctivity than mTR3. There is also a dramatic dependence for Sec in the second position 
demonstrated by mTR3 but not DmTR.    
 
ynthetic TR by using
e restored to full or partial activity by exogenous addition of a synthetic peptide that
 the active site with the missing amino acids. The most promine
o n
TR dem
own C-terminus is the cognate substrate (Figure 35). Using this assay we can isolate the 








were prepared by Fmoc solid-phase peptide synthesis and oxidized to the monomeric 
MALDI-TOF mass spectrometry using a Voyager-DE PRO from Applied Biosystems 
mTR3 using conditions similar to the DTNB assay and enzyme concentrations were 
corrected for background in the absence of enzyme as well as in the absence of substrate, 
to the uniqueness of this system, we have reported the activity values for each peptide as 
o T
 
tested in comparison with the ligated 
isynthetic mTR3 as only three amino acids out of a total of 490 are missing from the 
M
Activity of truncated TR towards C-terminal Tetrapeptide Substrates.   
Tetrapeptides Ac-GCUG(ox), Ac-GCCG(ox), Ac-SCUS(ox), and Ac-SCCS(ox) 
form using a newly described procedure for making disulfide bonds on-resin (143).  The 
peptides were purified by preparative HPLC and verified as intramolecular disulfides by 
(Framingham, MA).  The peptides were treated as substrates for the truncated DmTR and 
adjusted to get a signal at 340 nm as is seen in the thioredxin (Trx) assay.  Activity was 
measured by the decrease in absorbance at 340 nm for the consumption of NADPH, 
and plotted as mole of NADPH consumed per minute per mole of homodimeric TR. Due 
the slopes of the plot of V /E  vs. peptide concentration. Each peptide assayed is then 
evaluated as a fold difference in slope when compared to another peptide.   
 
RESULTS AND DISCUSSION 






e. Peptide Ac-GCUG was synthesized and tested for its ability to 
complement” the truncated enzyme missing tripeptide CUG. This tetrapeptide is N-
acylated and begins with a glycine residue and as such, cannot ligate to the thioester-
tagged enzyme produced from the intein fusion. Variations of the Trx assay were 
perform
Truncated TR as a Disulfide Reductase.   
Preliminary results demonstrated that the oxidized tripeptide Cys-Sec-Gly-
hen added to the assay mixture containing NADPH and 




ed in which Trx, insulin, or both were missing from the assay. The results of 
these experiments are summarized in Table 11 and demonstrate that the selenium-
containing peptide was required for NADPH consumption. The function of the insulin in 
the assay is to provide a source of oxidant for Trx so that the concentration of the 
oxidized Trx remains high during the course of the assay. When Trx was absent, the 
oxidized form of the peptide was reduced by the truncated form of the enzyme, resulting 
in the consumption of NADPH. The results in Table 1 show that more NADPH is 
consumed when both Trx and insulin are present in the assay mixture. The transiently 
formed enzyme/peptide complex may reduce Trx, or the resulting reduced peptide may 
reduce Trx. These results indicate that the peptide is primarily acting as a substrate for 
the truncated enzyme, rather than forming a reconstituted enzyme as in the S-protein/S-
peptide complex (134). 
OH(ox) is a substrate for mTR3 w
tr
 by the enzyme, is likely the result of minimal binding contacts in this 





G/GCUG) would not have a significant difference in Km as a 
result of the substitution of a selenium atom for a sulfur atom. The data demonstrates a 
dramatic difference in the rate of peptide turnover in this step of the reaction mechanism 
betwee
homologous peptide CCG(ox), the activity is reduce to 0.81 min-1, indicating that the ring 
opening step is greatly affected by the replacement of a selenium atom with a sulfur 
atom.  
We subsequently tested oxidized tetrapeptides as substrates for both DmTR and 
mTR3 so that we could fully examine the effect of flanking residues on either side of the 
Cys-Cys or Cys-Sec dyad.  We tested the tetrapeptides: Ac-GCUG(ox), Ac-GCCG(ox), 
Ac-SCCS(ox), and Ac-SCUS(ox) (all as the oxidized, monomeric-cyclic peptides) as 
substrates for the truncated enzymes.  A summary of the kinetic data for ring opening is 
given in Table 12 with the plots shown in Figure 37. Comparing Ac-GCUG(ox) to Ac-
GCCG(ox) demonstrates that there is a 308 fold decline in activity in mTR3 and only a 
36.2 fold decrease for DmTR. The ratio of ring-opening rates for the peptides Ac-
SCUS(ox) and Ac-SCCS(ox) with mTR3 is 511 fold while the equivalent comparison is 
only 5.65 fold with DmTR, Table 13. Since the assays do not reach saturation, 
differences in Km must still be taken in consideration when comparing Ser and Gly 
containing peptides. However, it is reasonable to assume that the equivalent peptide pairs 
(SCCS/SCUS and GCC
n the two enzymes. There is a 10 to 100 fold greater dependence on the Sec 
residue for mTR3 compared to DmTR for these peptide pairs.      
Prior to the cloning of DmTR, the peptide Ac-GCAUG(ox) was assayed in 
comparison to Ac-GCUG(ox) for truncated mTR3 (Figure 38). For this peptide, the Sec 





tide Ac-GUCG(ox). The peptide was not completely purified therefore a value for 
direct c
 Indication of a Critical Leaving Group Effect for mTR3.  
p because of the strong 
electro
difference for this pair GCUG/GCAUG was only 8.4 fold, which is minor in comparison 
to the 308 fold for GCUG/GCCG with mTR3. Preliminary results were also obtained for 
the pep
omparison to the other peptides is not possible. However, the crude peptide was 
assayed with both mTR and DmTR with no difference in activity observed between the 
two enzymes. Neither mTR nor DmTR showed activity to the disulfide substrates cystine, 
homocystine, or GSSG.  
Finally, we also assayed peptides containing the non-protein D-isomer of cysteine 
substituted individually for the two positions. There was no activity observed for Ac-
GCDCLG(ox) or Ac-GCLCDG(ox) for mTR3. DmTR (Figure 39) showed a 3 fold 
decrease in activity for Ac-GCDCLG(ox) compared to Ac-GCCG(ox) and no activity for 
Ac-GCLCDG(ox). This difference in activity observed by a stereo-isomer substitution 
indicates there is an additional structural component impacting the ring opening step. 
The data in Chapter 3 demonstrates that the truncated forms of both enzymes can 
catalyze the reduction of the disulfide DTNB.  An explanation of why DTNB is a 
substrate for TR but cystine is not has been partially addressed by Ascott and coworkers 
(94) in applications with the mixed disulfide R-S-S-TNB (TNB-S is 5-thio-2-
nitrobenzoate).  In this example, TNB-S- will be the leaving grou
n withdrawing properties of the 2-nitrobenzoate group. Such mixed disulfides are 
also easier to break than a typical disulfide bond because they are highly polarized.  This 









relative to Cys (C-terminal) is retained. It can therefore be hypothesized that the necessity 
for Sec in mTR3 is its function as the leaving group in the ring opening step. 
Correlation to C-terminal Structure-Function Results.  
between glutathione and TNB-S- (G-S-S-TNB) is a substrate for GR with kinetic isotope 
effects indicating a single proton transfer step as rate limiting (95). The interpretation of 
this data is that the departing GSH would require protonation but the TNB-S- would not. 
Therefore, we posit that DTNB is a substrate for TR due to the very low pKa (4.75) of the 
leaving group thiol that is formed upon reduction of this disulfide (159). 
The exact same situation exists in the peptide Ac-GCUG(ox), which has a low 
pKa leaving group (Se) a
ue to the polarization in the bond conferred by the Se atom. By comparing the rate 
of reduction of peptide Ac-GCUG(ox) vs. peptide Ac-GCCG(ox) by the truncated mTR3, 
this large difference in the rate of ring opening between these two peptides can be 
understood in terms of leaving group pKas. This is further supported by the 8.4 fold 
decrease in ring opening for the GCUG/GCAUG pair compared to the 308 fold decrease 
for the GCUG/GCCG pair for mTR3. In the Ac-GCAUG(ox) peptide, the Sec posi
A comparison of full-length TR activities determined by the steady-state Trx 
activity and the data for the ring opening step assayed with the truncated TR is shown in 
Table 14. Taking into consideration that the data from the two methods are derived rather 
differently, there is a remarkable level of agreement between the two methods. For 
DmTR, the GCUG/GCCG and SCUS/SCCS pairs correlate 20% and 30% of the loss in 





he Sec to Cys in 
mTR c
A second possibility is that the reaction cycle requires a second catalytic base 
which is functional in DmTR but non-functional or absent in mTR3. For example, one 
base w
there a greater fold difference in ring opening than observed in Trx activity. For mTR3, 
the fold difference in activity for the GCUG/GCCG pair for Trx is 292 and ring opening 
is 308. This near identical result is also observed for the GCUG/GCAUG pair with 6.3 
and 8.4 fold difference in activity observed by the methods respectively. From this 
analysis, we hypothesize that the loss in Trx activity upon mutation of t
an be attributed to the reduction in the rate of ring opening. 
While these results from the two methods are in agreement, and peptide 
complementation data lead us to a leaving group effect hypothesis, the question of why 
still remains. Why would Sec be required as a leaving group if the catalytic base is 
conserved in TR? A simplified interpretation would be that DmTR has a functional 
catalytic base but mTR3 does not. However, the well-established model based on 
mechanistic studies with GR and recently with TR from Plasmodium falciparum (93), 
indicate that the catalytic His is essential for multiple steps in the reaction cycle (see 
Figure 10 of Chapter 1). Therefore, if mTR3 did not have a functional base it should 
have little or no activity regardless of whether it contains Sec or not.  
ould be required for protonation of the first leaving group and another for 
protonation of the second leaving group that is generated upon resolution of the 
interchange mixed-disulfide. Based on sequence alignments, this residue was proposed to 
be His106 in DmTR (65). However, this residue is also conserved in mammalian TRs, 
and mutation of His106 to Phe in DmTR results in only a 3 fold reduction in activity 





oposed function of Ser 
acting 
 will examine this 
questio
 
considering its activity towards the Cys-Cys cyclic peptides. The same conundrum exists 
for GR where GSSG is a substrate but cystine activity is poor (160) even though both 
molecules are intermolecular cysteine disulfides.  
There is also an interesting observation when considering the Ser and Gly 
containing sequences for the two enzymes. DmTR shows no preference for SCCS or 
GCUG with either assay method yet mTR3 does. Based on the pr
as a general acid/base in the DmTR motif (65), there should be better agreement 
between the two enzymes. The peptide complementation data shows minor rate 
enhancement by replacing Gly with Ser in a Cys-Cys or Cys-Sec peptide indicating some 
potential functionality of the Ser residues. However, there is still no explanation as to 
why the SCCS motif cannot replace the GCUG motif in mTR3, as they appear 
interchangeable for DmTR. It also does not explain why the effect Sec has with both 
methods for mTR3 and why it is muted in DmTR. Our conclusion is that there is a 
structural difference between mTR3 and DmTR, other than the C-terminal tetrapeptide 
motif, responsible for the requirement for Sec in mTR3. Chapter 5










Using oxidized tetrapeptides equivalent to the C-terminal motif of TR as substrates for 
the truncated enzyme we are able to look at steps in the catalytic cycle in a manner 
equivalent to GR, TryR or LipDH and their cognate substrates (34, 37, 130). The 
tetrapeptides are the cognate substrate in the peptide complementation assay. 





Table 11. Summary of TR/Ac-GCUG peptide acomplementation kinetics. 
 




TRGly487 + + + 4.20 ± 0.60 
TRGly487 + - - 2.25 ± 0.21 
TRGly487 + - + 1.96 ± 0.086 
TRGly487 + + - 2.60 ± 0.062 
aEnzyme assays were performed in a volume of 600 µL containing 100 mM potassium 
phosphate buffer, pH 7.0, 1 mM EDTA, with 8.4 µM enzyme.  Other assay components 
are as indicated in the table. 
bIndicates that the truncated form of the enzyme ends at residue 487. 
monitoring the loss of NADPH at 340 nm. cThe rate is calculated by 
 
 
s observed as the concentration of tripeptide increases in the 
assay.  The truncated enzyme could not be saturated with tripeptide due to solubility 
tide turnover were 
calculated by measuring the slope of a plot of NADPH consumption (in min-1) vs peptide 
 
Figure 36. Peptide complementation of mTR3 with CUG(ox). 
Rate of reduction (ring opening) of oxidized tripeptide CUG(ox) with truncated mTR3.  
A linear increase in activity i
limits of the peptide under the assay conditions. The rates of pep














rate in min-1/mM)    
 Ac-SCCS(ox) Ac-SCUS(ox) Ac-GCCG(ox) Ac-GCUG(ox) 
bmTR3-G 0.21 107.3 0.06 18.5 
cDmTR-S 57.0 (271)d 322.6 (3) 2.4 (40) 87.0 (4.7) 
aThe rate of peptide turnover was determined at pH 7.0 in potassium
escribed in the methods.  The relative activities for the individual peptides are the slopes 
 phosphate buffer as 
d
from the titration curve in min-1/mM. 
bMouse mitochondrial TR missing the C-terminal tripeptide Cys-Sec-Gly. 
cDrosophila melanogaster TR missing the C-terminal tripeptide Cys-Cys-Ser. 
dThe ratio of rates (fold difference) between DmTR-S and mTR3-G are given in 


















Table 13. Ratio of peptide turnover rates for the truncated TRs. 
 
nzyme 
US/SCCS GCUG/ CG S 
a R3-G c511 308 mT 88.1 3.5 5.8 
b 5.65 36.2 .5 7 DmTR-S 1 23. 3.7 
aMouse mitochondrial TR missing the C-terminal tripeptide Cys-Sec-Gly. 
nce) between the peptide pair. 
bDrosophila melanogaster TR missing the C-terminal tripeptide Cys-Cys-Ser. 
cThe ratio of rates (fold differe
  
Figure 37. Rate of ring opening for tetrapeptides(ox). 
Rate of reduction (ring opening) using oxidized tetrapeptides as substrates for truncated 
enzymes DmTR (solid) and mTR3 (dashed).  (A) Peptide Ac-GCUG(ox) as substrate; (B) 
Peptide Ac-SCUS(ox) as substrate; (C) Peptide Ac-GCCG(ox) as substrate; and (D) 











Figure 38. Rate of ring opening Ac-GCAUG(ox) for mTR3. 
Rate of reduction (ring opening) using the oxidized tetrapeptides Ac-GCUG(ox) (solid) 
and Ac-GCAUG(ox) (dashed) as substrates for truncated mTR3. The Activity for the Ac-
GCUG(ox) was 14.0 while the Ac-GCUG(ox) activity was 1.66. This results in an 8.4 








TR. Figure 39. Rate of ring opening for Ac-GCDCLG(ox) with Dm
Rate of reduction (ring opening) using oxidized tetrapeptides as substrates for truncated 
DmTR. The peptide Ac-GCCG(ox) as substrate is shown in black. The peptide Ac-










Table 14. Rates of ring opening step compared to full-length TR activities. 
 
Peptide pair DmTR eDmTR-S mTR3 fmTR3-G 
 bFull length Ring Opening Full Length Ring Opening. 
GCUG/GCCGa c7.5 36.2 292 308 
SCCS/GCCG 7.5 23.7 0.7 3.5 
GCUG/SCCS 1 1.5 435 88.1 
8.4 GCUG/GCAUG N.D.d N.D. 6.3 
aThe DmTR full length data is taken from (65). 
bActivities from thioredoxin assay. 
cThe numbers represent the ratio of each pair. 
dNot determined. 
eMouse mitochondrial TR missing the C-terminal tripeptide Cys-Sec-Gly. 







CHAPTER 5.  
 
THE CRYSTAL STRUCTURE OF THIOREDOXIN 
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Figure 40. The crystal structure of mTR3. 
The homodimeric structure of the mTR3 with a zoom of the key conserved catalytic 
components NADPH (blue), FAD (yellow), and N-terminal disulfide from chain A 
(green backbone). The Glu-His pair from chain B (orange backbone) is also shown. The 
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In ord ires Sec but 
TR fro
crystal ptide 
sequence Cys-Cy e X-ray crystal 
structure of mouse mitochondrial TR (mTR3) in the truncated for (missing the C-terminal 
 
ed 
iglutathione bound to GR as a template. DmTR has a more open tetrapeptide binding 
enzyme and accommodates peptide Ser-Cys-Cys-Ser(ox) in a cis 
n 






er to explain why mammalian thioredoxin reductase (TR) requ
m Drosophila melanogaster (DmTR  we have solved the X-ray 
 structure of DmTR in the truncated form (missing the C-terminal tripe
s-Ser) at 2.4 Å resolution. We have also solved th
) can utilize Cys,
tripeptide Cys-Sec-Gly) at 2.25 Å resolution, though refinement is not complete. The 
NMR structures of the oxidized tetrapeptides used in the peptide complementation
studies were oriented in the active site of both mTR3 and DmTR using oxidiz
d
pocket than the mouse 
conformation that allows for protonation of the leaving group Cys by His464′. I
c
mammalian redox-active tetrapeptide Gly-Cys-Sec-Gly to a trans conformation. This 
places the Sec residue further away from the conserved catalytic histidine residue into a 
position unsuitable for protonation. The analysis here explains why DmTR can function 









300 mM NaCl and 1 mM EDTA then concentrated to 26 mg/mL.  Crystals were grown at 
containing 6 µL protein, 3 µL reservoir, and 1 µL of 10 mM NADP.  Crystals (280 x 100 
crystal in reservoir solution containing 4 % increments of ethylene glycol for 4 min per 
ir solution containing 150 
M MES pH 5.5, 2 % ethylene glycol, and 23 % PEG 6000.  Hanging drops were 8 µL 
 size with 5 µL of protein, 2 µL of reservoir, and 1 µL of 10 mM NADP.  Crystals 
1000 x 240 x 240 µm) were fully grown in 1 to 3 days. Cryoprotection was achieved by 
ipping the crystal in reservoir solution containing either a final concentration of 36 % 
EG 6000 or 25 % ethylene glycol for 5 minutes. 
 
M
Crystallization of TR from Drosophila.   
Purified DmTR was dialyzed against 10 mM potassium phosphate pH 7.4 with 
20 oC using the hanging drop diffusion method with a reservoir solution containing 200 
mM succinate pH 5.5 and 22 % PEG 6000.  Hanging drops were 10 µL in volume 
x 100 µm) were fully grown in 5 to 7 days. Cryoprotection was achieved by dipping the 
step until a final concentration of 20 % was achieved. 
Crystallization of TR from Mouse.   
Purified mTR3 was dialyzed against 10 mM potassium phosphate pH 7.4 with 
300 mM NaCl and 1 mM EDTA then concentrated to 25 mg/mL.  Crystals were grown at 










ollection, Structure Determination and Refinement for DmTR.   
Data was collected at –169 °C using a Rigaku RU-H3R generator with a copper 
rotating r. The data was indexed using DENZO 
and scaled and merged using SCALEPACK (161).  The structure of rat TR1 (PDB 
1H6V) was used for molecular replacement routines with CNS (v 1.1)(162).  The cross-
rotation search yielded a single peak 2.8σ above the mean and the translational search 
found a peak 2.1σ above the mean.  Rigid-body refinement reduced the R-factor to 0.46 
for data from 15 to 2.4 Å.  Data were processed using space group R32.  Model building 
was based upon simulated-annealing omit map interpretation with the graphics program 
O (163).  Successive rounds of refinement were performed by simulated annealing, 
occupancy, and B-factor refinement using CNS and CCP4 (164).  In the later stages of 
refinement, the position of the FAD as well as the NADP (minus the nicotinamide 
moiety aps. Final refinement was performed using 
REFMAC5 (
The oxidized tetrapeptides Ac-GCUG, Ac-GCCG, and Ac-SCCS were examined 
by NMR spectroscopy and found to exist as a population of four major conformers 
Data C
 anode on a Mar345 image plate detecto
) was determined by fitting omit m
165) in CCP4, version 5.0.2, with the entire model as a single TLS group. 
Electrostatic surface maps were computed using GRASP (166). All electrostatic maps are 
in units of kT/e where k is the Boltzmann’s constant, T is the absolute temperature, and e 
is the proton charge. The scale is –11 (red), 0 (white), and +11 (blue). Images were 
generated using PyMOL (167).    






with a vicinal disulfide bridge (58).  Each of the four conformers was placed at the 
reaction interface proximal to the conserved flavin-associated active site sequence 
CVNVGC of both DmTR and mTR3 (PDB 1ZKQ) (35).  Because of the high similarity 
between the reaction mechanisms of GR and TR, we used the orientation of oxidized 
glutathione (GSSG) in the active site of GR (PDB 1GRA, (34)) to orient the structures of 
our oxidized peptides in the active site of TR.  The disulfide bond of the oxidized 
peptides was placed in an orientation similar to that of the disulfide bond of GSSG and 
evaluated for the potential to form the interchange mixed-disulfide as well as for 
positioning of the leaving group in relation to the catalytic histidine of GR and TR.  
Additional restrictions on the placement of the peptide were imposed by the covalent 
interchange mixed-disulfide structure of GR (PDB 1GRE (34)).  Using the two GR 
structures, priority was given in the peptide modeling to the first step (interchange) of the 
GR GSSG-dependent oxidative half-reaction by super-positioning of the Cβ and sulfur 
(or selenium) atoms to the interchange cysteine of glutathione I (GSH I).   
Independent fits for each peptide were performed for both cysteines in peptide 
SCCS(ox), or the Cys and Sec in peptide GCUG(ox), as the interchange residue. 
Alignments were performed using the graphics program O (163). Each aligned 
conformation was evaluated for steric and electrostatic interactions. (Note: In the analysis 
below TR3 as deposited for the structure 
1ZKQ (
numbering system. For reference, this places Sec as residue 523 rather than residue 489.) 
 and Hondal, unpublished) as has been previously described for a similar peptide 
we have used the residue numbering for m
35) to make it easier for the reader should they wish to view the PDB file. The 





Crystallization of TR.  
 for mTR3 did 
provide
 
    
RESULTS AND DISCUSSION 
 
In the methods section of this Chapter are the optimized conditions for 
crystallization of mTR3 and DmTR. Both enzymes went through extensive screening to 
achieve these conditions and throughout the optimization process, some key trends and 
observations were made. The optimized conditions for mTR3 generated amazing crystal 
formation that could be observed in real time and resulted in extremely large crystals 
(Figure 41). It is expected that these crystals could be used for high-resolution studies in 
the future. The current space group is I4122 and the data is 95 % complete at 2.25 Å with 
the current Rfree at 31.7 % (Table 15). However, the mouse structure refinement was not 
completed, as it was published by another group (35). Therefore, this published structure 
was used for the analysis within this Chapter. The crystallization process
 the groundwork to crystallize DmTR in a much shorter time frame.  
Both enzymes have several observations in common. The primary challenge was 
hypernucleation, usually in the form of long thin needles. An example of this effect is 
shown in Figure 42. Both enzymes preferred PEG 6000 as the precipitant with lower 
molecular weight PEGs resulting in either increased hypernucleation or no development 
and higher molecular weight PEGs typically resulting in precipitation of the protein 
rather than crystal formation. This effect could also be reduced by the addition of a small 





re effective in the 1 % – 5 % range with the ethylene glycol being the most effective. 
0 could range from 18 % to 25 % with protein 
oncentrations in the 20 – 30 mg/mL range. This high concentration could be achieved by 
increasing the NaCl to 300 mM in the protein dialysis buffer prior to concentrating. 
Lower protein concentrations resulted in hypernucleation.  
zymes was a 
modifie
we
The concentration of PEG 600
c
An increase in buffer concentration was also a contributor to producing fewer and 
larger crystals. Most commercial screens begin with 100 mM buffer, but 150 – 200 mM 
buffer was most effective for these proteins. Both proteins preferred pH 5.5 and could 
form crystals with MES (preferred by mTR3), succinate (preferred by DmTR), or citrate 
as buffer. A decrease in pH inhibited crystal formation while an increase in pH increased 
the hypernucleation. Screens with pH > 7.0 most commonly resulted in either 
precipitation of the protein or conversion of the needles to clusters of a thin, hair-like 
morphology. Phosphate buffers were to be avoided as they often formed salt crystals, 
especially when screening with metal salts (often zinc or calcium) as the precipitant. As a 
result of this experience, the protein storage buffer was reduced to 10 mM phosphate 
buffer for crystallization samples. The final key to crystallization of these en
d droplet ratio. It is typical to use equal volumes of reservoir solution and protein. 
The best crystal conditions for TR used reservoir solution at half the volume of the 
protein. 
Cryoprotection was deemed necessary for diffraction of both proteins as room 
temperature capillary mounts were not suitably stable for the time to collect a data set, 
and as crystals of equal size were 1 – 2 Å higher in resolution when cryoprotected. The 





and d) 25 % ethylene glycol. 
This in
Crystal Structure of TR from Drosophila.   
VK).  Residues 487 and 488 showed weak density (Figure 44) and high B 
factors
were collected for mTR3 and three were collected for DmTR with each having different 
conditions. Each DmTR condition contained ethylene glycol but the method varied from 
a single concentration soak for 5 or 10 minutes to the 2 % incremental additions used for 
the data set resulting in the final structure. The mTR3 conditions were a) increasing to 36 
% PEG 6000, b) 30 % glycerol, c) 14 % ethylene glycol 
consistency in conditions resulted in the consumption of large numbers of crystals. 
Fortunately, crystals were not a limiting factor due to their rapid growth for both 
enzymes. However, for DmTR especially, individual droplets had a limited lifespan once 
we began removing crystals. Upon accessing a droplet, precipitation of non-crystallized 
protein began to develop and the remaining crystals mottled. An individual drop could be 
used for 1 – 2 hours before the crystals became unusable.  
A representative crystal used to collect the data is shown in Figure 43.  The 
crystal belongs to the space group R32, has a single monomer in the asymmetric unit, and 
the physiological dimer is generated by the two-fold symmetry axis. The final model has 
an Rfree of 24.7 % at a resolution of 2.4 Å (Table 16).  Truncated DmTR has 488 residues 
of which 8-488 were observed in the electron density and deposited in the final model 
(PDB 2N
, which agrees with previous results where the electron density of the C-terminal 
tail containing the second redox active disulfide of the enzyme was either very weak or 
absent in the crystal structures of rat TR1 (36) and mTR3 (35).  The overall fold is as 





n in Figure 47. DmTR shares 
55 % sequence identity with mTR3 and the majority of sequence deviations are found on 
external loops, primarily in the NADP-binding domain.  A distinct difference in the 
structu
binding central domain, and C-terminal dimerization domain (Figure 45).  The position 
of the FAD and NADP were verified during refinement by multiple iterations of 
annealing while omitting the cofactors. The enzyme has low affinity for the oxidized 
form of the NADP cofactor, which is evident in the crystal structure by the absence of 
clear density for the nicotinamide moiety and high B factors for the remaining atoms of 
the cofactor. The physiological dimer is generated by the crystallographic two-fold 
symmetry and is shown in Figure 46.   
 The DmTR model has a RMS residual of 0.84 Å upon least squares superposition 
of the Cα atoms to those of mTR3 (PDB 1ZKQ), 1.15 Å to rat TR1 (PDB 1H6V) (36), 
and 1.16 Å to human GR (PDB 1GRA) Table 17.  A structural overlay of DmTR and GR 
displaying the essential catalytic components of GR is show
res is observed at the interface where thiol-disulfide exchange takes place between 
the FAD-associated disulfide and the C-terminal disulfide motif of the adjacent monomer 
of TR.  Helix 1 (residues 19-29), helix 3 (residues 97-121) and helix 6 (residues 335-347) 
compose the Rossman fold helical face of the FAD-domain.  Helix 1 contains the 
conserved Lys26, previously suggested as a potential anchor for the carboxyl terminus 
(36), while helix 2 contains the conserved active site sequence CVNVGC.  
Helix 3 is of particular interest as the residues projecting toward the interface are 
each smaller compared to the mammalian enzymes containing Sec (Figure 48A).  For 
DmTR the residues are Val110, Thr114, and Asp117 as is the case for A. gambie and A. 





ted for Phe 
404’ fo
respectively).  While valine occupies position 110 in DmTR, bulkier amino acids Leu or 
Ile are found at the equivalent position in mammalian TRs.  Threonine114 of DmTR is 
replaced by either His or Tyr at this position in the mammalian enzyme (Figure 48B).  
The amino acid at position 117 is most variable when comparing sequences, Asp in 
DmTR, but is the bulkier Gln (numbered 146) in mTR3.  Additionally in both 
mammalian TR structures (rat TR1 (36) and mTR3 (35)), these residues also project 
towards the interface. 
In addition to residue substitutions in helix 3, the widening of the substrate-
binding site is contributed to by the rotation of helix 3 away from the active site and 
towards the dimer interface. This is analogous to the rotation observed for the equivalent 
helix, Figure 49, in trypanothione reductase (TryR) when compared to GR for 
accommodation of the larger trypanothione substrate (37, 168). The movement is limited 
to turns 2-5 of the 6-turn helix from Asn105 to Leu118 (this is Asn134 to Leu147 in 
1ZKQ) with a maximum shift of 1.68 Å at Val110. The source of this shift does not 
appear to be a function of residue substitutions at the packing between helix 2 and 3 but 
rather a packing interaction between His 106 in helix 3 and Phe404’. This residue is 
within the helix between stands 3 and 4 of the dimerization domain of the second 
molecule and follows a conserved bulky hydrophobic residue, which packs within the 
dimerization domain. While His106 is conserved in TR there is a Thr substitu
r the mammalian enzymes (Thr437’ in 1ZKQ). His 106 was previously suggested 
to be a base catalyst for DmTR (36) however results from recent mutagenesis studies 





The electrostatic surface potential calculated for DmTR was compared to that of 
mTR3, rat TR1, and GR (Figure 50). The most electropositive was GR and the most 
electronegative was rat TR1 in the general ranking (+++) GR, mTR3, (-) DmTR, (---) rat 
TR1. While the three TRs show significant differences, neither shows significant 
electropositive potential at the GR substrate-binding pocket. This is significant in three 
areas. The first is in the lack of activity for TRs toward GSSG. The GSSG molecule 
contains four acidic groups that must be stabilized in the substrate-binding pocket for GR. 
The unsuccessful attempt in the literature to convert human TR1 to a GR by a 16 amino 
acid C-terminal truncation and mutagenesis concluded the failure to do so was due to the 
negative electrostatic potential of TR (149). This conclusion is consistent with the 
equivalent observation in DmTR. 
The second point is in reference to the loss in activity reported upon mutation of 
the serines in the DmTR motif to aspartic acids (65).  Each of the mutants, DCCG, 
GCCD, and DCCD showed less activity than the GCCG mutant. Firstly, increasing the 
local negative charge surrounding and electron transfer step is expected to be 
unfavorable. Second, this introduction of local charge at an already electronegative active 
site would be less favorable as well.       
The final area of significance is the difference in DTNB reductase activity 
observed for truncated forms of TR. Truncated mTR3 shows very high DTNB reductase 
activity (856 min ), which is 60 % of the wild type activity. The truncated DmTR shows 
good activity (178 min ), which is nearly identical to the wild type activity. These results 







are in s forms of human TR1 (149) and mutant 
rat TR1 (109) which show very low DTNB reductase activity (33 min-1 and 63 min-1 
respectively) that are <5 % of the respective wild types. DTNB, like GSSG, is a 
negatively charged substrate with a carboxylic acid group on each TNB-. Upon reduction 
of the DTNB disulfide, the low pK  of the TNB thiolate means it will be unprotonated. 
This results in a significant generation of local negative charge during the reaction. The 
activity trends for DTNB with the truncated TRs follow the electronegativity trends 
where mTR3 is the least electronegative and has the highest activity while rat TR1 is the 
most electronegative and has the least activity. Similar results have been recently 
reported for the reactivity of a reversible disulfide on the surface of yellow fluorescent 
protein with GSSG (169). Engineering of a more positive electrostatic surface by 
mutagenesis of three local surface residues to Arg resulted in a 13-fold increase in the 
rate of thiol-disulfide exchange for the negatively charged GSSG but very little change in 
the reactivity towards the neutral substrate HED (2-mercaptoethanol in disulfide form) or 
the positively charge substrate cysteamine disulfide (169). Therefore, the increase in K  
for DTNB as well as the difference in activities between mutant forms of different TRs 
could be explained by comparing differences in the active site surface electrostatic 
potentials. This is further supported by the observed increase in DTNB efficiency upon 
neutralization of the C-terminal carboxylate in mTR3. 
One of the key questions in the TR mechanism is how the C-terminal redox dyad 
is reduced by the N-terminal redox center on the opposite subunit.  The C-terminal redox 
tark contrast to that reported fot truncated 
a
m





peptide Ac-SCCS(ox) to the thiol-
disulfide interchange step observed in GR ( mation of the mixed-disulfide 
between Cys57 and a Cys from the C-terminus of the second molecule of TR in the 
Drosop
center is either a Cys-Cys or Cys-Sec dyad as we have introduced earlier.  Our analysis 
begins with the known conformations of a Cys-Cys(ox) dyad (which are rare in protein 
structures) that have been reported previously.  For example, the solution structure of Ac-
Cys-Cys-NH2(ox) has been examined by NMR spectroscopy and found to exist as a 
mixture of four different conformers (58, 170).  These conformers are designated as C+, 
C-, T-, and T′-.  The designations “C” and “T” represent the geometry of the peptide 
bond as either cis or trans, whereas the designations “+” and “-” refer to the helicity of 
the disulfide bond.  It was found that peptide Ac-Cys-Cys-NH2(ox) also had a second T- 
conformer that is defined by a larger separation of Cα atoms and this peptide was 
designated as T′-.  Our NMR solution studies of peptides Ac-SCCS(ox), Ac-GCCG(ox), 
and Ac-GCUG(ox) also show that the same four major conformers described by Reitz 
and coworkers are also the major conformers of these three peptides which are 
summarized in Table 18 (Deker and Hondal, unpublished).   
The observation that oxidized tetrapeptides can serve as substrate for the 
truncated forms of TR demonstrate that TR, like GR, may be considered a disulfide 
oxidoreductase where its own C-terminus is the cognate substrate.  Using this 
relationship and the available structures for GR, we started by asking the question: which 
of the four known conformers of Cys-Cys(ox) aligns with GSSG in the GR structure?  
We therefore aligned the four known conformations of 
34).  The for
hila homodimer would represent the binding of GSSG in GR (PDB 1GRA) and 





r each of the alignments, no 
additio
hypothesize that this step, interchange, is to be structurally and biochemically conserved 
between GR and TR. The comparison of these two GR structures shows the primary 
difference is the movement toward each other of the interchange Cys (Cys58 of GR) side 
chain and the Cys side chain from GSH I.  Using GSH I of GSSG as a reference (Figure 
47), each tetrapeptide was fit such that the position and angle of the cysteines involved in 
the interchange step were equivalent.  
Altogether, we evaluated eight possible orientations for a given tetrapeptide in the 
active site of TR because each of the four conformations can be overlaid with the sulfur 
atoms of GSSG in two different orientations (by rotation of 180°), which would either 
place the N-terminal Cys in the interchange position or the C-terminal Cys in the 
interchange position. To form the interaction between the C-terminal carboxylate and 
Lys29 in rat TR1 (Lys26 in DmTR or Lys56 in 1ZKQ) proposed by Sandalova (36), the 
C-terminal Cys or Sec must be in the interchange position. Fo
nal electrostatic interactions or hydrogen bonds are predicted without requiring 
significant changes of the peptide positioning such that the chemistry is unlikely to occur. 
This is not unexpected as: 1) the C-terminal tail is quite mobile, 2) is normally covalently 
attached to the protein and likely does not require binding contacts (demonstrated by the 
peptide assays), and 3) even in GR, most of the contacts with the GSSG substrate are 
water mediated (see Chapter 1) only a few interactions are direct contacts.   
Upon alignment of the sulfur atoms of peptide SCCS(ox) with the sulfur atoms of 
GSSG, it is clear that peptides in the C+ conformation place the leaving group Cys (C-
terminal Cys) in a favorable position for protonation from His464′ (His467′ in GR, 





r to align the C-terminal sulfhydryl of peptide 
SCCS(
chains of Ser.  
The T-
(88) and proposed as a conserved acid/base catalyst throughout the protein family (97, 
168) including TR (93, 99).  Maintaining the interchange position and angle for the trans 
(T- and T-′) peptides, however, results in a rotation of the leaving group Cys by 
approximately 90o (Figure 51B) as is also observed for the C- conformation.  This moves 
it away from His464′ by increasing the distance from 3.5 Å to 5.1 Å and to an angle not 
reasonable for protonation.  In orde
ox) in the T- conformation with the GSH II Cys so that it would be in a favorable 
position for protonation from His464′, the interchange cysteine (N-terminal Cys of 
SCCS(ox)) must be rotated away from the interchange residue (Cys57). Therefore, for 
protonation of the first leaving group by His464′, the ring must be in the C+ 
conformation.  
Figure 52 models the interface between subunits where the oxidized tetrapeptide 
would be reduced by the N-terminal redox center in DmTR and mTR3, respectively.  As 
can be seen in the Figure, the binding pocket for the oxidized tetrapeptide is significantly 
larger in the case of DmTR (Figure 52A) compared to that of mTR3 (Figure 52B).  This 
larger binding pocket in DmTR can accommodate the larger size of the C+ conformer of 
the SCCS(ox) tetrapeptide.  The distance from the NH of the N-terminal Cys to the CO of 
the C-terminal Cys is larger in the C+ conformer than in the T- conformer.  In addition, 
the larger binding pocket of DmTR can also more easily fit the bulkier side 
 conformer is much more compact and forms a tight turn structure that is better 
accommodated in the binding pocket of mTR3.   
Using this same analysis with the mTR3 structure published by Biterova et al. 






residues of helix 3 that makes this a poor fit in the binding pocket. 
Sec with Cys greatly impairs this ring 
opening step as can be seen in 
unpublished), we find that GCUG(ox) in the T- conformation with Cys in the interchange 
position appears to be the most favorable conformation for interchange with Cys86 from 
chain A.  With Sec oriented in the interchange position, an unfavorable interaction with 
the carbonyl from the adjacent Cys residue occurs with His497′, but we would like to 
emphasize that we cannot rule out the T- orientation with Sec in the interchange position.  
The fit of the GCUG(ox) tetrapeptide in the binding pocket of mTR3 is shown in Figure 
52D. A surface representation of tetrapeptide SCCS(ox) in the C+ conformation docked 
in the binding pocket of DmTR is shown in Figure 52C for comparison.  A stereo 
diagram of tetrapeptide GCUG(ox) in the C+ conformation positioned in the binding 
pocket of mTR3 is shown in Figure 53.  This stereodiagram clearly shows the steric 
clashes from the 
The peptides GCDCLG and GCLCDG fall into structural classifications different 
than the other peptides. Introduction of the D-form amino acid in either position results in 
a rigid structure that is 100% in a single conformation. Placing D-Cys in the first position 
results in a T- like conformation while placing it in the second position results in a T+ 
like position. As seen in Figure 54A, the D-L peptide is more compact and is fits at the 
reaction interface while the L-D peptide shown in Figure 54B is very elongated and is 
not well fit to the reaction interface. 
Structural Explanation for the Peptide Complementation Data.  
In the mammalian enzyme, replacement of 
Table 12 Chapter 4.  For example, the ratio of turnover 







NB is a substrate for TR and cystine is not. Since 
DmTR can utilize cysteine in the SCCS or GCCG motif, the final piece of the answer is 
the structure. Both DTNB and cystine are linear intermolecular disulfides. A linear 
molecu
308 fold difference between peptides Ac-GCUG(ox) and Ac-GCCG(ox).  These data 
strongly support our hypothesis that the ability of mTR3 to protonate the leaving group in 
the ring opening step of the catalytic cycle is greatly impaired compared to DmTR.  Our 
interpretation that proton transfer to the leaving group is partially rate limiting is in 
agreement with conclusions made about the GR mechanism, where proton transfer from 
His467′ to the thiol of GSH II has also been shown to be partially rate limiting (94, 95). 
In DmTR, the presence of a Sec residue does not radically alter the rate of ring 
opening as it does for mTR3.  For example, if we compare the ratio of turnover rates for 
peptides Ac-SCUS(ox) and Ac-SCCS(ox) we see only a 5.65 fold difference.  This ratio 
is increased to 36 fold when comparing peptides Ac-GCUG(ox) and Ac-GCCG(ox).  A 
24 fold increase is observed for DmTR when the effect of flanking residues o
ptide motif is examined by comparing the ratio of turnover for peptides Ac-
SCCS(ox) and Ac-GCCG(ox).  In the mammalian enzyme, the presence of flanking 
serine residues on either side of the Cys-Cys or Cys-Sec dyad only slightly (3-6 fold) 
improves the activity (Table 13 Chapter 4).  These data indicate that the ability of 
DmTR to protonate the leaving group is not impaired, as is the case for the mammalian 
enzyme, since it allows for the C+ conformation. This interpretation provides a better 
answer to the question as to why DT
le in not likely to be able to adopt the C+ type conformation conferred by the 
intramolecular vicinal disulfide ring, which is why DTNB with its low pKa is a substrate 







Other crystallization trials.  
ed previously, the available TR structure from rat (1H6V) (36) and 
When this data is put in context with the structural data, we can explain the loss of 
activity when Sec is replaced with Cys in the mammalian enzyme and why Cys-
containing TRs (such as DmTR) can function with high activity. DmTR has a more open, 
interfacial active site than the mammalian enzyme.  The residues from helix 3 proximal 
to the FAD-associated active site are less bulky to more freely accommodate the 
hydroxyls of the adjacent serines (SCCS).  The increase in the available space is als
to make the enzyme more amenable to the conformational switching of the 
SCCS(ox) peptide from T- (trans) to C+ (cis) necessary to protonate the leaving group 
cysteine during interchange.  The GCDCLG(ox) peptide, due to its rigid nature, is likely to 
require extra space for rearrangement rather than a simple ring flip to receive the proton 
from His464′. This would account for the lower activity in DmTR compared to Ac-
GCCG(ox) and lack of activity with mTR3. In contrast to DmTR, the mammalian TRs 
have evolved a more restricted active site by incorporating bulkier residues on helix 3. 
This smaller active site shows a steric preference for Gly compared to Ser and was unable 
to accommodate either peptide in the C+ conformation without requiring significant 
rearrangement of the active site. Exclusion of the C+ conformation would make Sec 
essential as the first leaving group in the ring opening step for mTR3. 
Several other crystallographic approaches to study TR were investigated but are 
currently without success. The structure reported in this Chapter is of the truncated form 







 the cryoprotectant. 
The results from these experiments and absence of the C-terminus from the previously 
published TR structures demonstrates the significance of using the peptide 
comple
(1ZKQ) (35) do not have structural information for the C-terminus. Crystallization 
of the semisynthetic mTR and the wild type DmTR was attempted but have yet to 
produce diffraction quality crystals. In the case of mTR3, clusters of thin, hair-like quasi-
crystals developed. Attempts to furthur evaluate these were limited by material. 
With DmTR, the starting material is not limiting but issues with hypernucleation 
and rapid needle formation are currently hampering diffraction quality crystal 
development. Variations in buffer, PEG, pH, additives, and protein concentration that 
were successful with the truncated forms have not been useful with the full length 
enzyme. The addition of reducing agent or NADPH has also been explored and did 
partially reduce the hypernucleation, but this is counter to the aims of this project as it is 
the oxidized form of the C-terminus that we are interested in.  
Co-crystallization and soaking-in experiments have been explored with mTR and 
the peptide CUG(ox). Data sets were collected and difference Fourier did not reveal any 
bound peptide. These experiments are hampered by the low solubility of the mammalian 
motif and the low affinity the enzyme shows for the small peptide, as discussed in the  
previous Chapter. Not only are high concentrations of peptide required to saturate the 
enzyme, but the low affinity also means it is likely to be displaced by
mentation approach to establish a GR-like system for TR. Establishing this GR – 
truncated TR relationship demonstrates the relevance of the peptide modeling.   
As indicated in the Introduction, there is no structural or biochemical information 





 the Trx 
active 
ox state of mTR3 several 
other m
investigated. The crystals and a SDS-PAGE gel are shown in Figure 55. Addition of Trx 
to the droplet resulted in beautiful crystals (Figure 55A) but the Trx remained in the 
droplet (Figure 55B). Formation of a covalent complex was also investigated, as was 
done for TR from E. coli (49, 171). Following this previous work, we cloned
site mutant Cys32-Gly-Pro-Ser (wild type is Cys32-Gly-Pro-Cys) and the C-
terminal mTR mutant Gly-Ser-Cys-Gly. The Cys32 in Trx is reacted with DTNB to form 
a Trx-TNB mixed disulfide, which can be attacked by the C-terminal Cys in the mTR3 
mutant to form the complex. After many variations of this experiment, only Trx dimer 
and no complex was observed. It was concluded that several side reactions could be 
occurring. We first demonstrated that the truncated mTR3 reduced the Trx-TNB disulfide 
via the N-terminal active site. Secondly, depending on the red
ixed disulfides could form to prevent the desired complex.  
 
  
Figure 41. Crystal of mTR3 with x-ray diffraction pattern. 
The space group currently used in refinement is I4122. The data processed to >95 % 











Table 15. Crystallographic statistics for amTR3-G. 
 
Cell Parameters  
space group I4122 
a, b, c (Å) 110.509 
 110.509 
 208.025 
Data Collection Statistics  
     resolution range (Å) 15 – 2.25 
     unique reflections 29,494 
     completeness (%) 95.6 (95.4) 
     redundancy 5.23 
     Rmergeb (%) 8.1 
     I/σ 21.3 (6.6) 
Model Statistics  
     Rworkc 28.3 
     Rfreed 31.7 
     # Atoms, non-hydrogen  
        Protein 3679 
        Ligand 53 
     r.m.s. deviation, bonds (Å) 0.008 
     r.m.s. deviation, angles (o) 1.08 
     Ramachandran plot (%)  
        most favored regions 86.3 
        additionally allowed 12.7 
        generously allowed 1.0 
        disallowed regions 0.0 
aMouse mitochondrial TR missing the C-terminal tripeptide Cys-Sec-Gly. 
ment of diffraction intensity 
ction excluded from refinement 
b
PRmerge = ΣΣI(h)BjB - <I(h)>/ ΣI(h), where I (h)j is the jth measure
of reflection h and <I(h)> is the average intensity of reflection h for all j measurements.   
cRwork = Σ(|FBoB| - |FBcB|)/Σ|FBoB|.   





Figure 42. Hypernucleation of TR crystals. 









Figure 43. Crystal of DmTR with x-ray diffraction pattern. 
The crystal and diffaction pattern for the structure of DmTR solved at 2.4 Å resolution 












Table 16. Crystallographic statistics for aDmTR-S. 
 
Cell parameters  
space group R32 




Data collection statistics  
wavelength (Å) 1.5418 
resolution range (Å) 15 – 2.4 
unique reflections 22,987 
completeness (%) 98.7 (90.3) 
redundancy 7.85 
Rmerge (%)b 5.9 
I/σ 36.8 (2.8) 
Molecular replacement search models 1H6V 
Model statistics  
Resolution (Å) 15 – 2.4 
Rworkc 19.8 
Rfreed 24.7 
Refined model  
# amino acid residues 480 
# FAD molecules 1 
# NADP molecules 1 
# Water molecules 121 
# Atoms, non-hydrogen  
protein 3684 
ligand 92 
r.m.s. deviation, bonds (Å) 0.011 
r.m.s. deviation, angles (°) 1.359 
 
89.0 
additionally allowed 9.6 
49.14 
Range of B-factors (ÅP2P) 39.6 – 95.7 
Ramachandran plot (%) 
most favored regions 
generously allowed 0.7 
disallowed regions 0.7 
Average B-factor (ÅP2P) 
aDrosophilia melanogaster TR missing the C-terminal tripeptide Cys-Cys-Ser. 
bRmerge = ΣΣI(h)BjB - <I(h)>/ ΣI(h), where I (h)j is the jth measurement of diffraction intensity 
f reflection h and <I(h)> is the average intensity of reflection h for all j measurements.   
cRwork = Σ(|FBoB| - |FBcB|)/Σ|FBoB|.   







Figure 44. O  DmTR C-terminus. 
 






igure 45. The crystal structure of DmTR. 
he figure shows a cartoon representation of TR (left), the structure of DmTR (right), and 
the protein sequence (bottom). The color-coding correlates the linear sequence to 
mplified three-domain architecture. 
The dimerization domain (black) is continuous with the sequence while the FAD binding 
omain and NADP binding domain are not. For example, segment 1 extends beyond the 
NADP binding domain and contributes to the dimerization interface and segment 5 is 
within the FAD binding domain but is C-terminal to the NADP binding domain. 
F
T







Figure 46. The homodimeric model of DmTR. 
hain A in green and chain B in gray.  The The homodimeric model of DmTR with c
SCCS(ox) tetrapeptide in the C+ is oriented with Cys489′ as the interchange and shown 
in space-filling model. The NADP without the nicotinamide moiety is indicated in blue, 
the FAD in dark red. The prime designation for residue numbers indicates the B chain of 













Structural alignment of DmTR and GR. 
Structural alignment of Glutathione Reductase (1GRA) (34) and DmTR (Green). The 
tic components are shown along with 
Figure 47. 
residue numbers are for DmTR. Essential cataly






Table 17. Least squares structural comparison of the aGR family. 
 
Structure 1 Structure 2 bR.M.S.D. Å 
 
cDmTR dmTR3 (1ZKQ) 0.84 
DmTR eRat TR1 (1H6V) 1.15 
DmTR GR (1GRA) 1.16 
DmTR fTryR (1BZL) 1.23 
GR TryR 1.09 
 
aGlutathione Reductase (34). 
bC-alpha deviation. 
at cytosolic TR (36). 
fTrypanothione reductase (37).  
 
cDrosophila melanogaster TR. 
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DmTR1 HKLVQS EFFIP 
AmlTR EALRTAVQN FIP 
 AgTR ATLTES FFIP 
MmTR3 KTMAEA FTVA 
 HsTR2 RKMAEAVQNH L H Q TVA 
 RnTR1 EKMTES PLEWTVP 
 CeTR1 NHLRDS EYTIS 
 
Figure 48. Tetrapeptide binding pocket ribbon overlay. 
Panel A is a close-up view of the SCCS(ox) tetrapeptide (blue) in the C+ conformation 
with Cys 489′ as the interchange residue positioned in the DmTR structure (green) with 
an overlay of the mTR3 (PDB 1ZKQ) (35) colored in salmon.  The residues for mTR3 
are indicated in parentheses.  Panel B is a multiple sequence alignment generated with 
ClustalW (131) with either the PDB ID or accession number in parentheses. The 
sequences are TR1 from D. melanogaster (AF301144_1), TR from A. mellifera 
linguistica (AAP93583.1), TR from A. gambie (CAD30858.1), TR3 from M. musculus 
(PDB 1ZKQ), TR2 from H. sapiens (Q9NNW7), TR1 from R. norvegicus (PDB 1H6V), 
and TR1 from C. elegans (AF148217_1). The alignment shows helix 3 from Chain A 
along with the loop from the dimerization domain of Chain B. The numbering is in 
accordance with the TR from Drosophila. 










Figure 49. GR, TryR structural overlay. 
Structural overlay of glutathione reductase in blue/light blue (1GRA) (34) and 
 is identical to the previous figure 
modate the larger trypanothine 
trypanothine reductase (1BZL) ( 7) red/pink. The iew3  v
demonstrating the equivalent helical shift to accom














Figure 50. Electrostatic surface potentials. 
Electrostatic surface potential showing a close-up of the reaction interface where thiol-
disulfide exchange occurs between the conserved N-terminal dithiol and the C-terminal 
tetrapeptide of TR or the GSSG substrate for GR. A) GR (1GRA) (34); B) mTR3 (1ZKQ) 









Table 18. Tetrapeptide conformer distribution. 
Conformer distributions (%) determined by NMR for oxidized tetrapeptides (Deker and 
Hondal unpublished results). 
 
aConformer Ac-GCUG Ac-GCCG Ac-SCCS 
C+ b 9 33 47 
C- 0 6 5 
T- 70 47 40 
T-‘ 21 14 8 
 
aThe orientation of the peptide bond between the Cys-Cys or Cys-Sec 
dyad can be cis (C) or trans (T). 
 
  bThe helicity (+ or -) of the disulfide bond. 
  
Figure 51. SCCS(ox) aligned with GSSG. 
Alignment of The 
tetrapeptide st R spectroscopy and placed in the active 
sition) in the GR 
red) and the helical loop of the 
conserved active site sequence CVNVGC, which are components of chain A.  Also 
shown is Arg473′ from the B chain as well as His464′ and Glu469′, which are analogous 
to His467′ and Glu472′ in GR.  The oxidized C-terminal disulfide of the B chain is 
reduced by the FAD-associated disulfide of the A chain during the enzymatic cycle.  The 
residues from TR are in gray, oxidized glutathione is in purple, the tetrapeptide is in 
green, and omit electron density for the 2.4 Å structure is shown.  Cys57 of DmTR is in 
position for interchange with GSH I and the Cys489 of the SCCS(ox) tetrapeptide, which 
is indicated by the orange dashed line.  Glutathione II is in position from protonation 
from His464′ as is Cys490′ of the SCCS(ox) tetrapeptide when in the C+ conformation 
(Panel A), but not when in the T- conformation (Panel B) as indicated by the red dashed 





the tetrapeptide SCCS(ox) in the structure of TR from Drosophila.  
ructures were determined by NM
site of TR in accordance to the position of GSH I (the interchange po












Figure 52. DmTR and mTR3 surface potentials with peptide fits. 
Electrostatic surface potential calculated using for TR showing a close-up of the reaction 
interface where thiol-disulfide exchange occurs between the conserved N-terminal dithiol 
nd the C-terminal tetrapeptide of the adjacent subunit containing the 8-membered ring 
at must be opened during redox cycling. (A) Interface for DmTR; (B) Interface for 
TR3 (PDB 1ZKQ) (35); C) The tetrapeptide SCCS(ox) in the C+ conformation with 
ys489′ in the interchange position for DmTR; D) The tetrapeptide GCUG(ox) in the T- 








Figure 53. Stereo-view of mTR3 with GCUG(ox) C+. 
Stereo diagram for mTR3 (PDB 1ZKQ) (35) showing residues from helix 3 along with 
the tetrapeptide GCUG(ox) in the C+ conformation with Cys522′ (sulfur in yellow) in the 









Figure 54. Ribbon view of GCDCLG(ox) and GCLCDG(ox) fits. 
Alignment of the testrapeptides GCDCLG(ox) (A) and GCLCDG(ox) (B) in the active site 












Figure 55. Co-crystallization trial of mTR3 and Trx. 
A) Crystals (length 1.5 mm) with the oily background the thioredoxin. B) 12% SDS-
PAGE of the crystal drop. Lane 1, Markers; lane 2, purified mTR3; lane 3, purified Trx, 
lane 4, blank, lane 5; mTR3 crystal from condition without Trx; lane 6 and 8, mTR3 
crystal from co-crystallization trials; lanes 7 and 9, droplet solution from co-







CHAPTER 6.  
 








igure 56. Model for the requirement of SecF  in mammalian TR. 
Prior to the formation of the interchange mixed disulfide, the Cys-containing TR from 
Drosophila melanogaster undergoes conformational change to the cis (+) conformation 
for protonation of the first leaving group (left). The structure of DmTR accommodates the 
flanking Ser residues as well as the peptide in the cis (+) conformation. The structure of 
the mammalian enzyme restricts the peptide to the trans (-) conformation (right) 
preventing protonation of the first leaving group. The low pKa of the selenol (Se-) of Sec 








The dissertation presented here has completed three specific aims: 1) development 
of a semisynthetic technique (Ch 3 for structure-function studies 
(Chapter 3), 2) deve ion (Chapter 4), to 
vestigate the mechanism of TR, and 3) determination of the crystal structure of DmTR 
hapter 5) for comparison with mammalian TR. The results from these aims represent a 
gnificant contribution to our field. The structural comparison of mammalian and 
Drosophila melanogaster TRs, in combination with biochemical evidence from full 
length and truncated enzymes has generated the first hypothesis (Figure 56) for the 
requirement of Sec in mammalian TR in the 10 years since Sec was first identified in the 
enzyme. 
We have shown that maintaining Sec in the C-terminal position of the dyad is 
ssential to mTR3 function but that the vicinal motif is not. The data from the peptide 
tion of Sec in mTR3 is 
mily. Our hypothesis that protonation of the first leaving group is partially rate limiting 
in the catalytic cycle of TR is complete agreement with the current understanding of the 
mechanism of GR (88, 94, 95).  
 
  
apter 2) to produce mTR





complementation assays show that the loss in activity by muta
attributed to a loss in activity in the ring opening step. The structural positioning of the 
oxidized tetrapeptides in accordance with the interchange step of GR with GSSG explains 
why the low pKa of Sec is required for the mammalian enzyme but not DmTR even 






EEPING MECHANISMS IN PERSPECTIVE  
 
derstanding the common elements of a general mechanism is as important as 
underst
K
The GR protein family is an ideal module for the merger of a structural biology 
and biochemical analysis to understand how evolution selects for a common approach to 
an essential process. That process is thiol-disulfide exchange. Each enzyme then adapts to 
a specific need on the basis of a target or a cognate substrate. For example GR, TR and 
TryR function to reduce their cognate disulfides by consumption of NADPH whereas 
LipDH functions to generate NADH by consumption of the cognate dithiol. So, not only 
does a common architecture evolve for compensation of a different cognate substrate, but 
also allows for shifting of equilibrium to reverse the direction of the reaction.  
Un
anding the unique elements of a specific mechanism within a protein family. 
Taking both sets of elements into consideration is essential for structure-based design of 
therapeutics to be effective (6, 14). TR is unique within the protein family in that its own 
C-terminus is the cognate disulfide substrate for the conserved active site. This adds an 
additional thiol-disulfide exchange reaction prior to reduction of its true cognate substrate 
Trx. We expect that the common element is the interchange step resulting in the mixed 
disulfide with the conserved FAD-associated active site. We hypothesize that this step is 









 MAMMALIAN TR  
ccount for 
the nec
low pKa of the Sec would 
become essential due its inability to be protonated by His 497΄ (PDB 1ZKQ). The trans 
conform tion also shows an intramolecular hydrogen bond between the C-terminal 
carboxylate and the amide hydrogen of the penultimate cysteine in the NMR structures of 
the peptides containing a terminal Gly. This would contribute to the stability of the trans 
MODEL FOR THE REQUIREMENT OF SEC IN
 
Selenocysteine has been shown to account for the broad substrate range unique to 
mammalian TRs, including its ability to reduce peroxides (114) and ascorbate (115, 172). 
It has been assumed that the incorporation of the selenium atom in mammalian TR for the 
lower pKa expected for Sec compared to Cys (109), however, one must distinguish a 
selective advantage (broad substrate range) from a necessary function (reduction of Trx). 
The low pKa of Sec does not account for the requirement of Sec demonstrated by the 
dramatic loss in Trx activity upon mutation of the Sec to Cys if the base-catalyzed 
mechanism of the GR family is conserved. The structural analysis here could a
essity for the selenium atom in the mammalian TR.  
Both the Ac-GCUG(ox) and Ac-GCCG(ox) peptides show an equilibrium shift 
towards the trans peptide conformation while Ac-SCCS(ox) shows an equilibrium 
favoring the cis conformation.. Alignment of these peptides in the active site of mTR3 
according to the interchange step of GR also shows a preference for the peptides in the 
trans conformation. In our model, the more restricted tetrapeptide binding pocket of 
mammalian TR resulting from incorporation of bulkier residues and a shift of helix 3 
restricts the peptide to the trans conformation and does not accommodate the flanking 







 the rate of 
itching to the cis conformation. This could contribute to the decrease in activity 
reporte
conformer and result in the shift in equilibrium to trans and decreasing
sw
d for the mutation of the terminal Ser to Gly (Ser491΄) for the Drosophila TR that 
is not observed for the equivalent mutation for Ser488΄ (65).  
The TR from Drosophila has evolved a different tetrapeptide binding pocket than 
that of the mammalian form of the enzyme. The residues from helix 3 proximal to the 
FAD-associated active site are less bulky to accommodate the hydroxyls of the flanking 
serines of the SCCS motif and allow the peptide to adopt the cis conformation. The 
increase in the available space is likely to make the enzyme more amenable for the 
conformational switching of the GCCG peptide from trans to cis necessary to protonate 
the leaving group cysteine during interchange.  
Our hypothesis is that the catalytic cycle for TR is a dominated by a leaving group 
effect. The first leaving group (Sec in mTR3) must either be in position for protonation 
from the catalytic His during the ring opening step or have a significantly lower pKa. An 
alterative brought to light in the Introduction and in Chapter 3 is the question of 
nucleophilicity. While there is no disagreement in the likely nucelophilic difference 
between Sec and Cys or that the flanking serines in DmTR may increase nucleophilicity, 
the question is the fold contribution. Whitesides (173) and Hupe (156) have characterized 
the rates of thiol-disulfide exchange as a function of pKa, as reviewed in (174, 175). 
Using a series of alkyl and aromatic nucleophiles of determined pKa, Hupe and co-
workers determined an ~3.2 fold change in rate per pKa unit (156). While these systems 
are simplistic in that they do not account for protein conformations, it is rather striking 







 be more difficult to reduce. This is what 
we obs
rate. This is important in that a thee pKa unit difference is that which has been estimated 
for Cys compared to Sec (125).  
It has been postulated that the Sec residue is the attacking nucleophile in the 
reduction of Trx (109).  This is due to the selenolate of a Sec residue being more
hilic than the thiolate of a Cys residue.  Indirect evidence supporting this 
hypothesis is the hydrogen peroxidase activity of the enzyme (63, 68), which is abolished 
upon mutation of Sec to Cys (109). However another role for Sec is as the leaving group 
position of the dyad during the ring opening step as we have argued in our model.  
Placing the Cys residue in the leaving group position by switching positions of the Sec 
and Cys residues should significantly decrease the activity towards all three substrates is 
this study, as the C-terminal selenysulfide would
erved in our results in Chapter 3. 
The kinetic profile of the hydrogen peroxidase activity of the WT enzyme is more 
like that of a chemical reaction (2nd order kinetics) rather than an enzymatic reaction. 
Therefore one would expect the position of Sec to have little impact on the peroxidase 
activity. However, switching positions of the two atoms (S and Se) results in a 30 fold 
decrease in peroxidase activity when selenium content is normalized. A probable 
explanation for this is that the selenylsulfide in this mutant is poorly reduced in the assay. 
This interpretation is further supported by the near WT activity of the Ala insertion 
mutants for all three substrates. These mutants would maintain Cys in the interchange 







nce in the Trx assays for the equivalent mutants 
(Chapte
our model that the ring opening step is where Sec is required for mammalian TR 
and that it is likely a function of the chemistry.  
BINDING OR CHEMISTRY (kcat/Km). 
  
The structural interpretation here raises the question of what is actually being 
observed in the peptide complementation assays in Chapter 4. Since the assay conditions 
do not reach saturation, the representation of the plot is in the form of kcat/Km. Can we 
distinguish between binding or conformation and chemistry in our data? In terms of our 
interpretation, we have developed a model that results in the chemistry being dependent 
on binding the correct conformation of the peptide in the ring opening step. In this 
interpretation, the only assumption is that the selenium is not a binding determinant for 
the peptide, which is quite reasonable. The support for this comes from the agreement in 
the fold difference in the kcat/Km of the peptide pairs in the peptide complementation 
assays when compared to the fold differe
r 4, Table 14). 
In the Trx assay, there is very little difference in the apparent Km for Trx between 
the GCUG, GCCG and SCCS mutants of mTR3 (Chapter 3). Similar results are observed 
for the Trx activity with mutants of DmTR published by Gromer et al. (65), which 
included the C-terminal mutants GCUG, GCCG and SCUS in comparison with the wild 
type SCCS. Therefore, the >200 fold difference in kcat/Km for the mutants of mTR3 is 
attributed to the >200 fold difference in kcat. This is the same order of magnitude 
difference in the kcat/Km determined in the peptide complementation assays (308 fold for 






lating the results for the truncated TR assays in 
a more simplified form (Table 19) to that which has been observed in the literature for 
GR (T
y the latter (GS-STNB) is a substrate for GR since it has the low 
pKa TN
only require protonation upon resolution 
Our model can be understood by re
able 20). The truncated forms of mTR3 and DmTR have good activity towards 
DTNB (thiol pKa = 4.75 (159)) and GCUG (Sec pKa = 5.2 (125)). The peptide GCCG is a 
substrate for DmTR as the tetrapeptide binding pocket for DmTR allows for the C+ 
conformation whereas mTR3 does not. Neither enzyme has activity for cystine, since 
there is no ring structure to place the leaving group in the correct orientation for 
protonation by the catalytic His. This is the same interpretation that can be made for GR. 
The thiol pKa for glutathione is 8.6 (175), however GR binds GSSG in the correct 
disulfide orientation for the catalytic cycle to occur. This is not the case for the mixed 
disulfides GS-SCy (160) and GS-STNB (95) with each only having a single glutathione 
moiety and not likely to have the disulfide in the correct orientation for protonation of the 
first leaving group. Onl
B- leaving group, just like the tetrapeptide GCUG has the low pKa leaving group 
of Sec.   
 
OUR MODEL AND A MECHANISTIC EVOLUTIONARY ADVANTAGE 
  
Incorporation of Sec into mammalian TR may be an evolutionary advantage 
beyond a broader substrate range. In the proposed mechanism of GR, His 464΄ would 
protonate both the leaving group GSHII and then GSHI upon resolution of the 
interchange mixed disulfide. Incorporation of selenocysteine would eliminate the need 






formation of the FADH- - NADP+ charge-transfer complex then the formation 
f the thiolate-FAD charge-transfer complex EH2(B) (Please refer to Figure 10 in 
e 
the reduction of the C-terminal disulfide terminating at EH4(B). This indicates that 
reducti
nterchange. Upon re-oxidation of the vicinal disulfide with transfer of electrons to 
Trx, the peptide bond would likely be in the trans conformation. Incorporation of Sec as 
the first leaving group would remove the necessity for cis/trans conformational 
switching. The differences in the two ring opening steps we hypothesize here are shown 
in Figure 57 (mTR3) and Figure 58 (DmTR). 
 
SUPPORT FROM THE STOPPED-FLOW TR LITERATURE  
 
Minimal characterization has been done for the WT mammalian enzyme with the 
stopped-flow technique described in Chapter 1 (79). The initial characterization of DmTR 
(78) and analysis of mutants of PfTR (93) provide significant support to the model we 
have presented here. In the DmTR study (78), a kcat was determined for Trx as ~ 5 s-1. For 
the reductive half-reaction, three rate constants were determined; k1 ~ 100 s-1, k2 ~ 49 s-1, 
and k3 ~ 21 s-1. The first two rate constants are essentially the reductive half-reaction of 
GR with 
o
Chapter 1 for the remainder of this discussion). Therefore, the third rate constant must b
on of the C-terminal disulfide is rate limiting in the reductive half-reaction. This is 
not surprising as with GR the protonation of the first leaving group in the oxidative half-
reaction is rate limiting (88, 95). A single rate constant was determined for the oxidative 





oxidative half-reaction was rate limiting overall. This, however, does not necessarily 
mean the nucleophilic attack on Trx, as was clarified in the analysis PfTR. 
The PfTR work is most interesting as it includes the mutants of the His-Glu dyad 
(93). The results for the reductive half-reaction are similar to that of DmTR. Again k1 is 
the largest at 425 – 815 s-1 depending on the mutant or the pH. This is the formation of 
the FADH- - NADP+ charge-transfer complex and is only weakly affected by the 
ignificantly affected 
by the mutations, between ~ 30 to 150 fold. The k3 for PfTR, the reduction of the C-
terminu
mutations. As with DmTR, k2 is ~ 50 % of k1 for the WT PfTR and s
s by the N-terminus, is ~ 5 % of k2 and again is dramatically reduced by either 
mutation. With PfTR the reduction of the C-terminus is rate limiting in the reductive half-
reaction, to an even greater extent than in DmTR.  
For PfTR, three rate constants were estimated for the oxidative half-reaction. The 
k1 was the fastest of the three and similar to k3 of the reductive half-reaction with the His 
and Glu mutants ~ 50 % of wild type. The other two rate constants were very slow with 
k2 ~ 10  % of k1, and k3 rate limiting (wild type). Each of these constants was significantly 
lower for the mutants. In this analysis of PfTR it was proposed that k1 is the reduction of 
Trx (EH4(B) to EH2(B)) and that the other two rate constants are EH2(B) back to Eox. 
Therefore, in both half-reactions, the reduction of the C-terminus would be rate limiting 
and thereby rate limiting overall. This interpretation can then be extrapolated to the 
DmTR results where the step in the oxidative half-reaction that is rate limiting likely 
involves the EH2(B) to Eox steps. The k1 for PfTR being unaffected by the His or Glu 
mutations indicates that the dyad is not involved in the transfer of electrons to Trx as 










CONTRADICTIONS TO THE TR LITERATURE 
While there is a contribution of the flanking Ser residues to the activity of DmTR, 
it is only a 7 fold increase over the activity of flanking Gly residues (65). Therefore, the 
Ser can hardly be seen as critical when compared to the >100 fold loss in activity upon 
mutation of the Sec in mTR3 (157) or mutation of the catalytic base in PfTR (93). The 
other point of contention with our model is that the proposal for the Ser residues 
facilitating thiolate formation is that it is based on the tetrapeptide modeled in all trans 
configurations (65). Comparing the NMR structures of the SCCS(ox) tetrapeptide, the 
hydroxyls of the Ser residues face the eight
ration and not in the cis configuration (Figure 59). Based on our analysis, the Ser 
hydroxyls would not be correctly oriented in the cis configuration during the ring opening 
step.  
It is still feasible that the hydroxyls could impact the oxidative half-reaction by 
increasing the nucleophilicity of the attacking thiolate. The seven fold loss in activity for 
DmTR could be accounted for by a decrease in pKa of the attacking thiolate. However, it 
cannot account for the loss in activity for the SCCS mutant of mTR3, which is even 
below that of the GCCG mutant. The same results were also demonstrated for human TR 
where the SCCS mutant shows less activity than the GCCG mutant (154). The results 
from the human TR SCCS mutant (hTR-SCCS) were interpreted by the authors to be a 
function of the oxidative half-reaction. Both half-reactions were slow in comparison to 





mutant. A closer inspection of the data presented does raise a question of the reaction 
lf-reaction (A) spectra 6 to the 
xidative half-reaction (B) spectra 2, it would appear that the latter has not reached 
EH4(B)
c (36, 109) is the leaving group upon ring opening and those who suggest that it is 
the int
conditions (Figure 60). Comparing the reductive ha
o
. One of the primary characteristics of EH4(B) is an enhanced thiolate-flavin 
charge-transfer complex at 540 nm (93) which is much lower in Figure 60B spectra 2 
than Figure 60A spectra 6. The 460 nm peak also does not appear shifted to shorter 
wavelengths as would be expected. Figure 60C is the oxidative half-reaction of PfTR for 
spectral reference (93). 
 
SEC AS LEAVING GROUP OR INTERCHANGE 
  
The TR field is split as to the function of Sec in the catalytic cycle. While its role 
as the nucleophile for Trx reduction is universally accepted, there are those who suggest 
that Se
erchange (35). However, prior to the data we present here, no biochemical 
evidence was provided for either hypothesis. The high activity of the mTR3-GCAUG and 
mTR3-GCAAUG mutants would support our model that Sec is the leaving group position 
and not the interchange position. If Sec were the interchange, the insertion of residues 
would be expected to prevent the interchange step from occurring during ring opening. 
The Sec-relative position in DmTR (Cys490΄) has been suggested as the 
interchange (78) and is in partial disagreement with our model. This suggestion was 
generated from the difference in spectral properties of Cys489΄Ser and Cys490΄Ser 





he data produced in these studies and proposal for Sec as the leaving group in 
model generating an extended list 




complex. It was suggested that this was due to a stable mixed-disulfide between the 
interchange thiol Cys57 and Cys490΄. In our modeling, there is no chemical distinction in 
the SCCS or GCCG peptides as both residues in the dyad are Cys. Therefore, it is quite 
possible that Cys490΄ forms the interchange with Cys57. This would suggest that the two 
enzymes have different mechanisms, which we suspect is unlikely. 
 
SUPPORTING EXPERIMENTS  
 
T
the ring opening step for mammalian TRs is a testable 
of
tion of DmTR-SCAUS by semisynthesis. Recovering activity compared to the 
DmTR-SCACS mutant would support our model. In both mutants, there are still the 
flanking serines except that there is not the vicinal disulfide. We suggested, based on the 
high activity of mTR3-GCAUG and mTR3-GCAAUG, that the Sec position is the 
leaving group and that we have not moved the interchange position or dramatically 
affected the attack on Trx. Similar results for DmTR-SCAUS would make for a 
convincing argument that both enzymes have a similar mechanism. Standard molecular 
biology techniques can be used to test the effect of the residues from helix 3 proposed 
formational and peptide determinants for the two enzymes. The Thr114 DmTR 
substitution for His or Tyr in mammalian TR would be the position of choice. A 





evaluated enzymatically but whose likely functions have been discussed. These mutations 
provide opportunities for future crystallographic studies. 
     
 
Figure 57. Model for mTR3 ring opening steps. 
The steps of ring opening within the reductive half-reaction for mTR3 with the C-
terminal tetrapeptide GCUG in the tans (-) conformation. Binding of NADPH and 
formation of the FADH-NADP+ charge -transfer complex (Boxed k1), thiolate-FAD 
charge-transfer complex (k2), formation of the interchange mixed disulfide with Sec 
(orange) not requiring protonation (k3), resolution of the mixed disulfide (k4) and 






















Figure 58. Model for DmTR ring opening steps. 
The steps of ring opening within the reductive half-reaction for DmTR with the 
tetrapeptide SCCS in the cis (+) conformation. Binding of NADPH and formation of the 
FADH-NADP+ charge -transfer complex (Boxed k1). The peptide in the trans (-) 
conformation must undergo conformational change the cis (-) (k2) then cis (+) (k3). The 
thiolate-FAD charge-transfer complex (k4), formation of the interchange mixed disulfide 
(k5) with Cys489’ requiring protonation (k6), resolution of the mixed disulfide (k7) and 






able 19. Substrates for truncated TR. 
 




aDmTR-S + + + - 
bmTR-G + + - - 
 
aDrosophila melanogaster TR missing the C-terminal tripeptide Cys-Cys-Ser. 
b
 cGS-SCy dCyS-SCy 
Mouse mitochondrial TR missing the C-terminal tripeptide Cys-Sec-Gly. 
cCystine. 
 
Table 20. Substrates for glutathione reductase. 
 
nzyme E aGS-SG bGS-STNB
GR + + - - 
 
aThe natural substrate diglutathione (GSSG). 
bGlutathione-TNB mixed disulfide taken from (95). 
cGlutathione-cysteine mixed disulfide taken from (160). 
dCystine taken from (160). 
 
  
Figure 59. Orientation of flanking serine hydroxyls. 
Orientation of the flanking Ser hydroxyls in the SCCS(ox) tetrapeptide in trans 
onfiguration (left) and the cis configuration (right). The Ser hydroxyls would not be 
     
c










Figure 60. Interpretation of human TR-SCCS. 
Interpretation of the human Ser-Cys-Cys-Ser TR mutant (hTR-SCCS) from (154) 
reprinted with permission (176). A is the reductive half-reaction of hTR-SCCS. Spectra 
1 is oxidized hTR-SCCS, spectra 4 is the addition of 1.7 equivalents of NADPH, spectra 
5 is 3.3 equivalents of NADPH, spectra 6 is 7.7 equivalents of NADPH. B is the 
Oxidative half-reaction of hTR-SCCS. Spectra 1 is the oxidized hTR-SCCS, spectra 2 is 
reduction with 2.1 equivalents of NADPH, spectra 3 is reoxidation after addition of Trx. 
C is the oxidative half-reaction of wild type TR from Plasmodium falciparum (PfTR) as a 
reference (93). Spectra 1 is the oxidized PfTR, spectra 2 is reduction with 2.2 equivalents 
of NADPH, spectra 3 and 4 are time points following addition of Trx. It is possible that 
the slow oxidative half-reaction in the experiment is the incomplete reduction of hTR-
SCCS, based on the lack of shift in the 460 nm peak to shorter wavelength and the 
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AMP, Me, 2-mercaptoethanol; CATC, the sequence Cys-
CID, 
Crystal
diethylaminoethyl; DmTR, Drosophila melanogaster TR; dNTP, deoxyribonucleotide 
triphosphate; DTNB, 5,5’-Dithio-bis(2-nitrobenzoic acid); DTT, dithiothreitol; EDTA, 
ethylenediamintetraacetic acid; EH2, 2-electron reduced (1 NAPDH equivalent) 
flavoprotein; EH4, 4-electron reduced (2 NAPDH equivalent) flavoprotein; Eox, oxidized 
flavoprotein; EPL, expressed protein ligation; ESI-MS, electrospray ionization mass 
spectrometry; FAD, flavin adenine dinucleotide; Fmoc, 9-fluoroenylmethoxycarbonyl; 
GCCG, the tetrapeptide Gly-Cys-Cys-Gly; GCUG, the tetrapeptide Gly-Cys-Sec-Gly; 
GITS, the sequence Gly-Ile-The-Ser; GR, glutathione reductase; GSH, reduced 
glutathione (γ-glutamylcysteinylglycine); GSH I, interchange glutathione; GSH II, first 
leaving group glutathione; GSSG, oxidized diglutathione; HPLC, high pressure liquid 
chromatography; H2O2, hydrogen peroxide; ICP-MS, inductively coupled plasma mass 
spectrometry; IPTG, isopropyl-β-D-thiogalactopyranoside; LB, Luria-Betami Media; 
LipDH, dihydrolipoamide dehydrogenase; MALDI-TOF, matrix-assisted laser desorption 





Ala-Thr-Cys; CCG, the tripeptide Cys-Cys-Gly; CeTR; Caenorhabditis elegans TR; 
collision induced dissociation; CISS; the sequence Cys-Ile-Ser-Ser; CNS, 





Acid; Mr, molecular weight; MOPS; 3-(N-Morpholino) Propane-Sulfonic Acid; mTR3, 
mouse mitochondrial TR; NADH, reduced nicotinamide adenine dinucleotide; NADP+, 
oxidized nicotinamide adenine dinucleotide hosphate; NADPH, reduced nicotinamide 
denine dinucleotide phosphate; NF-ΚB, nuclear factor kappa B; NMA, N-
methylmeraptoacetamide; NMR, nuclear magnetic resonance; PDB, Protein Data Bank; 
PEG, polyethylene glycol; PfTR, TR from Plasmodium falciparum; RMSD, root mean 
squared deviation; RNR, ribonucleotide reductase; SCCS, the tetrapeptide Ser-Cys-Cys-
Ser; Sec, selenocysteine; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel 
electrophoresis; SECIS, selenocysteine insertion sequence;  TB, terrific broth; TNB-, 
thiobis(2-nitrobenzoic acid) anion; TR, thioredoxin reductase; Trx, thioredoxin; TryR, 
trypanothine reductase; U, the one-letter abbreviation for selenocysteine; WT, wild type; 









B. COMPREHENSIVE LIST OF MATERIALS 
cording to manufacturers guidelines. Recombinant E. coli thioredoxin 
as purchased from American Diagnostica (Greenwich, CT). DTNB, NADPH, NADP+, 
Bovine Pancreatic Insulin and N-Methylmercaptoacetamide (NMA) were purchased from 
Sigma-Aldrich (St. Louis, MO). Hydrogen peroxide 30% solution was purchased from 
J.T Baker (Phillipsburg, NJ). The PEG 6000 used for crystallization was purchased from 
Fluka (Sigma-Aldrich). All other chemicals were purchased from either Sigma-Aldrich or 
Fisher Scientific and were of reagent grade or better. 
 
Solvents for peptide synthesis were purchased from EMD Biosciences (San Diego, CA). 
Fmoc amino acids were purchased from Synpep Corp. (Dublin, CA). Resins for solid-
phase synthesis were purchased from Novabiochem (San Diego, CA). All PCR primers 
were purchased from Integrated DNA Technologies Inc., and PAGE purified (Coralville, 
IA). Restriction endonucleases Nco I, Sap I, Hind III, Eco RI, Nde I, Sal I, Kpn I, Vent 
DNA polymerase, plasmids pTYB1 and pTYB3, chitin agarose beads, T4 DNA ligase, 
and reaction buffers were supplied by New England Biolabs (Ipswich, MA). All 










CLONING OF DROSOPHILA TR WITH pTYB1 
 
Upstream primer 5′ – AACAGACATATGGCGCCCGTGCAAGG – 3′ (labaled dmup2).   
 
C. LIST OF PCR PRIMERS 
 
CLONING OF MOUSE TR3 WITH pTYB3 
 
Upstream mTR3  (labeled TRup2). 
Downstream mTR3-GCCG 5’-





ACAGCCGCTCTTCAGCAGCCACAGGAACCAGTCACA-3’ (labeled mTR-C488S). 
QuickChange Stratagene Mutagenesis Forward mTR3-Cys52Ser/Cys57Ser 5’-
GGTGGCACCTCTGTCAACGTGGGTTCCATACCCAAGAAGC-3’ (labeled 
mTRC52-57A-fwd). 











QuickChange Stratagene Mutagenesis Forward DmTR His464Ala 5’-
CAACACCGTGGGCATCGCCCCCACTACCGCCGAAGAG-3’ (labeled 
QuickChange Stratagene Mutagenesis Reverse DmTR His464Ala 5’-
HIS464reverse). 




Downstream truncated DmTR-S488 5′- 
A
dmdown2s). 
Downstream DmTR-SCACS 5′- 
ACAGCCGGTACCCTTGGCAAAGCAGCTGCAGGCGCAGCTGGCCGGCGTGGG-
3′ (labeled DmTR-CAC). 
Downstream DmTR-SCAACS 5′- 
ACAGCC








genesis Reverse DmTR His106Ala 5’-
orward DmTR Glu469Ala 5’-
 Stratagene Mutagenesis Reverse DmTR Glu469Ala 5’-
CGGTAGTG-3’ (labeled E469Areverse). 
 
QuickChange Stratagene Mutagenesis Forward Trx Cys36Ser 5’-
GGTGCGGTCGGTCCAAAATGATCGC-3’ (*labeled TrxC35Sfw).  
QuickChange Stratagene Mutagenesis Reverse Trx Cys36Ser 5’-
GCGATCATTTTGGACGGACCGCACC-3’ (labeled TrxC35Srev). 









QuickChange Stratagene Mutagenesis F




CLONING OF THIOREDOXIN 
 
 
 
